Dr. David Kessler has already fought one of the most powerful industries in America.

As Commissioner of the U.S. Food and Drug Administration in the 1990s, Kessler helped expose how tobacco companies manipulated nicotine and pushed the federal government to confront an industry whose products were contributing to an extraordinary burden of disease and death.

Now Kessler is warning that America may be facing another public-health crisis on an enormous scale.

This time, he is talking about our food.

In a recent 60 Minutes report, Kessler made an extraordinary statement:

“Over the last 40 years, the United States has been exposed to something that our biology was never intended to handle.”

He was referring to energy-dense, highly palatable, rapidly absorbable ultra-processed foods-and he connected their proliferation with the enormous rise in metabolic and chronic disease in the United States.

Think about what he is saying.

This is not a social-media wellness influencer.

This is not someone selling supplements.

This is a physician, former FDA commissioner, former dean of Yale School of Medicine, and one of the government officials who took on the tobacco industry.

And he believes the magnitude of the food problem is comparable to tobacco.

When asked how today’s food-related public-health crisis compares with tobacco, Kessler described it as “as large, if not larger.”

HOW DID WE GET HERE?

Walk through almost any American supermarket and look beyond the produce, meat, fish, beans, nuts, seeds and other recognizable foods.

Entire aisles are filled with products engineered to be inexpensive, convenient, shelf-stable, intensely flavored and incredibly easy to consume.

• Breakfast cereals.

• Cookies.

• Crackers.

• Chips.

• Sweetened drinks.

• Frozen meals.

• Packaged desserts.

• Snack bars.

• Candy.

• Instant foods.

• And hundreds of other industrial formulations.

This distinction matters: processing itself is not inherently harmful.

Frozen vegetables are processed. Canned beans are processed. Plain yogurt is processed. Olive oil is processed.

The concern is increasingly focused on ultra-processed foods-industrial formulations often containing refined starches, sweeteners, fats, flavorings, emulsifiers and other ingredients designed to produce highly palatable, convenient products.

The FDA itself estimates that approximately 70% of packaged products in the U.S. food supply are foods often considered ultra-processed, while American children obtain more than 60% of their calories from these foods.

Let that sink in.

We are not talking about an occasional cookie or bag of chips.

We are talking about a food environment in which ultra-processed products have become a dominant source of calories-beginning in childhood.

AND THEN THERE IS THE GRAS SYSTEM

One of Kessler’s major concerns involves a regulatory category called GRAS: “Generally Recognized as Safe.”

The system dates back to 1958.

Originally, the exemption made sense for familiar substances with well-established histories of safe use.

But over decades, the system evolved in a way that has allowed manufacturers to make certain safety determinations about substances without first obtaining FDA approval—and historically without necessarily notifying the FDA.

That means “legal to put in food” and “rigorously evaluated by the FDA for its long-term contribution to chronic disease” are not necessarily the same thing.

That distinction should concern every American.

The federal government is now attempting to tighten the GRAS notification system, but Kessler argues the proposed changes do not go far enough to address the fundamental drivers of chronic disease.

KESSLER WANTS THE FDA TO GO MUCH FURTHER

In 2025, Kessler petitioned the FDA to reconsider the GRAS status of categories of processed refined carbohydrates used extensively in ultra-processed foods-including refined starches and sweeteners.

His argument is provocative.

The question should not simply be whether an individual ingredient causes immediate toxicity.

We also need to ask what happens when a population consumes enormous quantities of rapidly absorbable, highly palatable industrial foods every day, for decades.

Kessler argues that our regulatory system was never adequately designed to answer that question.

In his petition, he compared the potential public-health importance of changing the food supply with the transformation that occurred when government finally confronted tobacco.

THE SCIENCE SHOULD MAKE US UNCOMFORTABLE

We cannot say that every ultra-processed food causes disease, and scientists are still trying to determine exactly which characteristics of these foods are responsible for particular health effects.

But dismissing the entire issue because every mechanism has not been established would be equally irresponsible.

In one of the most important controlled nutrition experiments conducted by the National Institutes of Health, researchers admitted participants to the NIH Clinical Center and gave them either an ultra-processed or minimally processed diet.

The diets were designed to be matched for presented calories, sugar, fat, sodium, fiber and macronutrients.

Yet something remarkable happened.

When participants were given the ultra-processed diet, they spontaneously consumed approximately 500 additional calories per day.

They gained approximately two pounds in two weeks.

When those same individuals consumed the minimally processed diet, they lost approximately the same amount.

They weren’t instructed to overeat.

They simply did.

That finding becomes particularly important when we stop thinking about two weeks and start thinking about 20, 30 or 40 years of exposure.

THEN WE NEED TO TALK ABOUT CANCER

As someone who has spent my professional life in cancer prevention, recovery and survivorship, this part of the conversation is impossible for me to ignore.

Cancer does not exist in isolation from metabolic health.

Obesity, insulin resistance, chronic inflammation, poor dietary quality and physical inactivity intersect with the development and progression of multiple chronic diseases, including several cancers.

Research examining ultra-processed food consumption and cancer is primarily observational, so we need to be careful not to confuse association with proof of causation.

But the associations are concerning.

A systematic review and meta-analysis found that every 10% increase in the proportion of ultra-processed food in the diet was associated with a 13% higher risk of overall cancer and an 11% higher risk of breast cancer. Higher consumption was also associated with colorectal and pancreatic cancer risk.

That does not mean eating a packaged cookie gives someone cancer.

It means that when dietary patterns are examined across populations, a signal continues to emerge that deserves serious scientific and public-health attention.

THIS IS BIGGER THAN “PERSONAL RESPONSIBILITY”

This is where the conversation often goes wrong.

We tell people:

Eat better.

Lose weight.

Control your blood sugar.

Lower your cholesterol.

Feed your children healthier foods.

Prevent chronic disease.

And personal choices absolutely matter.

But those choices are being made inside a food environment specifically built around products that are inexpensive, convenient, heavily marketed, widely available and exceptionally easy to consume.

If a substantial portion of the American food supply encourages overconsumption, telling millions of people simply to demonstrate more willpower is not a public-health strategy.

We cannot exercise our way out of a fundamentally unhealthy food environment.

And we cannot place the entire burden of chronic-disease prevention on individuals while refusing to examine the system supplying their food.

THIS DOES NOT MEAN FEARING EVERYTHING IN A PACKAGE

There is another danger here: turning legitimate concern into food hysteria.

Not every additive is dangerous.

Not every processed food is unhealthy.

Not every carbohydrate is harmful.

And “chemical” does not automatically mean toxic.

We need science-not fear.

But science also requires us to question assumptions when the evidence changes.

If ingredients or categories of ingredients received regulatory status decades ago, it is entirely reasonable to ask whether their safety should be reconsidered using modern knowledge of metabolism, obesity, insulin resistance, cardiovascular disease, cancer and long-term dietary exposure.

“Generally recognized as safe” should never mean “we stopped asking questions.”

WE ARE TREATING THE DOWNSTREAM CONSEQUENCES

This may be the most disturbing part of the entire discussion.

America spends extraordinary resources treating:

• Type 2 diabetes.

• Cardiovascular disease.

• Hypertension.

• Fatty liver disease.

• Stroke.

• Obesity-related complications.

• Certain cancers.

• And many other chronic conditions.

We have increasingly sophisticated medications, surgical procedures and medical technologies for treating disease after it develops.

But what if one of our most powerful opportunities for changing population health has been sitting in front of us three times a day?

Food.

Not a miracle diet.

Not a supplement.

Not a detox.

Not another weight-loss gimmick.

Food.

A dietary pattern centered around vegetables, fruits, legumes, nuts, seeds, whole grains, healthy fats and quality sources of protein-while substantially reducing reliance on ultra-processed products.

That isn’t radical.

It may be one of the most conservative health recommendations imaginable.

KESSLER’S WARNING DESERVES TO BE HEARD

More than three decades ago, Americans were assured that cigarettes were a matter of personal choice while an enormously profitable industry engineered products and marketed them aggressively.

Eventually, the evidence became impossible to ignore.

Kessler was there.

That history is precisely why his warning about the modern American food environment deserves our attention.

The comparison with tobacco is not perfect. Food is essential to life; tobacco is not. Ultra-processed foods are also a broad and scientifically debated category rather than a single toxic product.

But the lesson from tobacco remains painfully relevant:

Public-health disasters can develop gradually.

Commercial interests can become deeply embedded in everyday behavior.

Regulation can lag decades behind science.

And by the time society recognizes the magnitude of the problem, millions of people may already be sick.

We should not wait another 40 years to decide whether we should have paid attention.

We need better research.

We need greater transparency.

We need modernized food regulation.

We need healthier school food.

We need affordable access to whole and minimally processed foods.

We need physicians, dietitians, exercise professionals and other healthcare providers talking seriously about nutrition and physical activity as fundamental components of chronic-disease prevention.

And we desperately need to stop pretending that America’s epidemic of chronic disease can be solved exclusively inside hospitals and pharmacies.

Health begins long before someone becomes a patient.

It begins with the food environment we create.

It begins with what our children grow up eating.

It begins with movement.

It begins with education.

And it begins with having the courage to ask whether a food system developed largely around profitability, convenience, shelf life and palatability is actually serving human health.

David Kessler is asking that question.

After what he witnessed with tobacco, perhaps we should listen.

READY TO DO SOMETHING ABOUT IT?

Knowing what ultra-processed foods may be doing to our health is one thing. Changing how we eat is another.

For paid members, I created a downloadable 14-Day Ultra-Processed Food Detox- a practical, no-gimmicks reset to help you reduce ultra-processed foods, retrain your palate, rebuild your plate, and make whole, nutrient-dense foods your new normal.

No juice cleanses. No detox teas. No starvation.

Just real food, better choices, and a plan you can actually follow.

Become a paid member and download the complete 14-Day Reset below.

REFERENCES

1. CBS News. Human “biology was never intended to handle” ultraprocessed foods, former FDA head David Kessler warns. 60 Minutes. Updated August 9, 2026.

2. U.S. Food and Drug Administration. Ultra-Processed Foods. FDA. Updated 2025–2026.

3. Williams AM, Couch CA, Emmerich SD, Ogburn DF. Ultra-processed Food Consumption in Youth and Adults: United States, August 2021-August 2023. NCHS Data Brief. 2025 Aug;(536):10.15620/cdc/174612. doi: 10.15620/cdc/174612. PMID: 41027400; PMCID: PMC12516466.

4. U.S. Food and Drug Administration. Generally Recognized as Safe (GRAS) Notification Program. FDA. Updated August 2026.

5. U.S. Food and Drug Administration. Substances Generally Recognized as Safe: Proposed Rule. FDA. August 2026.

6. Kessler DA. Citizen Petition: Limit the Exposure of Refined Carbohydrates Used in Industrial Processing in Order to Prevent Obesity, Diabetes, and Cardiovascular Disease in Children and Adults. FDA Docket No. FDA-2025-P-3071. Filed August 12, 2025.

7. Hall KD, Ayuketah A, Brychta R, et al. Ultra-processed diets cause excess calorie intake and weight gain: an inpatient randomized controlled trial of ad libitum food intake. Cell Metab. 2019;30(1):67-77.e3. doi:10.1016/j.cmet.2019.05.008.

8. Isaksen IM, Dankel SN. Ultra-processed food consumption and cancer risk: a systematic review and meta-analysis. Clin Nutr. 2023;42(6):919-928. doi:10.1016/j.clnu.2023.03.018.

Read more

For decades, we have celebrated the moment a person finishes chemotherapy, completes radiation, or reaches the end of active cancer treatment.

There are bells to ring.

There are hugs.

There are photographs.

There are celebrations.

And then, far too often, there is a frightening question:

Now what?

For millions of cancer survivors, completing treatment does not mean completing recovery.

The oncologist may say, “I’ll see you in three months.”

The surgeon may discharge the patient.

Radiation oncology may schedule a future follow-up.

Friends and family assume the worst is over.

But the survivor may still be dealing with profound fatigue, muscle loss, weakness, neuropathy, balance problems, restricted shoulder mobility, lymphedema risk, osteoporosis, cardiovascular damage, weight changes, cognitive impairment, sexual dysfunction, anxiety, depression, fear of recurrence, metabolic changes, and numerous other acute, chronic, and late effects of treatment.

In other words:

The cancer treatment may be finished. The consequences of cancer treatment may not be.

That disconnect is finally receiving the attention it deserves.

The United States is moving toward a model in which cancer survivorship is recognized not as an optional wellness service added after medical treatment, but as a legitimate component of the cancer care continuum.

And for those of us working in oncology exercise and cancer rehabilitation, this shift is enormously important.

First, Let’s Be Clear About What Is-and Is Not-a “New Mandate”

There are several developments occurring simultaneously, and they are easy to confuse.

The Lainie Jones Comprehensive Cancer Survivorship Act of 2026 (H.R. 8839/S. 5052) was introduced in the House on May 14, 2026, and in the Senate on July 21, 2026.

As of August 2026, it has not become federal law.

The Senate bill has been referred to the Senate Committee on Finance, while the House version has been referred to the relevant House committees.

Therefore, it would be inaccurate to say that this legislation currently mandates oncologists to provide specific survivorship services.

What is remarkable, however, is what the legislation proposes.

Its stated purpose is to address unmet needs across the entire continuum of cancer care—from diagnosis through active treatment, post-treatment recovery, survivorship, quality of life, palliative care, and long-term health—and to move toward a minimum standard of survivorship care.

That is a profound change in philosophy.

Cancer survivorship is no longer being viewed simply as what happens after oncology.

It is increasingly being viewed as part of oncology.

Survivorship Requirements Already Exist

While the 2026 federal legislation remains proposed legislation, survivorship requirements are not theoretical.

The American College of Surgeons Commission on Cancer (CoC) already requires accredited cancer programs to maintain a survivorship program.

Importantly, beginning January 1, 2025, CoC Standard 4.8 clarified that survivorship services must specifically address patients who have completed their first course of treatment.

These services cannot simply consist of a once-a-year survivorship fair, a brochure handed to a patient, or a single educational event.

Services used to satisfy the standard must be available throughout the year or at defined intervals.

That distinction matters.

Survivorship is becoming a process-not an event.

The National Cancer Institute’s National Standards for Cancer Survivorship Care reinforce this concept even further.

Those standards describe survivorship care that includes assessment of physical consequences of cancer treatment, late effects, chronic conditions, emotional and psychological effects, recurrence and second-cancer risk, lifestyle behaviors, health promotion, nutrition, physical activity, rehabilitation, specialty care, financial toxicity, and coordination among oncology, primary care, allied health professionals, and community-based services.

That is much closer to what cancer survivors actually need.

The Missing Piece Has Always Been Continuation of Care

Cancer treatment has traditionally been organized around destroying or controlling disease.

That is obviously essential.

But surviving cancer requires more than eliminating malignant cells.

A person may survive cancer and still emerge from treatment with dramatically altered physiology and function.

Chemotherapy can contribute to cardiotoxicity, peripheral neuropathy, sarcopenia, fatigue, cognitive impairment and metabolic dysfunction.

Radiation can cause fibrosis, restricted mobility, cardiopulmonary complications and tissue changes that may continue developing years after treatment.

Hormonal therapies may accelerate bone loss, alter body composition, reduce muscle mass and increase cardiometabolic risk.

Cancer surgery can alter posture, range of motion, lymphatic function, gait, balance, strength and biomechanics.

Stem cell transplantation can produce profound deconditioning and prolonged functional impairment.

And these effects do not conveniently disappear because the last infusion was completed.

This is why continuation of care matters.

The survivor needs a bridge between:

diagnosis → treatment → recovery → rehabilitation → survivorship → long-term health.

Historically, too many people have fallen through the spaces between those stages.

What the 2026 Survivorship Legislation Would Change

One of the most important provisions of the proposed Lainie Jones Comprehensive Cancer Survivorship Act is coverage for cancer care planning and coordination services.

Under the proposed legislation, cancer care planning could occur at several critical points:

• At diagnosis and treatment planning

• When the patient’s condition or treatment preferences change

• At the end of active treatment and beginning of survivorship

• If cancer recurs

The legislation also specifically recognizes the need for better transition between specialty oncology care and long-term care.

That is critical.

It acknowledges something survivors have been saying for years:

There needs to be a handoff—not a cliff.

The bill defines survivorship navigation broadly as helping patients overcome healthcare barriers and obtain timely access to high-quality medical, physical and psychosocial care throughout the cancer experience.

For oncology professionals, that potentially changes the conversation from:

“Your treatment is complete.”

to:

“Your active treatment is complete. Now let’s determine what you need for the next phase of recovery and survivorship.”

Those are two very different conversations.

Physical Activity Is Actually Written Into the Proposed Legislation

This is particularly significant for oncology exercise professionals.

Physical activity is not buried somewhere in an appendix.

It appears directly in the legislation.

The proposed Comprehensive Cancer Survivorship Program would provide grants to eligible cancer programs, NCI-designated cancer centers and qualifying community organizations to improve survivors’ quality of life and long-term outcomes.

Among the services specifically identified is helping survivors:

engage in moderate physical activity and other health-promoting behaviors.

The legislation also identifies nutrition education and counseling, psychological support, community support, survivorship care-plan implementation and adherence to surveillance for recurrence and second primary cancers.

For those of us who have spent decades advocating for exercise as part of cancer recovery, this is significant.

Exercise is increasingly moving out of the category of:

“Something healthy you should probably do.”

And into the category of:

“Something that should be considered within comprehensive survivorship care.”

That is an enormous difference.

But “Exercise More” Is Not an Exercise Prescription

This is where the oncology exercise profession needs to be very careful.

Recognition of physical activity within survivorship care does not mean every cancer survivor should simply be told to join a gym.

Nor does it mean that a generic exercise prescription is appropriate.

Consider a breast cancer survivor who has undergone bilateral mastectomy, lymph-node surgery and reconstruction.

She may have:

restricted shoulder flexion,

pectoralis tightness,

scapular dysfunction,

postural compensation,

axillary web syndrome,

lymphedema risk,

radiation fibrosis,

fatigue,

bone loss from endocrine therapy,

and chemotherapy-induced cardiotoxicity.

“Exercise 150 minutes per week” does not tell us how to safely restore her shoulder mechanics.

It does not tell us whether an exercise is exacerbating an existing postural deviation.

It does not tell us how to progress resistance exercise following reconstruction.

It does not tell us how to accommodate neuropathy.

It does not tell us how to modify exercise for bone metastases, osteoporosis, an ostomy, cardiotoxicity or significant treatment-related fatigue.

Physical activity recommendations and individualized cancer exercise programming are not the same thing.

Both have value.

But they serve different purposes.

What This Means for Oncologists

This evolving survivorship model should not mean that oncologists personally become responsible for providing every component of survivorship care.

That would be unrealistic.

Oncology professionals are already working within an enormously demanding healthcare environment.

Rather, the emerging model emphasizes identification, communication, coordination and referral.

The oncologist does not need to become the physical therapist.

The oncologist does not need to become the registered dietitian.

The oncologist does not need to become the mental-health professional.

And the oncologist certainly does not need to become the cancer exercise specialist.

The oncology team needs to recognize when those professionals are needed and establish reliable pathways for patients to reach them.

That is multidisciplinary survivorship care.

And that is precisely why developing strong referral networks is going to become increasingly important.

What This Means for Nurses, Navigators and Allied Health Professionals

Oncology nurses and patient navigators may become even more important in identifying unmet survivorship needs.

Imagine a structured transition process in which the survivor is evaluated for:

physical function,

fatigue,

pain,

neuropathy,

balance,

fall risk,

range-of-motion limitations,

lymphedema,

cardiovascular risk,

bone health,

nutrition,

psychological distress,

sexual health,

financial toxicity,

return-to-work issues,

and physical activity.

No single professional should be expected to manage all of those issues.

But someone must identify them.

Someone must connect the dots.

And someone must make sure that referrals actually lead somewhere.

A referral that disappears into a fax machine is not continuity of care.

What This Means for Cancer Patients

For survivors, perhaps the most important message is this:

You should not have to interpret “no evidence of disease” as “you no longer need care.”

Surveillance is only one component of survivorship.

Your follow-up care should also consider the effects that cancer and its treatment have had on your body and your life.

That may include asking:

Why am I still exhausted?

Why can’t I raise my arm normally?

Why have I lost so much muscle?

Why am I suddenly having balance problems?

Why is my bone density declining?

Why has my body composition changed?

Why am I experiencing neuropathy?

Why am I afraid to exercise?

How much exercise is safe?

Can I lift weights?

What should I do about lymphedema risk?

How do I reduce my risk of other chronic diseases?

What can I do to improve my long-term health?

Those are not frivolous questions.

Those are survivorship questions.

The Primary Care Handoff Is Critical

One of the greatest vulnerabilities in survivorship care occurs when responsibility shifts from oncology back to primary care.

The National Cancer Institute has acknowledged this challenge.

Some survivors continue long-term follow-up with oncology, while others transition primarily to their primary-care provider.

But primary-care professionals may not always have complete information about the survivor’s treatment history, treatment exposures, late-effect risks or recommended surveillance.

The result can be fragmented care.

The proposed 2026 legislation specifically attempts to improve this transition.

For survivors of childhood and adolescent cancers, for example, the legislation proposes Medicaid coverage for healthcare transition services from active oncology care to primary care, including survivorship care plans, evidence-based late-effect surveillance and at least two survivorship transition visits annually.

The larger message applies across oncology:

Cancer history needs to follow the patient.

The patient’s treatment exposures need to follow the patient.

The patient’s risks need to follow the patient.

And the plan for managing those risks needs to follow the patient.

What This Means for the OncoVie® Cancer Exercise Specialist

This may be one of the most important developments our profession has seen.

But we need to approach it responsibly.

An OncoVie® Cancer Exercise Specialist is not replacing the oncologist, physical therapist, occupational therapist, registered dietitian, nurse or other licensed healthcare professional.

We work within our professional scope.

Our role is different.

And extremely valuable.

The qualified cancer exercise professional can help translate medical history, treatment history, physical assessment and functional limitations into safe, progressive and individualized exercise programming.

That may include addressing:

cancer-related fatigue,

loss of muscular strength,

sarcopenia,

cardiorespiratory deconditioning,

balance impairment,

postural deviations,

restricted range of motion,

treatment-related weight and body-composition changes,

neuropathy-related exercise limitations,

bone-health considerations,

lymphedema precautions,

and the prevention or management of cancer-associated comorbidities.

Equally important, we can provide continuity.

The survivor may see the oncologist every three or six months.

The exercise professional may see that person two or three times every week.

That provides an extraordinary opportunity to observe changes.

A good Cancer Exercise Specialist knows when something is within their scope.

A great Cancer Exercise Specialist also knows when it isn’t.

New swelling.

Unexplained shortness of breath.

Sudden neurological changes.

Unusual bone pain.

Significant changes in fatigue.

Unexpected functional decline.

Signs of infection.

New cardiovascular symptoms.

These are not opportunities to “modify the workout.”

They are reasons to stop, refer and communicate with the medical team.

That is what being part of a multidisciplinary survivorship team looks like.

Exercise Professionals Must Earn Their Place at the Table

There is another side to this conversation that our profession cannot ignore.

If oncology professionals are going to increasingly refer cancer survivors to community-based exercise programs, they need to know that the professionals receiving those patients have the specialized education necessary to work with them safely and effectively.

A standard personal training certification is not oncology exercise education.

Cancer survivors may present with extraordinarily complex combinations of cancer surgeries, reconstruction, radiation, chemotherapy, endocrine therapy, immunotherapy, targeted therapies, stem cell transplantation, cardiovascular complications, osteoporosis, sarcopenia, peripheral neuropathy, lymphedema risk, postural and biomechanical changes, and other acute, chronic, and late effects of cancer treatment. These issues can profoundly affect exercise assessment, selection, progression, and safety.

This is precisely the gap that the Cancer Exercise Training Institute (CETI) and the OncoVie® Cancer Exercise Specialist qualification were created to fill.

CETI’s comprehensive oncology exercise curriculum is grounded in current science, clinical evidence, and practical application. The curriculum underwent an extensive update completed in August 2026, incorporating current research, evolving cancer treatments, surgical procedures and reconstruction techniques, treatment-related toxicities, contraindications and precautions, survivorship concerns, and evidence-based exercise programming.

Rather than simply teaching exercise guidelines for people with cancer, OncoVie® education teaches professionals to understand the entire cancer journey and how it affects the individual standing in front of them.

OncoVie® Cancer Exercise Specialists learn how cancer type, stage, treatment history, surgery, reconstruction, medications, treatment toxicities, comorbidities, and functional limitations influence exercise assessment and programming. They are trained to recognize postural deviations, range-of-motion restrictions, strength deficits, balance and gait impairments, cancer-related fatigue, neuropathy, bone-health concerns, lymphedema risk, cardiopulmonary considerations, and other treatment-related issues that may require exercise modification or referral.

Just as importantly, the curriculum emphasizes scope of practice and multidisciplinary communication. OncoVie® Cancer Exercise Specialists are taught to recognize when exercise is appropriate, when medical clearance or additional information is needed, when programming must be modified or temporarily discontinued, and when a change in a survivor’s condition warrants referral back to the oncology or healthcare team.

This distinction is critical.

The goal is not to turn exercise professionals into oncologists, physical therapists, nurses, or other licensed healthcare providers. It is to create highly educated cancer exercise professionals who understand their role within the larger continuum of cancer care and can collaborate responsibly with the medical professionals caring for the survivor.

As survivorship care continues to evolve, oncology professionals need qualified community-based professionals to whom they can confidently refer patients for individualized, evidence-informed exercise programming.

CETI and the OncoVie® Cancer Exercise Specialist qualification provide that bridge-from medical treatment and rehabilitation to safe, structured, individualized exercise and long-term survivorship.

For more than two decades, CETI has worked to establish cancer exercise as a specialized field requiring far more than good intentions and a general fitness credential. As the healthcare system increasingly recognizes exercise and physical activity as important components of cancer survivorship, that distinction becomes even more important.

Oncology professionals should be able to refer a survivor knowing that the exercise professional understands what that person has been through, recognizes the potential consequences of treatment, knows what questions to ask, understands when not to exercise, and can design a program around the survivor’s unique medical and functional history.

That is how trust between medicine and the exercise profession is built.

And that is the standard CETI and OncoVie® are working to bring to cancer survivorship care worldwide.

The Opportunity-and the Challenge

The potential benefits of this evolving approach to cancer survivorship care are substantial. Greater recognition of survivorship as an essential part of the cancer care continuum could create a more coordinated transition from active treatment into recovery and long-term health. It could also strengthen communication between oncology, primary care, rehabilitation, nutrition, mental health, and qualified cancer exercise professionals, while expanding survivors’ access to supportive services that address the physical, functional, and psychosocial consequences of cancer treatment.

The growing recognition of physical activity and exercise within survivorship care is particularly important. However, simply advising a cancer survivor to “exercise more” is not enough. Exercise recommendations must account for cancer type, stage, treatment history, surgery and reconstruction, medications, comorbidities, functional limitations, and the acute, chronic, and late effects of treatment. This creates an important opportunity for appropriately trained cancer exercise professionals, including OncoVie® Cancer Exercise Specialists, to become part of a coordinated multidisciplinary survivorship model.

There are also significant challenges that must be addressed. Proposed federal survivorship legislation must still pass Congress and be enacted before its provisions become law, and oncology practices are already facing considerable workforce, time, and resource limitations. Referral networks remain inconsistent, particularly in rural and underserved communities, and reimbursement for many supportive survivorship services continues to be a barrier. Effective survivorship care will also require better communication across healthcare systems so that patients do not become lost during the transition from oncology to primary and community-based care.

As community-based survivorship programs expand, quality and professional competency will become increasingly important. Programs will need clearly defined standards, measurable outcomes, appropriate referral protocols, and professionals with specialized oncology education. Exercise professionals working with cancer survivors must understand treatment-related toxicities, contraindications, surgical precautions, late effects, and when a survivor needs to be referred back to the medical team. This is an area in which CETI and the OncoVie® Cancer Exercise Specialist qualification can help bridge the gap between medical care and safe, individualized exercise programming.

Ultimately, the greatest opportunity is to redefine what successful cancer care looks like. Survival is the beginning of survivorship-not the end of cancer care. The goal must extend beyond treating the disease to helping survivors restore function, maintain independence, reduce preventable health risks, improve quality of life, and live as fully as possible for years and decades after treatment ends.

This Is Bigger Than Exercise

I have spent decades advocating for exercise to become part of the cancer care continuum.

But this movement is not really about exercise.

It is about changing how we define successful cancer care.

For much of modern oncology, success has understandably centered around outcomes such as tumor response, progression-free survival and overall survival.

Those outcomes remain critically important.

But as more people live years—and increasingly decades—after a cancer diagnosis, another question becomes unavoidable:

What happens during those years?

Can the survivor climb stairs?

Can they return to work?

Can they play with their grandchildren?

Can they regain strength?

Can they restore shoulder mobility?

Can they reduce their cardiovascular risk?

Can they maintain bone density?

Can they improve metabolic health?

Can they live independently?

Can they exercise without fear?

Can they trust their body again?

Can they move from merely surviving cancer to actually living well after it?

Those outcomes matter too.

We Are Moving From Cancer Treatment to Cancer Continuum Care

The language appearing across federal survivorship proposals, National Cancer Institute standards, Commission on Cancer requirements and modern oncology care models reflects a larger transformation.

Diagnosis is not the beginning of one isolated episode of treatment.

It is the beginning of a healthcare journey that may extend for the remainder of a person’s life.

That journey requires surveillance.

It requires communication.

It requires prevention.

It requires rehabilitation.

It requires management of late effects.

It requires physical activity.

It requires nutrition.

It requires psychosocial support.

And it requires qualified professionals working together rather than operating in separate silos.

For medical professionals, that means developing stronger systems for survivorship assessment, referral and communication.

For cancer survivors, it means recognizing that they have legitimate healthcare needs after treatment—and asking for help addressing them.

And for OncoVie® Cancer Exercise Specialists, it means preparing for an increasingly important responsibility.

We are not there to replace medicine.

We are there to help continue what medicine started.

Oncology may save the patient’s life.

Survivorship care must help that person live it.

And perhaps that is the most important evolution of all.

References and Further Reading

American College of Surgeons Commission on Cancer. Optimal Resources for Cancer Care: Commission on Cancer Standards. Updated 2026.

National Cancer Institute, Office of Cancer Survivorship. National Standards for Cancer Survivorship Care. 2024–2026.

U.S. Congress. Lainie Jones Comprehensive Cancer Survivorship Act of 2026. H.R. 8839, 119th Congress. Introduced May 14, 2026.

U.S. Congress. Lainie Jones Comprehensive Cancer Survivorship Act of 2026. S. 5052, 119th Congress. Introduced July 21, 2026.

National Cancer Institute. Follow-Up Medical Care After Cancer Treatment.

American Society of Clinical Oncology. Quality of Survivorship Care.

Many cancer survivors describe it the same way:

“I know what I want to say, but I can’t find the word.”

“I walk into a room and forget why I’m there.”

“I can’t concentrate like I used to.”

“I used to multitask without thinking about it. Now I get overwhelmed.”

“My brain just feels slower.”

For years, these symptoms were commonly lumped together under the term “chemo brain.”

But that term doesn’t tell the whole story.

The more appropriate term is cancer-related cognitive impairment (CRCI) because cognitive changes can occur before, during, and after cancer treatment—and they are not limited to people who receive chemotherapy.

CRCI may affect memory, attention, concentration, processing speed, executive function, language, visuospatial abilities, and the ability to perform multiple tasks simultaneously.

And here is something we don’t talk about nearly enough:

Cognition affects movement.

Walking across a crowded room requires cognition.

Reacting when someone steps in front of you requires cognition.

Remembering the sequence of an exercise requires cognition.

Maintaining balance while talking requires cognition.

Following a multi-step exercise program requires cognition.

Driving, navigating stairs, carrying groceries, responding to changes in terrain, and safely exercising in a busy gym all require the brain and body to work together.

That means cancer-related cognitive impairment isn’t simply a memory problem.

It can become a mobility, exercise, independence, and safety issue.

What Is Cancer-Related Cognitive Impairment?

Cancer-related cognitive impairment describes changes in cognitive function associated with cancer itself and/or cancer treatment.

The symptoms can vary considerably between individuals.

Some people experience subtle changes that are primarily noticeable to them. Others experience deficits that interfere with work, household responsibilities, exercise, driving, social activities, or other aspects of daily life.

Common complaints include:

• Difficulty concentrating

• Shortened attention span

• Slower thinking or information processing

• Problems remembering names, appointments, conversations, or instructions

• Difficulty finding words

• Difficulty learning new information

• Problems organizing or planning

• Trouble switching between tasks

• Feeling overwhelmed by multiple sources of information

• Difficulty multitasking

• Mental fatigue

• Problems with spatial awareness or navigation

Importantly, subjective cognitive complaints and objective neuropsychological testing do not always match.

A survivor may report substantial cognitive difficulties while performing relatively normally on standardized testing—or testing may identify deficits the individual has compensated for remarkably well.

That does not mean the person’s symptoms aren’t real.

A laboratory test and the cognitive demands of living independently in the real world are very different things.

It Isn’t Just Chemotherapy

The term “chemo brain” became popular because cognitive changes were frequently reported by people receiving chemotherapy.

But CRCI is considerably more complex.

Potential contributors include cancer itself, systemic inflammation, chemotherapy, radiation involving the brain, surgery and anesthesia, endocrine therapies, immunotherapies and other systemic treatments, sleep disturbance, cancer-related fatigue, pain, depression, anxiety, nutritional deficiencies, anemia, menopause or treatment-induced hormonal changes, medications, physical inactivity, and pre-existing health conditions.

For many survivors, several of these factors occur simultaneously.

Consider someone undergoing breast cancer treatment who experiences medically induced menopause, disrupted sleep, fatigue, anxiety, decreased physical activity, chemotherapy, and endocrine therapy.

Which one caused the cognitive symptoms?

The answer may be: several of them.

This is one reason CRCI requires individualized assessment rather than assumptions.

What Happens to the Brain?

Researchers continue to investigate the biological mechanisms responsible for CRCI.

Several mechanisms have been proposed, including:

Neuroinflammation

Cancer and cancer treatment can increase inflammatory signaling. Chronic neuroinflammation may interfere with neuronal communication and cognitive processes.

Oxidative Stress

Some cancer treatments increase oxidative stress, potentially affecting neuronal structures and cellular function.

Changes in Brain Structure and Connectivity

Neuroimaging studies have identified treatment-associated changes in areas and networks involved in memory, attention, and executive function in some cancer populations.

Hormonal Changes

Estrogen and testosterone influence brain function. Treatments that dramatically alter hormone levels may therefore contribute to cognitive symptoms in susceptible individuals.

Vascular Changes

Cardiovascular and cerebrovascular health are closely connected to cognitive function. Cancer therapies that adversely affect vascular health may indirectly influence cognition.

Neurogenesis and Neuroplasticity

Some cancer therapies may influence processes involved in the formation, maintenance, and adaptation of neural networks.

This last point becomes particularly interesting when we begin discussing exercise.

Because exercise is not simply training muscle.

Exercise is also a neurological stimulus.

The Cognitive Skills Required to Move Safely

When we think about mobility, we tend to think about muscles, joints, flexibility, and balance.

But movement is heavily dependent upon cognition.

Attention

Walking safely requires continuous processing of information.

The brain must monitor:

• The environment

• Obstacles

• Other people

• Changes in surface

• Body position

• Direction

• Speed

Reduced attention can make these tasks more difficult.

A quiet hallway may present very little challenge.

A busy airport, grocery store, city sidewalk, or fitness facility is an entirely different cognitive environment.

Processing Speed

Processing speed refers to how quickly the brain receives information, interprets it, and generates a response.

Imagine stepping off a curb and suddenly seeing a bicycle approaching.

Your brain must:

See the bicycle → determine its speed and direction → recognize the potential danger → decide what to do → initiate the appropriate movement.

If processing is slower, the physical response may also be delayed.

This is why cognitive impairment can become relevant to reaction time and fall prevention.

Executive Function: The Brain’s Project Manager

Executive function allows us to plan, organize, sequence, problem-solve, inhibit inappropriate responses, and adapt when circumstances change.

It plays an enormous role in exercise.

Consider a seemingly simple strength-training circuit:

1. Perform 10 squats.

2. Walk to another station.

3. Adjust the resistance.

4. Perform 12 rows.

5. Remember your repetitions.

6. Maintain proper form.

7. Monitor your breathing.

8. Remember which exercise comes next.

That is a substantial cognitive workload.

For someone experiencing CRCI, the problem may not be an inability to perform a squat or row.

The problem may be processing everything required to perform the workout safely and correctly.

Motor Planning

Before movement occurs, the nervous system must organize it.

The brain determines:

• What movement is required

• Which muscles need to activate

• In what sequence

• With how much force

• At what speed

• In which direction

When cognition, sensory input, neuropathy, fatigue, weakness, or balance deficits are layered together, movement can become considerably more challenging.

This is one reason simply telling someone to “exercise more” can be woefully inadequate.

Dual-Tasking: Where Cognitive Impairment Meets Mobility

One of the most important concepts in understanding cognition and mobility is dual-task performance.

Dual-tasking means performing a physical task and cognitive task simultaneously.

For example:

• Walking while talking

• Walking while counting backward

• Carrying groceries while navigating stairs

• Walking while looking for a street sign

• Exercising while following verbal instructions

• Changing direction while responding to a question

Healthy adults constantly dual-task without realizing it.

But when cognitive resources are limited, the brain may have difficulty allocating attention between the two tasks.

One task may deteriorate.

The person may slow down.

Stride length may change.

Balance may become less stable.

The cognitive task may deteriorate.

Or the individual may stop walking altogether while answering a question.

For the oncology exercise professional, these responses provide valuable information.

Movement performed perfectly in a quiet environment does not necessarily predict how someone will move when cognitive demands are added.

Cancer-Related Cognitive Impairment and Falls

Falls are rarely caused by one factor.

Cancer survivors may simultaneously experience:

• Peripheral neuropathy

• Lower-extremity weakness

• Vestibular changes

• Reduced proprioception

• Fatigue

• Sarcopenia

• Bone loss

• Vision changes

• Medication effects

• Orthostatic hypotension

• Cognitive impairment

Now add a cognitively demanding environment.

The person is walking while talking.

Their phone rings.

Someone crosses their path.

They need to change direction.

The surface changes.

That is when deficits that weren’t obvious during a standard exercise may suddenly become apparent.

This is why I believe oncology exercise professionals should think beyond muscle strength when evaluating mobility.

The brain is part of the movement system.

CRCI Can Also Affect Exercise Adherence

There is another side of cognitive impairment that deserves attention.

A survivor may genuinely want to exercise but struggle to:

Remember the program.

Remember which resistance they used.

Remember how many sets they completed.

Organize exercise into their day.

Follow complicated written instructions.

Learn several new exercises simultaneously.

Maintain concentration through a long workout.

Return to a program after an interruption.

These difficulties can easily be mistaken for lack of motivation.

They aren’t necessarily the same thing.

Sometimes the exercise program itself is simply demanding more cognitive bandwidth than the client currently has available.

Good exercise programming doesn’t just challenge the body. It respects the brain’s current capacity.

Can Exercise Improve Cancer-Related Cognitive Impairment?

This is where the research becomes encouraging.

A 2026 umbrella review examining eight systematic reviews, 80 primary studies, and more than 7,500 participants found that exercise was associated with improvements in both self-reported and objectively measured cognitive function. The strongest and most consistent findings involved self-reported cognition, while smaller significant improvements were identified in areas including executive function and processing speed. Moderate-intensity aerobic programs lasting approximately 12 weeks were among the most consistent interventions.

Another umbrella review published in 2025 evaluated 28 systematic reviews and found evidence supporting aerobic exercise for specific cognitive outcomes, while mind-body exercise appeared beneficial for subjective cognitive complaints. Combined training also demonstrated preliminary evidence of benefit, although the researchers emphasized the need for better-quality trials and more individualized exercise prescriptions.

A 2025 meta-analysis examining exercise in people with breast cancer found an overall positive, although relatively small, effect on cognitive function.

And an individual-participant meta-analysis involving almost 2,000 cancer survivors across 16 randomized exercise trials also found improvements in self-reported cognitive functioning following exercise.

The evidence isn’t perfect.

Different studies use different exercise protocols, cognitive assessments, cancer populations, and treatment stages.

But the direction is increasingly compelling:

Exercise belongs in the conversation about cancer-related cognitive health.

Walking May Be More Powerful Than We Give It Credit For

You don’t necessarily need complicated “brain-training” exercises to begin.

A 2026 network meta-analysis included 56 randomized controlled trials involving 5,297 adults with cancer. Walking, combined exercise, yoga, and HIIT demonstrated benefits for self-reported cognitive function, although the overall certainty of evidence was low. Walking produced particularly robust results.

That’s worth remembering.

Sometimes the most clinically useful intervention isn’t the fanciest one.

It is the one someone can perform safely, consistently, and progressively.

FREE MEMBER TAKEAWAYS: START HERE

If you are experiencing cognitive changes during or after cancer treatment, there are several practical ways to make exercise safer and more manageable.

1. Simplify the Environment

Early in an exercise program, reduce unnecessary distractions.

A quiet room may be preferable to a crowded gym filled with televisions, music, conversations, equipment, and people moving in multiple directions.

As capacity improves, environmental complexity can gradually increase.

2. Keep the Program Simple

Five exercises performed consistently may be far more effective than 15 exercises the person can’t remember.

Use predictable sequences.

Repeat movements across sessions.

Build familiarity before adding complexity.

3. Use External Memory Tools

Write the program down.

Use pictures.

Use a phone.

Keep an exercise log.

Record resistance, repetitions, duration, and symptoms.

Memory aids aren’t “cheating.”

They’re intelligent compensatory strategies—and recent clinical guidance specifically recognizes approaches such as notes and smartphone reminders as useful strategies for CRCI.

4. Walk

If medically appropriate, walking is one of the simplest ways to combine cardiovascular conditioning, sensory input, coordination, environmental processing, and cognitive stimulation.

Start where you are.

Progress from there.

5. Don’t Add Cognitive Complexity Too Quickly

If balance is already impaired, don’t immediately add complicated cognitive challenges.

Master the physical task first.

Then gradually layer in cognitive demand.

Safety comes before novelty.

When Cognitive Changes Need Medical Evaluation

Exercise professionals should never assume every cognitive complaint is simply CRCI.

New, severe, rapidly worsening, or unusual cognitive or neurological symptoms require medical evaluation.

Potential contributors such as medication effects, infection, anemia, metabolic abnormalities, sleep disorders, depression, anxiety, endocrine dysfunction, nutritional deficiencies, neurological conditions, or cancer progression may need to be considered.

Recent oncology guidance also emphasizes evaluating and treating contributing conditions such as sleep disturbance, pain, anxiety, depression, and other causes of cognitive dysfunction.

Exercise professionals do not diagnose cognitive impairment.

But we are often in a unique position to observe changes in real-world function.

And those observations matter.

PAID SUBSCRIBERS: TURNING THE SCIENCE INTO AN EXERCISE PROGRAM

This is where understanding CRCI becomes practical.

For paid subscribers, I’m going beyond “exercise is good for the brain” and showing you how I would actually approach exercise programming for a cancer survivor experiencing cognitive impairment.

We’ll look at:

• Exercise assessment considerations

• Aerobic programming

• Resistance training

• Balance and mobility training

• Dual-task exercise

• Cognitive-motor progressions

• Exercise sequencing

• When to progress

• When to regress

• Safety considerations

• A sample weekly program

Access to Download is Below References for Paid Subscfribers

References

Gómez-Almeida F, González-Devesa D, Gacparski C, et al. Effects of exercise on cancer-related cognitive impairment: an umbrella review of systematic reviews and meta-analysis. Psycho-Oncology. 2026;35(6).

Hu C, Zheng Y, Xing S, et al. Exercise interventions in cancer-related cognitive impairment: an umbrella review. American Journal of Physical Medicine & Rehabilitation. 2025;104(12):1162-1176.

Hung CS, et al. Effect of exercise interventions on cognitive function in breast cancer patients and survivors: a systematic review with meta-analysis. Breast Cancer. 2025.

Hiensch AE, et al. Moderators of exercise effects on self-reported cognitive functioning in cancer survivors: an individual participant data meta-analysis. Journal of Cancer Survivorship. 2024.

Li L, Hui Z, Zhang Y, Wang X, Fan T. Efficacy of walking or exercise for improving perceived cognitive function in adults during and after cancer therapy: a systematic review and network analysis. Journal of Cancer Survivorship. 2026.

American Society of Clinical Oncology. Assessment and management of cancer-related cognitive impairment. ASCO Educational Book. 2026.

American Society of Clinical Oncology. Cancer-related cognitive impairment: a practical guide for oncologists. JCO Oncology Practice. 2026.

Read more

There is a dangerous assumption in cancer survivorship that we need to start talking about.

If exercise and nutrition were really important for me, my doctor would tell me exactly what to do.

It sounds perfectly reasonable.

We trust oncologists with our lives. They diagnose cancer, interpret extraordinarily complex testing, select treatments, manage potentially life-threatening complications, monitor disease progression and recurrence, and make decisions most of us cannot begin to comprehend.

So, naturally, many cancer patients assume their oncologist also knows exactly what they should eat, how they should exercise, which muscles they need to strengthen, which movements they should avoid, how treatment has changed their biomechanics, how to manage treatment-related fatigue through exercise, and how to safely progress a resistance-training program.

But that is not what oncologists are trained to do.

And expecting them to be experts in all of those areas is neither reasonable nor fair.

An oncologist is an expert in treating cancer.

A registered dietitian with oncology expertise is trained to provide individualized medical nutrition therapy when needed.

A physical or occupational therapist addresses rehabilitation needs and functional impairments within their respective scopes of practice.

And a properly educated Cancer Exercise Specialist can help bridge the enormous gap between medical treatment, rehabilitation, and safe, individualized, long-term exercise.

The problem is not that one profession has failed.

The problem is that cancer survivorship has become too complex for one profession to do everything.

And for more than 30 years, I have been trying to prepare the cancer community for exactly this moment.

“Ask Your Doctor Before Beginning an Exercise Program”

We have all seen that sentence.

But think about what we are actually asking.

Imagine a 62-year-old woman who has undergone bilateral mastectomy, lymph node surgery and reconstruction, followed by chemotherapy and endocrine therapy.

She has restricted shoulder range of motion, weakness, fatigue, weight gain, reduced bone density and concerns about lymphedema.

She asks her oncologist:

“What exercises should I do?”

What exactly are we expecting the oncologist to provide?

A postural assessment?

Shoulder range-of-motion testing?

A progressive resistance-training program?

Cardiovascular intensity parameters?

An evaluation of muscular imbalances?

Exercise modifications based on reconstruction?

A progression strategy based on treatment-related fatigue?

Specific exercises to improve scapular mechanics?

Bone-loading recommendations appropriate for her fracture risk?

Lymphedema-related exercise considerations?

A twelve-week periodized exercise program?

That is not oncology.

That is specialized exercise programming.

Medical clearance and medical exercise prescription are two different things.

An oncologist may determine whether there are medical reasons that exercise should be restricted or modified. But that does not mean the physician should be expected to design and supervise a comprehensive individualized exercise program.

We need to stop confusing the two.

The Research Tells Us There Is a Gap

This is not simply my opinion.

Despite overwhelming evidence supporting exercise during and after cancer treatment, a significant gap remains between recommending exercise and actually providing cancer survivors with the individualized guidance and referral pathways necessary to implement it safely and effectively. Recent literature continues to identify limited clinician knowledge of exercise-oncology guidelines and best practices, inadequate referral resources, time constraints, and competing demands within increasingly complex cancer care as barriers to integrating exercise into routine oncology practice. A 2025 review in JNCI Monographs reported that while many oncology clinicians routinely encourage physical activity, relatively few patients are actually referred to structured exercise programs. The authors emphasize the need for multidisciplinary referral systems connecting oncology clinicians with rehabilitation professionals, exercise physiologists, fitness professionals, and community-based exercise programs (Stout et al., 2025).

This is not a failure of oncology. It is evidence that we have been asking oncologists to do something they were never intended to do. The oncologist's role is to diagnose and treat cancer, manage treatment and its medical complications, and identify patients who may benefit from exercise. The solution is not to expect oncologists to become exercise specialists. The solution is to create clear referral pathways to appropriately trained professionals who understand cancer, its treatments, their potential long-term effects, and how to translate that information into safe, individualized exercise programming.

The knowledge gap is not new. In an earlier survey of 120 oncology care providers, at least 77% rated their knowledge as poor regarding counseling patients according to exercise guidelines and knowing when, how, and which patients should be referred to supervised exercise programs (Nadler et al., 2017). More recent evidence suggests that, although awareness of exercise oncology has increased, significant barriers remain—including limited clinician knowledge of exercise-oncology guidelines and best practices, inadequate referral resources, time constraints, and competing clinical demands (Stout et al., 2025).

That should not be interpreted as an indictment of oncologists.

It should be interpreted as evidence that we need multidisciplinary survivorship teams.

Oncologists should not have to become Cancer Exercise Specialists any more than Cancer Exercise Specialists should attempt to become oncologists.

We need each other.

“Exercise More” Is Not an Exercise Prescription

Thankfully, cancer patients are increasingly being told to exercise.

That represents enormous progress.

ASCO recommends regular aerobic and resistance exercise during active treatment with curative intent because exercise can help reduce fatigue and preserve cardiorespiratory fitness, physical function and strength.

The American Cancer Society likewise recognizes physical activity and healthy eating as important components of survivorship.

But there is a tremendous difference between telling someone to exercise and showing that person how to exercise safely and effectively for their unique circumstances.

“Walk more.”

“Do some strength training.”

“Stay active.”

“Try yoga.”

Those may be reasonable general recommendations.

But they are not individualized cancer exercise prescriptions.

Consider two women who both have breast cancer.

One undergoes lumpectomy and radiation with no lymph node involvement.

The other undergoes bilateral mastectomy, axillary lymph node dissection, chemotherapy, radiation and DIEP flap reconstruction and subsequently develops shoulder dysfunction and lymphedema.

They have the same broad diagnosis.

They do not have the same body.

They should not automatically receive the same exercise program.

This is precisely why specialized oncology exercise education matters.

Nutrition Presents the Same Problem

Cancer survivors frequently ask their oncologists:

“What should I eat?”

And again, we have placed physicians in an impossible position.

Nutrition during cancer treatment can be extraordinarily complicated.

The needs of someone experiencing cachexia and unintended weight loss may be completely different from those of someone experiencing treatment-related weight gain.

A survivor with dysphagia has different needs from someone with an ostomy.

Kidney dysfunction, diabetes, gastrointestinal surgery, treatment-related nausea, altered taste, diarrhea, constipation, mucositis, food-drug interactions, bone loss, cardiovascular risk and numerous other factors can affect nutrition recommendations.

There is also an enormous amount of misinformation surrounding cancer nutrition.

Sugar feeds cancer.

Soy causes breast cancer.

Everyone with cancer should fast.

Everyone should follow a ketogenic diet.

Supplements are natural, so they must be safe.

Cancer survivors are bombarded with claims—many presented with far more confidence than scientific evidence warrants.

ASCO’s guideline on diet during active cancer treatment found insufficient evidence to recommend several popular dietary interventions for improving cancer outcomes, including ketogenic or low-carbohydrate diets and fasting.

This is another reason multidisciplinary care matters.

The solution isn’t expecting the oncologist to become a dietitian.

It is making qualified nutrition professionals part of cancer care when individualized nutrition intervention is required.

Then Came the Evidence We Had Been Waiting For

For decades, observational research has associated higher levels of physical activity with better outcomes in several cancer populations. Then the evidence became even harder to ignore.

The landmark CHALLENGE trial, published in the New England Journal of Medicine in 2025, randomized 889 patients with resected colon cancer who had completed adjuvant chemotherapy to either a structured three-year exercise program or health-education materials. Participants assigned to the exercise intervention experienced a 28% lower risk of disease recurrence, a new primary cancer, or death and a 37% lower risk of death compared with those receiving health-education materials (Courneya et al., 2025).

There is an important detail here that should not be overlooked.

The intervention wasn’t simply:

“Here’s a brochure. Go exercise.”

It was structured exercise support.

There was coaching.

There was accountability.

There was progression.

There was human involvement.

That distinction should fundamentally change the conversation.

The CHALLENGE trial didn't simply demonstrate that people who exercise tend to have better outcomes. As a randomized controlled trial, it provided evidence that a structured exercise intervention itself can improve clinically meaningful cancer outcomes.

Now Washington Is Beginning to Pay Attention

The proposed Lainie Jones Comprehensive Cancer Survivorship Act of 2026 could move this conversation another significant step forward.

The legislation recognizes survivorship as extending from diagnosis throughout the remainder of a person’s life and proposes a broader infrastructure addressing quality of life and long-term survivorship.

Importantly for our profession, proposed survivorship quality-of-life programming includes helping survivors engage in moderate physical activity and other health-promoting activities.

Think about the significance of that.

For decades, exercise was often treated as something cancer patients might do after the “real” treatment was finished.

Now exercise is increasingly being discussed as part of survivorship itself.

For me, watching this evolution is extraordinarily personal.

I Saw This Problem in 1995

I am Andrea Leonard, President and Founder of the Cancer Exercise Training Institute, a 42-year cancer survivor, and a pioneer in oncology exercise.

I began pursuing this work in 1995.

At that time, oncology exercise was barely a field.

Cancer patients weren’t routinely being referred to specialized exercise professionals.

“Exercise oncology” wasn’t a phrase most fitness professionals had ever heard.

And comprehensive cancer survivorship programs incorporating individualized exercise were certainly not the norm.

But I saw something.

There was a missing piece between cancer medicine and conventional fitness.

Doctors were doing what they had been trained to do: treating cancer.

Physical therapists were rehabilitating patients with specific functional impairments.

But eventually many survivors left formal medical care and rehabilitation.

Then what?

Who helped them rebuild their strength?

Who understood the implications of their surgeries?

Who knew how chemotherapy, radiation and hormonal therapies might affect exercise?

Who understood lymph node removal, reconstruction, neuropathy, osteoporosis, fatigue, balance problems, cardiotoxicity and other treatment-related concerns?

Who helped them progress from rehabilitation to lifelong fitness?

Far too often, the answer was:

No one.

I believed we could change that.

They Didn’t Need Another Oncologist. They Needed a Bridge.

This distinction has guided my work for more than three decades.

Cancer Exercise Specialists were never intended to replace physicians.

Quite the opposite.

We were created because physicians shouldn’t have to do this job too.

The oncologist treats the cancer.

The rehabilitation professional addresses rehabilitation needs.

The registered dietitian provides individualized nutrition therapy when indicated.

The qualified Cancer Exercise Specialist helps translate medical information, treatment history, functional assessment and exercise science into safe, individualized exercise programming within their professional scope.

That is multidisciplinary cancer survivorship.

And it is the model I envisioned more than 30 years ago.

It Took More Than 30 Years for the World to Catch Up

There were plenty of times when this would have been easier to abandon.

But I didn’t.

I founded the Cancer Exercise Training Institute (CETI) in 2004 because I realized I could personally work with only so many cancer survivors.

If we wanted to change survivorship on a meaningful scale, we needed to educate other health and fitness professionals.

So that became my mission.

Today, CETI has trained nearly 20,000 health and fitness professionals in approximately 60 countries.

What began as one person’s conviction has become an international community of professionals committed to helping people living with and beyond cancer exercise safely and effectively.

And now something remarkable is happening.

The evidence is catching up.

Clinical guidelines are catching up.

Cancer survivorship is catching up.

Policy is beginning to catch up.

It took more than 30 years for the world to see what I saw in 1995.

But I never stopped seeing it.

And I never gave up.

The Comprehensive Cancer Survivorship Act Could Create an Unprecedented Opportunity

If the Comprehensive Cancer Survivorship Act advances and ultimately contributes to expanded survivorship services, community programs and health-promoting interventions, there may be an extraordinary opportunity for qualified oncology exercise professionals.

That does not mean the legislation automatically provides reimbursement for Cancer Exercise Specialists.

It does not make an OncoVie® Cancer Exercise Specialist a licensed health care provider.

And it does not guarantee that hospitals or cancer centers will begin hiring Cancer Exercise Specialists.

We must be careful not to promise something the legislation does not say.

What it does provide is something potentially very important:

Momentum.

The issues we have spent decades addressing are moving into the national survivorship conversation.

Physical activity.

Nutrition.

Quality of life.

Long-term health.

Community-based survivorship.

Health promotion.

Survivorship care planning.

These concepts are no longer sitting quietly outside the oncology clinic.

They are moving toward center stage.

OncoVie® Cancer Exercise Specialists: This Is Your Opportunity to Position Yourself

Do not wait until hospitals, physicians and survivorship programs suddenly begin looking for solutions.

Start building relationships now.

Meet the oncologists in your community.

Meet physical and occupational therapists.

Meet oncology nurse navigators.

Meet survivorship coordinators.

Meet oncology dietitians.

Introduce yourself to cancer centers, community cancer organizations, medical fitness facilities and survivorship programs.

But don’t walk into an oncology office claiming you know more than the doctor.

That is not the message.

Walk in saying:

“You shouldn’t have to do this alone.”

Explain that you understand your scope of practice.

Explain that you do not diagnose or treat cancer.

Explain that you don’t provide physical therapy.

Explain that you don’t provide medical nutrition therapy unless separately credentialed to do so.

Explain that your role is to provide cancer-specific exercise assessment, programming, progression and support while communicating appropriately with the survivor’s medical and rehabilitation team.

Then ask one incredibly important question:

“What happens to your patients when rehabilitation ends but they still aren’t ready for conventional fitness?”

That question may open more doors than any sales pitch ever could.

What Physicians Need Isn’t Competition. It’s Collaboration.

The future of cancer survivorship should not be:

Doctor versus dietitian versus therapist versus exercise professional.

It should be:

Oncologist + rehabilitation + nutrition + oncology exercise + psychosocial support + the survivor.

Every professional contributes something different.

The OpportunityThe BoundaryOncologists recommend and medically clear appropriate patients for exercise. They should not be expected to design individualized fitness programs. Cancer Exercise Specialists provide individualized exercise programming within scope. They do not diagnose or treat cancer. Registered dietitians provide individualized nutrition therapy. Cancer Exercise Specialists should not practice medical nutrition therapy without appropriate credentials. PTs and OTs provide skilled rehabilitation. Cancer Exercise Specialists can help provide a bridge into long-term exercise after appropriate rehabilitation. Survivorship programs coordinate long-term needs. No single professional can realistically address every survivorship need. Exercise professionals can become part of multidisciplinary survivorship. Specialized oncology education and professional collaboration are essential.

Maybe We’ve Been Asking the Wrong Question

For years, cancer survivors have asked:

“Why didn’t my doctor tell me this?”

Perhaps that’s the wrong question.

Maybe we should be asking:

“Why have we built a cancer care system in which we expect one physician to tell patients everything?”

Your oncologist should know your cancer.

Your oncologist should understand your treatment.

Your oncologist should identify medical concerns and coordinate appropriate care.

But your oncologist does not need to know how to correct your scapular mechanics after mastectomy.

They don’t need to design your resistance-training progression.

They don’t need to coach you through six months of behavior change.

They don’t need to analyze your squat.

And they certainly shouldn’t be expected to write your grocery list.

They need qualified professionals to whom they can confidently refer you.

That is the missing piece.

We Don’t Need Oncologists to Become Exercise Specialists

We need Cancer Exercise Specialists who are qualified to work alongside oncologists.

That difference matters.

It respects medicine.

It respects professional scope of practice.

It protects survivors.

And it creates the multidisciplinary model of survivorship care that cancer patients deserve.

I began working toward that model in 1995.

For more than 30 years, I have watched oncology exercise evolve from an idea few people understood into an international field supported by a rapidly expanding body of evidence.

I have watched nearly 20,000 professionals carry that vision into communities around the world.

And today, we are witnessing something I have waited decades to see:

The conversation is no longer about whether exercise belongs in cancer survivorship.

The question increasingly is:

How do we make sure every survivor has access to the right exercise, delivered at the right time, by the right professional?

That is a very different question.

And OncoVie® Cancer Exercise Specialists should be prepared to help answer it.

The World Is Finally Catching Up

Cancer treatment saved my life 42 years ago.

Cancer survivorship gave me my life’s work.

In 1995, I saw a gap between medicine and fitness that I believed someone needed to fill.

I could have waited for the medical system to create the solution.

I didn’t.

I could have stopped when people didn’t understand why cancer survivors needed specialized exercise programming.

I didn’t.

I could have decided the world wasn’t ready.

Instead, I spent more than three decades helping to get it ready.

Nearly 20,000 professionals. Approximately 60 countries. More than 30 years. One mission.

Help people living with and beyond cancer become stronger, healthier, more functional and more confident in their bodies.

Now the research, clinical guidelines and national survivorship conversation are moving in the same direction.

The world may finally be catching up with the vision.

And we are just getting started.

For decades, the dominant story of cancer has gone something like this: a carcinogen - cigarette smoke, UV radiation, a stray chemical - damages your DNA, a mutation takes hold, and a tumor slowly grows from that single corrupted cell. It’s a clean, linear story. Mutation causes cancer.

Siddhartha Mukherjee - the Columbia oncologist, Pulitzer Prize winner, and author of The Emperor of All Maladies (a must-read for anyone who wants to know the history of cancer and cancer treatments) has spent the last year telling a different, stranger story. And remarkably, over the course of 2025, three separate research teams independently published hard laboratory evidence that backs up exactly the mechanism he’s been describing: dormant cancer cells, sitting quietly in the body for years, being jolted awake by inflammation.

This isn’t just an author’s theory anymore. It’s now a documented phenomenon, published in Nature and PNAS, with a name, a mechanism, and - increasingly - a drug target

The Standard Model Might Be Backwards

In recent interviews about the newly updated edition of The Emperor of All Maladies, which adds four new chapters synthesizing fifteen years of cancer science since its 2010 publication, Mukherjee has described a model that inverts decades of cancer orthodoxy.

The old model: carcinogen → mutation → cancer.

The emerging model: mutation happens constantly, quietly, almost casually, throughout our lives - and most of the time, nothing comes of it. In discussing the new edition, Mukherjee has described discovering a whole class of carcinogens that don’t cause cancer by damaging DNA at all, but by changing the surrounding tissue environment - the “soil” - often by triggering inflammation, which then allows previously dormant cancer cells to start growing in that newly pro-malignant soil. [1]

That reframing leads to a genuinely eerie idea: tumors may not evolve fresh from a single exposure to a mutation-causing carcinogen at all. The cells may already be sitting inside us, dormant, as “sleeper” cells, waiting for the right inflammatory conditions to wake them up. [1]

That reframing leads to a genuinely eerie idea: tumors may not evolve fresh from a single exposure to a carcinogen at all. The original mutant cells may already be sitting inside us, dormant, as “sleeper” cells, waiting for a signal to wake up.¹

Meet the “Sleeper Cells”

This is the phrase that’s been generating headlines: sleeper cells. On a recent episode of The Oprah Podcast, Mukherjee discussed the possible reasons behind the rise of cancer in younger people - genetic factors, environmental triggers, chronic inflammation, and the “sleeper” cells that may lie dormant in the body until something activates them.²

The implication is unsettling precisely because it’s so different from the “bad luck exposure” narrative most of us carry around. It suggests many of us are walking around with pre-cancerous or mutant cells already present in our tissues - quiescent, invisible on any scan, biologically inert - and that the thing standing between us and disease isn’t the absence of mutation. It’s the absence of the right biological weather to wake those cells up.

2025: The Year the Lab Caught Up With the Theory

Here’s what makes this moment different from prior decades of cancer-inflammation speculation: in 2025, this stopped being an inference from population data and became something researchers could directly watch happen in living tissue.

The Colorado study - respiratory infections as a trigger. In July 2025, a team led by Dr. James DeGregori at the University of Colorado Anschutz Medical Campus published findings in Nature showing that common respiratory virus infections can awaken dormant disseminated cancer cells - cells that had broken away from an original tumor and traveled to other organs, then sat dormant for years or decades, sometimes long after the original tumor was already removed.³ Using mouse models of breast cancer, the researchers found that within three days of infection with influenza, the lungs showed a striking increase in the number of these dormant cancer cells, a rise that continued for two weeks and remained elevated even nine months after the initial infection, with similar effects seen after SARS-CoV-2 infection.⁴ Critically, the awakening depended on a specific inflammatory signaling molecule, IL-6.⁴

DeGregori described the underlying idea with a memorable image: dormant cancer cells behave like embers left over from a fire, and a respiratory virus acts like a gust of wind that fans them back into flame.⁵ The study also found that CD4+ T cells - ordinarily part of the immune system's defenses - actually helped sustain the newly awakened cancer cells by suppressing the immune response that would otherwise have cleared them.⁵

The Weinberg Lab study - inflammation as the direct wake-up call. Just weeks later, in September 2025, a team at MIT’s Whitehead Institute led by veteran cancer biologist Robert Weinberg published a parallel finding in PNAS. The group set out to determine what causes dormant cancer cells to erupt into a frenzy of growth and division months, years, or even decades after treatment - and found the answer wasn’t a spontaneous internal process, but a wake-up call from the inflamed tissue surrounding the cells.⁶ One identified trigger was even a chemotherapy drug itself, bleomycin, which can scar and thicken lung tissue and, in doing so, inflame it.⁶ As Weinberg summarized the finding: “The inflammation jolts the dormant cancer cells awake.”⁶

The underlying biology, reported in the paper itself, showed that dormant breast cancer cells lodged in the lungs normally sit in a highly mesenchymal, non-proliferative state, and that inflammation of the surrounding tissue microenvironment is what provokes the shift out of that dormancy - a shift the researchers link directly to the clinical relapses seen in patients whose primary tumors had been successfully treated months or even years earlier.⁷

The broader review - a mechanism finally coming into focus. Reviewing this emerging field, researchers Jeong-Seok Nam and So-Yeon Park noted that disseminated dormant cancer cells often enter dormancy specifically to evade attack by the immune system, and that once lodged in a new tissue, they can be reactivated by chronic inflammation - with therapies designed to block that reactivation now in active development as a way to prevent cancer recurrence.⁸

Together, these three 2025 papers give Mukherjee’s “sleeper cell” framing something it didn’t fully have before: a mechanism, a trigger molecule (IL-6), and a growing consensus among independent labs that chronic or acute inflammatory events - infection, chemotherapy-induced tissue damage, or long-term smoldering inflammation - are what convert dormancy into disease.

Not All Inflammation Is Created Equal

Mukherjee is emphatic, in his recent conversations, that he isn’t talking about inflammation in the vague wellness-industry sense - not “inflammation” as a catch-all boogeyman you fight with turmeric and green juice. He’s talking about a specific, mechanistically defined process, and the 2025 research bears that out: it isn’t inflammation in general that reactivates dormant cells, it’s specific signaling pathways like IL-6, triggered by specific events.

Discussing this on NPR’s On Point, Mukherjee was careful to draw the line: this is a very particular form of inflammation, not inflammation in general, and it’s closely tied to a specific immune cell type - the macrophage.⁹

He goes further on Sam Harris’s Making Sense podcast, introducing a term that may be his most consequential coinage since “the emperor of all maladies” itself: inflammogens - substances that trigger a particular form of chronic inflammation in which cancer cells thrive, in the same way that mutagens like radiation or tobacco smoke damage DNA.¹⁰ The framing extends his earlier work: mutagens damage the cell itself, while inflammogens create the surrounding soil in which damaged or dormant cells can germinate into disease.

Why This Could Change How We Screen for Cancer - and Who Gets Sick After Recovery

The practical payoff of this model, per Mukherjee, isn’t just theoretical. If researchers could find a reliable measure of this particular kind of chronic inflammation, it could function as a biomarker for future cancer risk - a blood test, potentially, that flags danger before a tumor is large enough to find on imaging, in the same way scientists eventually devised tests to detect known mutagens.¹⁰

The 2025 lab findings sharpen this further, and raise a genuinely new clinical question: should cancer survivors be more cautious about respiratory infections than the general population, given that a 2025 Nature study found infections like influenza and COVID-19 can trigger dormant cancer cells to awaken in mice, potentially raising the risk of recurrence and metastasis?¹¹ Researchers are now exploring therapies that specifically target IL-6 signaling and related immune pathways, with longer-term human studies needed to determine whether vaccines, antivirals, or immune-based treatments could reduce the danger of dormant cells reawakening.⁵

Oprah’s Interview: Putting Faces on the Statistic

The sleeper-cell theory has gotten its widest audience yet through The Oprah Podcast, framed around a question that’s been quietly alarming oncologists for years: why is cancer on the rise among younger people? Oprah Winfrey sat down with Mukherjee specifically to explore that question, discussing the new edition of his book and what has changed in the science of cancer over the last fifteen years - with Mukherjee walking through possible explanations including genetic factors, environmental triggers, chronic inflammation, and dormant “sleeper” cells.²

What makes the episode land differently than a standard science interview is who else was in the room. Joining the conversation were actress and breast cancer survivor Olivia Munn; Simone Ledward Boseman, wife of the late actor Chadwick Boseman, who died of colon cancer at 43; and a 28-year-old woman from Texas who battled stage 4 endometrial cancer after years of dismissed symptoms.² Pairing Mukherjee’s mechanistic explanation - mutation plus inflammatory trigger - with real people whose early-onset cancers were initially missed or minimized by the medical system gives the “sleeper cell” idea a different kind of weight: it’s not just a theory about biology, it’s a possible explanation for why doctors are seeing tumors in patients whose age alone used to put them off the radar for screening.

It's also worth noting Mukherjee has pushed back, elsewhere, on any single tidy explanation for the youth-cancer trend. In a separate conversation on the Boston Globe's Say More podcast, he cautioned that a meaningful share of the cancers now being diagnosed in young people are showing up because of better diagnostics, not necessarily because more young people are actually developing cancer.¹² That's a reminder that improved detection and the sleeper-cell/inflammation mechanism are likely working together, not as competing explanations, and that untangling how much of the apparent "rise" is truly biological versus a byproduct of catching cancer earlier and more often remains an open, actively contested question.

A Broader Body of Work

It’s worth situating Mukherjee’s framing within his career. He is a hematologist and oncologist whose lab at Columbia studies the biology of blood development, particularly malignant and pre-malignant blood diseases like myelodysplasia (MDS) and acute myeloid leukemia (AML), with the eventual goal of developing new drugs against them.¹³ This isn’t a science writer speculating from the sidelines - it’s a working cancer researcher whose day job involves exactly the kind of pre-malignant cell states (”sleeper cells,” essentially) that MDS represents, watching cells sit on the edge of becoming leukemia for years before something tips them over.

He’s also been closely tracking the evolving scientific definition of what cancer is, mechanistically. As covered in his conversation on On Point, the classic “six hallmarks of cancer” framework - autonomous proliferation, insensitivity to growth-inhibitory signals, and so on - has expanded to include newer hallmarks: cancer cells reprogramming their energy metabolism, evading immune detection and destruction, and possessing genomes that remain unstable and continually mutating.⁴ Chronic inflammation intersects with several of these - a smoldering inflammatory environment doesn’t just wake sleeper cells, it can help those awakened cells evade the immune system that would otherwise mop them up, exactly as the Colorado team found with CD4+ T cells shielding reactivated cells rather than destroying them.⁵

What This Means for You (Not Just Cancer Patients)

You don’t need a mutation lurking in your tissue to care about this. The chronic inflammation Mukherjee describes, and that the 2025 studies mechanistically confirm, is downstream of extremely ordinary, extremely modifiable things:

• Visceral fat and metabolic dysfunction

• Poor sleep and chronic stress

• Ultra-processed diets low in fiber and high in refined sugar

• Sedentary behavior

• Respiratory infections and other acute inflammatory triggers

• Environmental exposures we haven’t yet identified as “inflammogens” - the way we once didn’t know asbestos was dangerous

The unifying message across Mukherjee’s recent interviews, now reinforced by direct laboratory evidence, isn’t fatalism about the mutations - or the dormant cells - we may already be quietly carrying. It’s the opposite: it reframes chronic inflammation as a genuinely modifiable lever sitting between “dormant risk” and “active disease.” You may not be able to erase a mutation. You may have real leverage over the inflammatory soil it grows in.

That reframing - from “prevent the mutation” to “starve the soil” - may end up being one of the more practically important ideas to come out of cancer research in years.

Become a Paid Subscriber: Get Your Personal Inflammation Action Plan

Here’s the honest pitch. Everything above is the science - real, cited, current through 2025. But knowing that chronic inflammation can wake a dormant cancer cell doesn’t do you any good if you don’t know what to actually do with that information. That’s the gap paid subscribers get access to.

For the price of a coffee a month, you get:

• A ranked, evidence-graded action plan - not a generic “eat healthy, sleep well” list, but the six specific levers worth your effort, ordered by how strong the evidence actually is, including the one genuinely new, specific recommendation to come out of the 2025 research that almost nobody is talking about yet.

• A myth-busting section built to save you money - what this research does not support, so you stop wondering whether you need to buy the supplement your algorithm keeps showing you.

• A downloadable, printable Word document - “The Inflammation Action Plan” - formatted as a one-page reference you can keep on your fridge, share with your doctor, or revisit anytime. It’s yours to keep, no matter what.

• Gut Fix 7-Day Meal Plan PDF Download

• The Top 5 Anti-inflammatory Foods PDF Download

• Every future deep dive, the moment new research drops - this is a fast-moving field, and paid subscribers get the analysis before it’s old news.

References

1. Lichtman, F. "'A Many-Headed Beast': Telling The Story Of Cancer." Interview with Siddhartha Mukherjee. Science Friday, November 21, 2025.

2. “The Oprah Podcast.” Apple Podcasts, 2026.

3. “Respiratory viruses may trigger dormant cancers.” NIH Research Matters, National Institutes of Health, August 19, 2025.

4. “Siddhartha Mukherjee on understanding cancer now.” On Point, WBUR, December 16, 2025.

5. “Making Sense #485: w/ Siddhartha Mukherjee – The New Science of Cancer” (Transcript). The Singju Post, 2026.

6. “Dormant cancers can be reawakened by flu, COVID: Study.” LiveNOW from FOX, August 20, 2025.

7. “The force awakens: metastatic dormant cancer cells.” Experimental & Molecular Medicine (Nature Portfolio).

8. “Dormant cancers can be reawakened by flu, COVID: Study.” FOX 4 Dallas-Fort Worth, August 20, 2025.

9. Zhang, J., et al. “Inflammation awakens dormant cancer cells by modulating the epithelial–mesenchymal phenotypic state.” Proceedings of the National Academy of Sciences (PNAS), Vol. 122, No. 36, September 9, 2025.

10. Chia, S.B., Johnson, B.J., Hu, J. et al. Respiratory viral infections awaken metastatic breast cancer cells in lungs. Nature 645, 496–506 (2025). https://doi.org/10.1038/s41586-025-09332-0

11. Zia, S. “Inflammation jolts ‘sleeping’ cancer cells awake, enabling them to multiply again.” Whitehead Institute, MIT Department of Biology, September 3, 2025.

12. Leung, S. “The C-Word: Dr. Siddhartha Mukherjee wrote the book on cancer.” Say More, The Boston Globe, May 8, 2025.

13. “Siddhartha Mukherjee, MD.” Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center.

    ---

Read more

For decades, “cancer prevention” meant the same handful of blanket rules: don’t smoke, wear sunscreen, get your mammogram at 40, your colonoscopy at 45. Good advice, but generic - the same recommendation whether you were high-risk or low-risk, whether your biology looked like your neighbor’s or nothing like it at all.

That’s changing fast, and it’s arguably the hottest topic in oncology right now: precision prevention - using an individual’s genetics, biology, and AI-powered risk modeling to figure out who needs what intervention, and when, instead of handing everyone the same pamphlet.

Why This Moment, Specifically

A few things are converging at once:

It’s estimated that a huge share of cancer is preventable in principle. Cancer Research UK researchers now put the number at roughly 40% of cancers being preventable - but that potential has been chronically underused, in part because prevention efforts haven’t been targeted well enough to reach the people who’d benefit most.

Meanwhile, at this year’s ASCO Annual Meeting, researchers presenting on the global burden of cancer made the case bluntly: primary prevention remains dramatically underutilized relative to how much impact it could have - even though we’ve had decades of evidence about what works.

A third thread is reshaping the conversation entirely: GLP-1 drugs. Research presented at ASCO 2026 found that people taking GLP-1 medications like semaglutide saw meaningfully lower rates of several obesity-related cancers - in one study, close to 70% lower risk among men - and separate research found that patients already diagnosed with cancer who started a GLP-1 after diagnosis were significantly less likely to have their disease progress to stage 4, with the biggest drops seen in lung and breast cancer. Researchers stress the evidence is still correlational, not proof of cause and effect, but the fact that a drug already taken by millions of people for diabetes and weight loss might also be quietly lowering cancer risk has turned this into one of oncology's most closely watched storylines this year.

A fourth thread: multi-cancer blood tests are quietly crossing from research into real clinical use. This year alone brought UnitedHealth's decision to cover Guardant Health's blood-based colorectal screening test for over 40 million Americans, a new AI-powered multi-cancer early detection test from Caris Life Sciences, and updated NCCN guidelines recommending blood-based monitoring for bladder cancer recurrence. Screening is starting to mean a blood draw, not just an invasive procedure - which changes who's willing to get screened at all.

The missing piece, increasingly, is precision. And that’s where AI comes in.

AI is Rewiring How We Calculate Risk

Traditional cancer risk assessment leaned on a short list of variables - age, family history, a handful of lifestyle factors. It was a blunt instrument. AI models can now digest enormous, messy, multidimensional datasets - genomic markers, imaging, bloodwork, environmental exposure history - and surface risk patterns that a human reviewing a checklist would simply miss.

The payoff isn’t just a more accurate number. It’s actionability. These models are being used to identify which specific people should get earlier screening, which should be considered for chemoprevention, and which are fine to stay on a standard schedule - instead of pushing everyone toward the same intervention regardless of actual risk.

This is exactly the theme that’s anchoring 2026’s biggest prevention conference - the joint American Cancer Society / Cancer Research UK Cancer Prevention Research Conference - which is built around bridging “discovery biology” (the science of why cancer starts) with real-world implementation, including AI risk prediction and the clinical implications of subtler biological signals like clonal hematopoiesis of indeterminate potential (CHIP), a blood condition that can quietly raise cancer risk years before diagnosis.

The “Upstream” Reframe

There’s a philosophical shift happening alongside the technical one. AACR’s Chief Scientific Advisor William Hait has been framing it around a question he heard constantly from patients over 30 years of oncology practice: “I didn’t smoke, I didn’t drink, no one in my family has cancer. What could I have done to prevent this?”

His answer, in effect, is that the field needs to move upstream - understanding causation and biological drivers well enough to intervene before a tumor forms, not just catch it early. That’s a meaningfully different ambition than “screen more” - it’s about interception: identifying and neutralizing precancerous biology itself.

Where The Friction Is

None of this is frictionless. Precision prevention needs data infrastructure, equitable access to genetic testing and novel biomarkers, and health systems willing to pay for prevention the way they pay for treatment - which, historically, they haven’t. Cancer Research UK’s own reporting on this frames it as real scientific momentum running into real structural barriers: promising science that isn’t yet matched by policy or funding incentives built for a prevention-first model.

There’s also a global equity dimension that’s easy to miss if you’re only reading US or UK coverage: a large share of the world’s preventable cancer burden sits in regions - much of Africa, for instance - where the basic infrastructure for prevention (HPV vaccination coverage, screening access, treatment of precancerous lesions) is still the binding constraint, long before anyone gets to AI-driven personalization. Precision prevention is exciting, but it can’t be the whole strategy while foundational prevention tools remain out of reach for millions of people.

The Takeaway

Cancer prevention is having a genuine inflection moment: the field is shifting from “everyone follow the same generic checklist” to “here’s your specific risk profile, and here’s what it means for you.” That’s a real, substantive change - but it will only deliver on its promise if the underlying infrastructure, funding priorities, and global access issues get solved alongside the science.

If there’s one thing to watch this year, it’s whether “prevention” starts getting funded and reimbursed the way “treatment” already is. The science is arguably ready before the system is.

Survivorship Isn’t the Finish Line - It’s a New Starting Point

If you’ve been following along here, you know I’ve been writing about the shift toward precision prevention - the idea that cancer prevention shouldn’t be one generic checklist handed to everyone. That same principle applies just as powerfully on the other side of a diagnosis: survivorship. That’s why I’ve decided to open something up personally: the Individualized Survivorship Plan.

A Little About Me

I’m Andrea Leonard, President and Founder of the Cancer Exercise Training Institute (CETI). I’m not a wellness influencer who discovered oncology exercise last year - I’m a 42-year cancer survivor myself, diagnosed with thyroid cancer at eighteen. I’ve also walked the caregiver path: I lost my father to cancer, and I’m currently supporting my mother through metastatic breast cancer. Over the past three decades, I’ve built the clinical frameworks that now define oncology exercise as a field, trained more than 20,000 Cancer Exercise Specialists in 60 countries, and written 21 books on cancer and exercise, including Essential Exercises for Breast Cancer Survivors, developed with a medical advisory team from Georgetown, GW, and Johns Hopkins.

I stopped taking individual clients years ago. This program is me stepping back in - personally, one-on-one.

What I’ve Built Into This Program

Here’s the thinking behind it: genetics matter, but a lot of what drives long-term health after cancer comes down to things you can influence - oxidative stress, environmental toxin exposure, nutrition, movement, sleep, and stress. I built the plan around that idea, and it includes:

• A step-by-step integrative care plan tailored to your specific treatment history and goals

• A practical guide to non-toxic household, beauty, and personal care products

• A personalized coaching session focused on goal-setting and mental well-being

• A full fitness assessment and health history review

• A custom 2-month exercise program addressing both current treatment side effects and future disease risk (things like lymphedema, osteoporosis, cardiovascular disease, and second cancers)

I keep coming back to a stat that grounds all of this for me: Harvard’s School of Public Health estimates that up to 75% of American cancer deaths are preventable - which is exactly why I don’t treat survivorship as “you’re done, go live your life.” I treat it as an active, ongoing risk-reduction strategy.

Why I’m Doing This Now

Cancer care has gotten remarkably good at treatment. It’s historically been much weaker at what happens after - helping people rebuild strength, manage lingering side effects, and actually lower their risk of recurrence or a second cancer. To me, individualized survivorship planning is the natural extension of everything the precision-prevention movement is pushing toward: less generic advice, more plans built around the actual person in front of me.

If you’re a survivor, or supporting one, I’d love for you to take a look:

👉 Individualized Survivorship Plan with Andrea Leonard

(This is a paid 1:1 program I run personally - $999, or three payments of $350/month.)

You Don’t Need $999 to Start Taking Your Recovery Seriously

I’ve had a few of you reach out since I shared my Individualized Survivorship Plan, and the message has been some version of the same thing: I want this, I need this, and I just can’t afford it right now.

I hear you. Cancer already drains people financially before you even get to the “now what” part of recovery. So I want to make sure cost is never the reason someone walks away from taking care of themselves after treatment. Here’s what I’m putting together, free, for anyone who needs it.

The Free Survivorship Starter Guide

I’ve pulled together the core, foundational pieces of what I teach in the full program - the parts that don’t require a personalized assessment to start using today. This includes:

• My “10 Commandments of Cancer Prevention” - the same evidence-based fundamentals I built my entire career around: avoiding tobacco, eating well, exercising regularly, staying lean, moderating alcohol, avoiding unnecessary radiation and known environmental carcinogens, addressing infections linked to cancer, prioritizing sleep, and getting enough vitamin D.

• A basic non-toxic living checklist - simple, low-cost swaps for household, beauty, and personal care products, so you’re not left guessing at a store shelf.

• A gentle starter exercise sequence - safe movement basics appropriate for people recovering from treatment, designed to rebuild strength without overwhelming a compromised body.

• A simple daily tracker - for sleep, movement, and how you’re feeling, so you can start noticing your own patterns even without a formal assessment.

None of this replaces a personalized plan built around your specific diagnosis, treatment history, and goals - that’s what the full program is for. But it’s real, usable guidance, and it’s yours at no cost.

Why I’m doing this

I’ve spent more than three decades in this field, and I’ve never believed good information should be locked behind a price tag. The paid program exists because personalized, one-on-one work with me takes real time. But the foundational knowledge - the things that move the needle most for most people - shouldn’t be out of reach for anyone.

FREE Survivorship Guide Download

Beginning Exercise Program for Cancer Survivors Video

REFRENCES:

• Cancer Research UK – “Unlocking a new era for cancer prevention research,” June 2, 2026
  https://news.cancerresearchuk.org/2026/06/02/unlocking-a-new-era-for-cancer-prevention-research/
  (Source for the “~40% of cancers are preventable” figure and the precision-prevention/policy-barriers framing.)

• AACR Blog – “Experts Forecast Cancer Research and Treatment Advances in 2026,” Jan 8, 2026
  https://www.aacr.org/blog/2026/01/08/experts-forecast-cancer-research-and-treatment-advances-in-2026/
  (Source for William Hait’s “upstream”/interception framing and the patient quote about prevention.)

• PubMed – “Global Cancer Prevention: Current Approaches and Future Directions,” derived from 2026 ASCO Annual Meeting Education Session
  https://pubmed.ncbi.nlm.nih.gov/42190157/
  (Source for the point about primary prevention being underutilized, and the global/Africa equity angle on HPV vaccination and screening access.)

• OncoDaily – Cancer Prevention Research Conference 2026 (ACS + Cancer Research UK), June 3–5, Atlanta
  https://oncodaily.com/event/cancer-prevention-458926
  (Source for the conference details, AI risk prediction focus, and CHIP as a research frontier.)

If you spend any time in longevity circles, you’ve encountered the NAD+ conversation. And increasingly, you’re hearing about a strange, previously ignored saturated fatty acid called C15:0. The supplement world is awash with hype, so this post cuts through the noise and examines what peer-reviewed science actually says about TruNiagen (a clinically studied form of nicotinamide riboside, or NR) and Fatty15 (a pure C15:0 supplement) - and why the combination, while not yet directly tested in a clinical trial, has a compelling mechanistic rationale.

A few caveats upfront: this is not medical advice, and the science on both compounds is still maturing. But the evidence base for each is unusually strong by supplement standards, and the potential synergies are worth understanding.

Part I: The NAD+ Crisis in Your Cells

What Is NAD+, and Why Does It Decline?

Nicotinamide adenine dinucleotide (NAD+) is arguably the most important coenzyme in your body. It sits at the crossroads of energy metabolism, DNA repair, and longevity signaling - serving as a co-substrate for enzymes including the sirtuins (SIRT1–7) and poly-ADP-ribose polymerases (PARPs), both of which are critical regulators of cellular health and stress response.

The problem is that NAD+ levels fall dramatically with age. By some estimates, blood NAD+ in a 60-year-old is roughly half what it was at 20 [1]. This decline has been directly implicated in the hallmarks of aging - impaired mitochondrial function, accumulating DNA damage, dysregulated inflammation, and cellular senescence [2]. Age-associated NAD+ depletion has been specifically linked to metabolic, cardiovascular, and neurodegenerative disorders [1].

The sirtuin connection is especially important. Sirtuins are NAD+-dependent enzymes that regulate everything from gene expression and metabolic homeostasis to inflammation suppression. When NAD+ drops, sirtuin activity falls with it, leading to impaired regulatory control over inflammation and deficient DNA repair responses [10]. Restoring NAD+ is therefore not a narrow biochemical intervention — it’s an attempt to re-engage some of the body’s core aging-defense systems.

Enter Nicotinamide Riboside (NR)

NR is a form of vitamin B3 that serves as a direct precursor to NAD+. Unlike niacin (which causes flushing) or nicotinamide (which can inhibit sirtuins at high doses), NR has a favorable safety and tolerability profile at doses up to 2,000 mg/day in humans.

TruNiagen is ChromaDex’s trademarked NR product (NIAGEN), and it is the most clinically studied commercial NR formulation available. In an 8-week, randomized, double-blind, placebo-controlled trial, NR supplementation at doses of 100, 300, and 1,000 mg dose-dependently and significantly increased whole blood NAD+ levels by 22%, 51%, and 142% respectively, with increases maintained throughout the study - and with no reports of flushing and no significant adverse events [3].

Part II: What TruNiagen Actually Does in Humans

Muscle Mitochondria and Biogenesis

One of the more rigorous NR trials to date examined 20 BMI-discordant monozygotic twin pairs supplemented with escalating doses of NR (250 to 1,000 mg/day) for five months [28]. This design elegantly controls for genetic variation. Results showed that NR improved systemic NAD+ metabolism, increased muscle mitochondrial number (mitochondria became roughly 14% more abundant in type I muscle fibers [30]), improved myoblast differentiation, and favorably altered gut microbiota composition -in both the leaner and heavier co-twins. NR also modulated epigenetic control of gene expression in muscle and adipose tissue. Body composition and standard metabolic markers did not improve, reinforcing the idea that NR’s primary benefits are in the realm of cellular and mitochondrial health rather than rapid metabolic rescue.

Walking Distance in Peripheral Artery Disease

A randomized, double-blind clinical trial published in Nature Communications enrolled 90 people with peripheral artery disease (PAD) - a population with significant mitochondrial dysfunction in skeletal muscle [32]. After six months of NR supplementation, participants improved their 6-minute walk distance by +7.0 meters compared to −10.6 meters in the placebo group. Among those who took at least 75% of their pills, the improvement was 31.0 meters. This is a clinically meaningful functional outcome in a high-risk aging population, and it aligns with the known mechanisms: NAD+ activating SIRT1, improving mitochondrial activity, and enhancing nitric-oxide-mediated endothelial function.

Cognition and Neurodegeneration

A 2025 crossover, double-blind, randomized placebo-controlled trial conducted at Massachusetts General Hospital tested NR (TruNiagen, 1 g/day) for 8 weeks in older adults with subjective cognitive decline and mild cognitive impairment [1]. The trial examined both cognitive performance and plasma Alzheimer’s disease biomarkers - establishing NR as a candidate therapeutic avenue against neurodegenerative pathologies in aging populations, where NAD+ depletion plays an established mechanistic role.

Accelerated Aging Syndromes

Perhaps the most striking recent NR trial came from Chiba University, Japan, published in Aging Cell in June 2025 [5]. Researchers conducted the world’s first rigorous clinical trial of NR in patients with Werner syndrome - a rare hereditary progeroid (accelerated aging) syndrome causing early mortality. The results showed NR improved arterial stiffness (cardio-ankle vascular index) and reduced skin ulcer area, with a trend toward mitigating heel pad thinning. This landmark trial is significant not just for Werner syndrome but as a proof-of-concept for NAD+ restoration in accelerated biological aging.

Inflammation: The SIRT2 Connection

A 2025 study published in Aging Cell from UC Berkeley demonstrated that SIRT2, an NAD+-dependent deacetylase, suppresses multiple immune pathways that become activated during aging [11]. Boosting NAD+ via supplementation reactivates SIRT2-mediated suppression of aging-associated inflammation - across multiple immune pathways simultaneously. This makes NAD+ restoration an unusually broad anti-inflammatory strategy, not targeted at a single cytokine but at the upstream regulatory machinery.

You’ve reached the subscriber section

This article continues with the parts that matter most.

The free section covered the biology. What’s behind the paywall is where it gets practical - the combination rationale, exact dosing protocols, timing guidance, who actually benefits, and an honest breakdown of what the science still can’t tell us.

✓ Why C15:0 and NR may work better together - the mechanism explained ✓ Exact doses, timing, and how to take both supplements correctly ✓ Who benefits most - and who should wait for more evidence ✓ An honest verdict on the gaps - what the science can’t yet confirm

Read more

The packaging changes. The promise never does: lose weight fast, feel amazing, transform your body - with this one simple thing.

And every time, millions of people try it. Many lose a few pounds in the first week or two. They feel hopeful. They post about it. Then, quietly, the weight comes back - and usually brings a little more with it.

This is not a failure of willpower. It is a failure of design. Fad diets are engineered - sometimes intentionally, sometimes accidentally - to feel like they’re working. Understanding why they feel real is the first step to breaking free from the cycle.

What Is a Fad Diet, Exactly?

The term “fad diet” sounds dismissive, but it has a fairly precise scientific meaning. Researchers characterize fad diets by a specific set of features that distinguish them from legitimate nutritional approaches.

They promise rapid weight loss. They promote short-term changes rather than lifelong habits. They focus obsessively on one food or eliminate an entire food group. They lack long-term scientific evidence. They cannot realistically be maintained for life. And critically - they often fail to include health warnings for people with existing medical conditions.

Notice what that definition does not say: it doesn’t say fad diets never produce any results. Many of them do - initially. That initial result is actually the core of the problem.

The Placebo Effect of Early Weight Loss

Here is something the wellness industry does not want you to understand: almost any significant dietary change will cause short-term weight loss. This is not because the diet is working. It is because of three almost universal mechanisms.

Water weight. Most fad diets restrict carbohydrates to some degree, or significantly reduce overall caloric intake. When your body has less glycogen stored in the liver and muscles, it also retains less water - roughly 3 grams of water per gram of glycogen. The result: you can lose 3–5 pounds in the first week of almost any diet, purely from fluid. This feels dramatic. It registers on the scale. It is completely unrelated to fat loss.

The novelty effect. New rules create new awareness. When you’re following a specific protocol - counting macros, eliminating sugar, eating only before noon - you become more conscious of what you consume. That awareness alone tends to reduce mindless eating and caloric intake. But it fades. Studies consistently show that dietary compliance drops significantly after the first 3-6 months, regardless of which diet is followed.

Caloric restriction by proxy. Most fad diets work, to whatever extent they do, by creating a caloric deficit through indirect means. Keto works partly because fat and protein are more satiating per calorie. Intermittent fasting works partly because eating windows compress the number of meals. The gelatin trick works, if at all, because consuming protein before a meal slightly reduces how much you eat at that meal. The mechanism is almost always: eat fewer calories without realizing you’re eating fewer calories. This is useful to know - because it means the “magic” of the specific diet is usually incidental.

The Gelatin Trick: A Case Study in Viral Nutrition

The “bariatric gelatin” trend is a perfect recent example of how modest science gets transformed into miraculous marketing.

The actual mechanism is straightforward: unflavored gelatin consumed before a meal absorbs water, forms a gel in the stomach, and creates a sense of fullness that may mildly reduce how much you eat at that meal. It provides about 6 grams of protein per tablespoon. That protein, like any pre-meal protein, may stimulate modest GLP-1 release — the same satiety hormone targeted by drugs like Ozempic, a comparison that gets amplified enormously in the marketing of these trends.

What the science actually shows is considerably less exciting. Studies do find that people who consume gelatin-based meals feel slightly more satisfied and eat modestly fewer calories at their next meal. Registered dietitians confirm the basic mechanism: gelatin expands in your stomach, so you feel fuller sooner. But when researchers followed participants on gelatin-enriched diets for four months and compared them to those eating equivalent protein from other sources, the results were nearly identical. No extra fat loss. No metabolic boost. No meaningful difference.

The “lose a ton of weight” framing is marketing. The actual effect, deployed consistently and combined with a caloric deficit, might contribute to gradual weight loss of around 1-3 pounds per month - the same rate you would get from any modest dietary improvement.

This pattern - real but modest mechanism, wildly overstated promise - runs through virtually every fad diet on the market.

A Taxonomy of Fad Diets and Their Tricks

The Ketogenic Diet

The promise: Eat fat, burn fat, lose weight effortlessly by putting your body in a state of ketosis.

The real mechanism: Keto works primarily through appetite suppression and caloric restriction. High fat and protein intake is satiating, so people naturally eat fewer calories. There is also a legitimate initial water weight loss as glycogen stores are depleted.

What science actually finds: Keto can produce meaningful short-term weight loss, and some people do maintain it long-term. But the diet was originally developed as a medical intervention to control epileptic seizures - not as a lifestyle weight loss tool. Long-term adherence rates are poor. Most people regain weight when they return to normal eating. Health risks associated with prolonged keto include potential strain on kidney function, elevated LDL cholesterol in susceptible individuals, reduced fiber intake, and gaps in several key micronutrients.

The trick: Initial results are real and often dramatic, driven by water loss and genuine caloric restriction. People attribute those results to the state of ketosis itself rather than the underlying deficit - which makes them reluctant to consider that any dietary change producing the same deficit would achieve comparable results.

Intermittent Fasting

The promise: Eat within a restricted window, fast for the rest of the day, and your body’s metabolic machinery will do the work for you.

The real mechanism: For most people, intermittent fasting works by compressing the eating window, which reduces total daily caloric intake. There is some evidence of modest metabolic benefits beyond simple restriction, but these effects are small and inconsistent across studies.

What science actually finds: Intermittent fasting is a legitimate dietary approach with real evidence behind it. A major study in the New England Journal of Medicine found that time-restricted eating produced weight loss essentially equivalent to continuous caloric restriction - the timing itself was not the magical variable. It works for some people because it simplifies food decisions and reduces mindless snacking. It does not work meaningfully better than other approaches that achieve the same caloric deficit.

The trick: It feels like a clever hack - you are not counting calories, you are just watching the clock. That simplicity makes early compliance easier and produces results that feel attributable to the method’s cleverness rather than its basic underlying mechanism.

Juice Cleanses and Detox Diets

The promise: Flood your body with nutrients, flush out toxins, reset your digestive system, and emerge lighter and healthier.

The real mechanism: Weight loss from juice cleanses is almost entirely water weight and the consequence of severe caloric restriction. Your liver, kidneys, and lymphatic system continuously filter waste products whether you juice or not. The concept of “detoxing” with food has no scientific basis. No specific toxins are identified, no mechanism by which juice removes them exists in the literature, and no evidence supports the idea that “cleansing” produces lasting metabolic benefit.

What science actually finds: No convincing clinical evidence supports detox diets. Nutritional inadequacy is a significant concern - most cleanses are deficient in protein, essential fatty acids, and several micronutrients. What they do provide is a powerful psychological experience of having done something significant and restorative.

The trick: They work on narrative and ritual. The preparation, the commitment, the discomfort, the completion - it creates a compelling story of transformation. The psychological experience is real. The physiological mechanism largely is not.

The Carnivore Diet

The promise: Eliminate all plant foods, eat only meat and animal products, and experience dramatic weight loss, reduced inflammation, and improved mental clarity.

The real mechanism: Extreme restriction of food choices naturally reduces caloric intake. The high protein and fat content is satiating. Some people report improved symptoms of certain autoimmune or digestive conditions, though the mechanisms are not well understood.

What science actually finds: The carnivore diet is one of the least studied major dietary trends, with essentially no long-term randomized controlled trials in humans. The elimination of all fiber and plant foods raises serious concerns about gut microbiome diversity, colorectal cancer risk, cardiovascular health, and micronutrient deficiency. High red meat consumption is an established risk factor for certain cancers. The consequences of long-term adherence may take years or decades to fully emerge.

The trick: Rapid early weight loss combined with anecdotal reports of improved wellbeing - partly driven by the elimination of ultra-processed foods and refined carbohydrates that most people were consuming - generates powerful testimonials that spread on social media. The absence of long-term data means no one can definitively quantify the full cost yet.

The Exception Worth Knowing About: The Fasting Mimicking Diet

I want to be direct here: not everything in the space of alternative nutrition belongs in the same category as juice cleanses and the gelatin trick. One intervention I have done myself, experienced meaningful results from, and feel confident discussing with readers is the Fasting Mimicking Diet - and it deserves to be understood entirely on its own terms.

The FMD was developed by Dr. Valter Longo, a gerontologist and director of the Longevity Institute at USC’s Leonard Davis School. It works on a fundamentally different principle than weight-loss fad diets. The primary goal is not to lose weight. It is to activate autophagy - the body’s built-in cellular repair and renewal system.

Autophagy is the process by which cells identify and break down damaged or dysfunctional components, recycling them into usable energy and raw materials. It is not a wellness buzzword. Its fundamental importance to human biology was recognized with the 2016 Nobel Prize in Physiology or Medicine. Our biology evolved this mechanism during periods of food scarcity; in the face of famine, autophagy helped organisms not just survive but emerge with repaired, more resilient cells.

Until very recently, autophagy had only been directly measured in animal models. In December 2025, a landmark pilot clinical trial - the first of its kind in nutrition science - published data showing that the five-day FMD was directly associated with measurable increases in autophagic flux in human participants, alongside significant improvements in key metabolic health markers. The study was led by scientists at Cedars-Sinai Medical Center and UT Health San Antonio. Critically, the cellular effects persisted beyond the fasting window itself - meaning the protocol continued working after participants returned to normal eating.

This is not a peripheral finding. Multiple randomized clinical studies now consistently show that FMD cycles reverse insulin resistance, promote regression of pre-diabetes markers, and result in reduced reliance on diabetes and hypertension medications - through mechanisms that are not simply correlated with weight loss. A 2024 study in Nature Communications found that three cycles of the FMD were associated with a reduction of 2.5 years in median biological age, independent of how much weight participants lost.

The protocol itself is a five-day period of low-calorie, low-protein, high-unsaturated-fat eating - designed to mimic the metabolic state of a water-only fast while still providing enough nutrition to be completed safely and without the extreme difficulty of true fasting. It is typically done periodically - once every one to three months - rather than continuously, which means it does not ask you to permanently restructure your entire relationship with food.

What distinguishes the FMD from every other intervention discussed in this article is precisely this: it is not a weight loss trick. It is a periodic, science-backed intervention designed to trigger the body’s own regenerative machinery. Weight loss, when it occurs, is a secondary effect and not the point.

A few important caveats. The FMD is not appropriate for everyone. People with certain medical conditions, those who are underweight, those who are pregnant or breastfeeding, and those with a history of eating disorders should consult a physician before attempting it. And while the science is genuinely compelling, it is still developing - the human trial data, while promising, remains early-stage relative to the decades of animal research behind it.

For healthy adults interested in longevity science and cellular health rather than rapid weight loss, the FMD is the one intervention in this space I return to personally and discuss with confidence.

Why We Keep Falling For It: The Psychology

Understanding the psychology of fad diet susceptibility is not about intelligence. Highly educated, scientifically literate people follow fad diets. The mechanisms that make us vulnerable are deeply human.

Hope is a powerful motivator. When you are carrying weight that affects your health, energy, and self-image, the offer of a solution - even an implausible one - activates real neurological hope circuitry. Motivated reasoning makes us generous in evaluating evidence that supports what we want to believe.

Short-term results anchor beliefs. Because almost any significant dietary change produces early weight loss, we attribute that loss to the specific diet’s mechanism. The logic feels airtight: I lost eight pounds in two weeks on keto, therefore keto works, therefore I should continue - even as subsequent losses slow dramatically and the initial loss proves to be largely water.

Social proof compounds quickly. Social media algorithms amplify success stories and suppress failures. People who regain weight typically do not post about it. The result is a profoundly skewed information environment where fad diets appear to work constantly and universally, because the failures are invisible.

The diet industry profits from failure. A diet that worked permanently would be purchased once. The weight loss industry - valued at over $70 billion annually - is structurally dependent on recidivism. The more diets fail, the more products, books, plans, and programs get sold to the same people cycling through the same hope.

The Real Costs: Long-Term Health Risks of Yo-Yo Dieting

This is where the conversation becomes medically serious. The cycle of losing and regaining weight - known as yo-yo dieting or weight cycling - carries significant and well-documented health risks that extend far beyond the disappointment of a failed diet.

Cardiovascular damage. Research shows that weight cycling increases the risk of heart disease by up to 66%, independent of final body weight. The repeated metabolic stress of losing and regaining weight appears to have cumulative negative effects on cardiovascular health.

Metabolic disruption. Repeated periods of significant caloric restriction can impair metabolic rate over time, making future weight management progressively more difficult. This is not a myth or a convenient excuse - it is a documented physiological adaptation to perceived food scarcity that makes each successive diet attempt harder than the last.

Muscle loss. Rapid weight loss, particularly from very low calorie diets, tends to sacrifice lean muscle mass alongside fat. Since muscle is metabolically active tissue, this further suppresses resting metabolic rate and makes maintaining weight loss harder with every cycle.

Psychological toll. Weight cycling is strongly linked to elevated rates of depression, anxiety, and disordered eating behaviors. The cycle of restriction, failure, guilt, and renewed restriction creates a powerful negative feedback loop that can develop into clinical eating disorders over time.

Nutritional deficiencies. Many fad diets eliminate entire food categories for extended periods. Prolonged ketogenic dieting can result in deficiencies of magnesium, potassium, and B vitamins. Juice cleanses are critically protein-deficient. Carnivore diets eliminate fiber, vitamin C, and hundreds of phytonutrients with established health benefits. These deficiencies may not produce obvious symptoms quickly, but they accumulate silently.

What Actually Works (And Why It’s Less Exciting)

The frustrating answer - backed by decades of nutritional science and the consensus of major health organizations including the American Heart Association and the American College of Lifestyle Medicine - is that sustainable weight management requires approaches with essentially no viral potential.

A modest, consistent caloric deficit of roughly 300–500 calories per day produces slow, sustainable fat loss without triggering the metabolic adaptations that undermine rapid restriction. It is not dramatic. It works.

High protein intake genuinely supports satiety and muscle preservation during weight loss. This is well-evidenced. But it does not require a fad diet - it requires eating adequate protein at regular meals.

The best diet is the one you can actually maintain for life. If you cannot imagine following your current dietary approach in five years, it is by definition not a sustainable solution. This single criterion eliminates most fad diets immediately.

Regular physical activity, particularly resistance training, preserves muscle mass during weight loss and provides metabolic and cardiovascular benefits that are largely independent of weight.

Sleep and stress management have outsized and underappreciated effects on appetite hormones - particularly ghrelin and cortisol - that can silently undermine any dietary approach when chronically dysregulated.

None of this fits a 30-second video format. None of it produces eight pounds of loss in the first week. All of it works.

How to Evaluate the Next Viral Diet

When the next trend appears - and it will - ask these questions before engaging.

What is the proposed mechanism? If it cannot be explained in terms of basic biochemistry, or if the explanation involves vague language like “toxins,” “resetting your metabolism,” or “tricking your hormones,” be skeptical.

Is the evidence from short-term or long-term studies? Results measured over six weeks are almost meaningless for a chronic condition. Look for studies measuring outcomes at one year or more, with adequate sample sizes and independent replication.

What is the source? A peer-reviewed study in a nutrition journal carries different evidential weight than a registered dietitian’s commentary, which carries different weight than a wellness influencer’s testimonial. Understanding these distinctions matters.

Who profits? If the person promoting the diet is also selling a supplement, program, book, or product related to that diet, the incentive structure should inform how you weigh their claims.

Does it promise rapid, dramatic results? This remains the single most reliable predictor of a fad diet. Legitimate nutritional interventions describe modest, gradual improvements measured over months. “Lose 20 pounds in a month” is not a scientific claim. It is a sales pitch dressed in the language of health.

The Bottom Line

The bariatric gelatin trend is not the problem. It is a symptom of a much larger pattern: our collective hunger for a simple solution to a genuinely complex problem, combined with an industry perfectly designed to feed that hunger indefinitely and profitably.

Gelatin before meals might help you eat slightly less at lunch. That is real, modest, and harmless. The part that is not real - the “lose a ton of weight” promise, the Ozempic comparison, the dramatic before-and-afters - is the machinery of fad diet culture doing what it always does: taking a grain of physiological truth and inflating it into a miracle.

The miracle does not exist. The science does. And the science says: eat mostly whole foods, get enough protein and sleep, move your body regularly, maintain a modest and sustainable caloric balance, and be deeply skeptical of anything that promises otherwise.

It is not exciting. It does not go viral. But it is the only thing that actually works - and for those interested in going further, the Fasting Mimicking Diet offers one of the few genuinely science-backed paths to something more: not just weight management, but cellular renewal and longevity. Those are different goals, grounded in different and far more rigorous science.

Know the difference. Your health depends on it.

FOR PAID SUBSCRIBERS ONLY:

I spent more than 40 years trying diets that felt like they were working - right up until they didn't. What I've built for paid subscribers is what I wish I'd had from the start: three practical, science-backed resources that cut through the noise for good. The Fad Diet Red Flag Checklist gives you 12 questions to evaluate any diet before you try it. The Post-Diet Reset Checklist gives you 10 questions to ask before you start again after one fails - the step nobody talks about but everyone needs. And the FMD Beginner Guide walks you through the one protocol I trust after four decades in this field, grounded in Nobel Prize-recognized science and validated in human clinical trials. No programs. No supplements. No starting over in the dark.

The second checklist - the Post-Diet Reset - is the strongest addition. It fills a gap nothing else in the bundle covers: what to do in the 48 hours after a diet fails, before the next bad decision gets made. It covers sleep, protein, metabolic stabilization, psychological readiness, and exit strategy - and closes with a natural bridge into the FMD guide.

Read more

In a culture obsessed with optimization - biohacking, wearable data, AI-generated workout plans - it might seem like we finally have the tools to personalize fitness for everyone. And yet, when it comes to cancer survivors, the gap between what technology promises and what the body actually needs has never been wider. Generic algorithms don’t know about your axillary dissection. Your fitness app doesn’t account for radiation fibrosis in your chest wall. And the trending “evidence-based” program your well-meaning friend forwarded? It was built for healthy, non-medically-complex adults - not for you.

That distinction isn’t a minor detail. For cancer survivors, it’s the difference between recovery and regression.

As an ACE Certified Personal Trainer, NASM Corrective Exercise Specialist and Performance Enhancement Specialist, 2019 PFP/Club Industry Personal Trainer of the Year, and president and founder of the Cancer Exercise Training Institute, I have spent over 30 years working with clients whose bodies have been profoundly reshaped by cancer and its treatments. What I know - and what the research increasingly confirms - is this: exercise science applied without oncology context is not neutral. It carries real risk.

The Body Cancer Leaves Behind Is Not the Body You Started With

One of the most dangerous assumptions in fitness is that the human body is a stable, predictable system. For cancer survivors, it simply isn’t.

Surgery alters structural integrity. A mastectomy doesn’t just remove breast tissue - it can disrupt the entire kinetic chain of the shoulder, scapula, and thoracic spine. A prostatectomy can affect pelvic floor mechanics and hip stability. Lung resections change breathing mechanics and directly impact exercise capacity in ways that traditional cardiorespiratory assessments miss entirely.

Chemotherapy introduces systemic toxicity that persists long after the final infusion. Cardiotoxicity from anthracyclines can impair cardiac output for years. Peripheral neuropathy from platinum-based agents or taxanes alters proprioception and balance, making even simple lower-body exercises a fall risk. Cognitive effects - what survivors aptly call “chemo brain” - affect focus, motor learning, and the ability to self-monitor for exertion and pain signals.

Radiation hardens tissue. It creates fibrosis that restricts mobility, reduces extensibility of fascia and muscle, and can compress lymphatic vessels - significantly increasing lymphedema risk when the wrong exercises are applied.

None of these realities are captured in a generic program. And none of them can be responsibly addressed without a thorough, oncology-informed assessment before a single rep is prescribed.

The Assessment Isn’t Optional - It’s the Foundation

In mainstream fitness, assessments are often treated as a formality - a quick overhead squat, a posture photo, a resting heart rate. In oncology exercise, they are the cornerstone of safety.

Before prescribing any movement for a cancer survivor, a qualified specialist must understand not just how the body moves today, but why it moves that way - and what tissue, structural, or neurological factors are driving every compensation.

A comprehensive oncology movement assessment includes:

• Postural and alignment screening to identify adaptations from surgery, scar tissue contracture, or radiation-induced tightening

• Goniometric range-of-motion measurements to establish baseline joint mobility and track changes over time - before any external load is introduced

• Gait and balance analysis to reveal asymmetry, neuropathic weakness, or proprioceptive deficits that increase fall risk

• Functional movement screening including squat patterns to assess trunk stability, particularly relevant following thoracic or abdominal surgeries

Functional strength and fatigue tolerance testing to determine safe resistance thresholds without triggering overtraining or exacerbating treatment-related fatigue

Lymphedema risk stratification including assessment of affected lymph node regions, edema history, and current limb circumference measurements

This information doesn't just guide exercise selection - it determines the sequence of intervention. The clinical process moves from releasing and lengthening overactive, restricted tissue, to activating underactive muscles, to integrated functional movement. A 2024 integrated framework published in Frontiers in Oncology made the case that current clinical guidelines for cancer patients closely adhere to general population exercise guidelines with little or no consideration of physical function, physiological or psychological health, or disease state - precisely the gap that sequenced, oncology-informed corrective programming is designed to close. Loading a dysfunctional pattern doesn't build fitness. It builds dysfunction.

What Happens When the Wrong Exercise Meets a Post-Treatment Body

The consequences of poorly matched exercise in cancer recovery are not hypothetical. They are the lived experience of far too many survivors who were told that “any movement is good movement” - and paid a significant price for that oversimplification.

The wrong exercise for a cancer survivor can:

• Aggravate post-surgical and radiation-affected tissue, causing pain, inflammation, capsular contracture, or restricted range of motion that sets recovery back by weeks or months

• Trigger or worsen lymphedema (lower-extremity lymphedema shown in above picture) through excessive, unmonitored loading of affected limb quadrants - a complication that, once established, is chronic and life-altering

• Reinforce movement asymmetries caused by muscle atrophy, nerve damage, or compensatory patterns adopted during treatment, creating compounding dysfunction over time

• Exceed current healing capacity, particularly in survivors managing ongoing treatment, immune suppression, or anemia - pushing the system into a recovery deficit rather than a training adaptation

• Precipitate overtraining in individuals whose rest and regeneration are already compromised, amplifying fatigue rather than alleviating it

• Increase fracture risk in survivors with treatment-induced osteoporosis - a frequently overlooked consequence of hormone therapies, corticosteroids, and extended inactivity

A 2025 narrative review published in Frontiers in Oncology found that survivors with multiple comorbidities experienced higher rates of musculoskeletal injury when prescribed generic resistance protocols, underscoring the need for pre-participation risk stratification and individualized progression. The same review found that conventional one-size-fits-all exercise prescriptions often fall short of addressing the diverse needs of cancer patients, who differ significantly in tumor type, treatment modality, baseline fitness, and comorbidities - and that personalized programs consistently produce superior safety and clinical outcomes. Precision, not intensity, is what drives meaningful recovery.

The Treatment Variables No Generic Program Can Anticipate

Consider two breast cancer survivors, both two years post-treatment, both in their mid-50s, both motivated and physically active before diagnosis. On paper, they look the same. In reality, they require entirely different programs.

Survivor A had a lumpectomy with sentinel node biopsy, followed by radiation and hormonal therapy. She has mild range-of-motion restriction in her left shoulder, early lymphedema risk in her left arm, and radiation-induced tissue tightness along her anterior chest wall. Her program must prioritize shoulder mobility, lymphatic precautions, and a gradual approach to upper body resistance.

Survivor B had a bilateral mastectomy with immediate reconstruction, followed by chemotherapy that included a cardiotoxic regimen. She has significant postural changes from the reconstruction, some cardiac function compromise, and peripheral neuropathy in her feet. Her program must prioritize balance training, core stability, postural correction, and careful cardiac monitoring - with upper body work deferred until reconstruction has fully healed.

A single program cannot serve both women safely. And yet, without proper training in oncology exercise science, a well-credentialed general fitness professional might not recognize these distinctions at all - because they were never taught to.

This is why the Cancer Exercise Training Institute trains and certifies OncoVie Cancer Exercise Specialists: professionals who understand not just exercise science, but the intersection of oncology, physiology, surgical anatomy, treatment pharmacology, and the psychosocial dimensions of cancer survivorship.

Credentialing Matters - Especially Here

The fitness industry has no shortage of certifications. Not all of them are created equal, and in the oncology space, the difference between a knowledgeable specialist and a well-meaning generalist can have serious clinical consequences.

When selecting a trainer or exercise specialist for cancer recovery, ask directly:

• What oncology-specific training have you completed? General personal training certifications do not include oncology exercise content. Look for designations specifically designed for cancer populations.

• Are you familiar with lymphedema precautions and contraindicated exercises for my diagnosis and treatment history? A qualified specialist should be able to speak fluently to this.

• Can you explain how my specific surgeries, treatments, and medications affect my exercise programming? If the answer is vague, that’s informative.

• Do you collaborate with my oncology team or physical therapist? The best oncology exercise specialists work within a coordinated care model, not in isolation from it.

Personal training credentials from reputable organizations - including ACE, Canfitpro, ISSA, NASM, NSCA, along with a specialty certifications like the OncoVie® Cancer Exercise Specialist through the Cancer Exercise Training Institute - represent verified education and competency standards. They matter.

Movement as Medicine - Prescribed Correctly

The evidence for exercise in cancer recovery is now unambiguous. Research consistently demonstrates that appropriately dosed, well-supervised physical activity during and after cancer treatment improves fatigue, body composition, bone density, cardiovascular health, mood, immune function, and quality of life - and in some cancers, is associated with reduced recurrence risk.

But the operative phrase is “appropriately dosed and well-supervised.” Exercise is pharmacologically active. Like any intervention with real physiological effects, it has a therapeutic window - and consequences for exceeding it.

When exercise programming for cancer survivors is done right, the outcomes are genuinely transformative:

• Restored mobility and joint function that chemotherapy, radiation, or surgery had compromised

• Reduced pain, including chronic musculoskeletal pain driven by movement compensation and postural dysfunction

• Improved balance, coordination, and fall prevention - especially significant for survivors with neuropathy

• Mitigation of treatment-related side effects including osteoporosis, metabolic disruption, cardiac deconditioning, and fatigue

• Enhanced functional capacity for the activities of daily life that define quality of life

• Rebuilt confidence and a re-established relationship with a body that cancer profoundly altered

Perhaps most importantly, an expert coaching relationship - one grounded in autonomy, education, and honest communication - transforms survivors from passive recipients of a plan into active, empowered participants in their own recovery. A 2024 systematic review and meta-analysis published in Worldviews on Evidence-Based Nursing found that motivational interviewing, as a client-centered counseling technique applied as a behavior change strategy, meaningfully improved physical activity behavior and associated outcomes in cancer patients. The review confirmed that the coaching relationship itself - not just the exercise prescription - drives results. Precision in programming matters. So does the human connection behind it.

The Standard Should Be Higher

We don’t accept “good enough” from oncologists, radiologists, or surgical teams managing cancer care. We shouldn’t accept it from the fitness professionals tasked with rebuilding the bodies those treatments have altered.

Cancer survivors deserve exercise programming that is clinically grounded, individually assessed, and delivered by specialists who understand the full complexity of what cancer and its treatments do to the human body. Not because it’s ideal - because it’s the minimum standard of responsible care.

Every body that has been through cancer has a story written in tissue, compensation patterns, and hard-won resilience. The exercise program built for that body should be written with equal care.

Andrea Leonard has been at the forefront of exercise oncology since 1995, helping build the field from the ground up at a time when cancer and exercise were rarely mentioned in the same sentence. A world-renowned specialist and prolific author of more than 20 books on cancer exercise and survivorship, she has personally trained more than 20,000 OncoVie® Cancer Exercise Specialists across 56 countries - a global legacy that reflects her lifelong conviction that specialized, oncology-informed exercise is not optional, but essential. As president and founder of the Cancer Exercise Training Institute, she holds credentials including ACE Certified Personal Trainer, NASM Corrective Exercise Specialist, NASM Performance Enhancement Specialist, and a Master's in Functional Nutrition, and was named the 2019 PFP/Club Industry Personal Trainer of the Year.

Upgrade to Paid: Unlock the Clinical Advantage

If you’re serious about working safely and effectively with cancer survivors, this is where knowledge becomes impact.

Paid subscribers gain exclusive access to the Fitness Pro’s Oncology Playbook - in-depth clinical resources, case studies, and practical tools that bridge the gap between fitness and oncology care. Each edition delivers evidence-based programming strategies, adaptable templates, and continuing education insights designed to help professionals work confidently with cancer survivors and complex clients. It’s where science meets application - empowering you to build safer, smarter, and more impactful programs while growing your expertise, credibility, and business in the process.

Bonus for Paid Subscribers:

• Customized exercise programming for prostate cancer

• Post-mastectomy mobility progression chart

• Breast reconstruction flowchart

• Upper and lower extremity lymph drainage exercises

Upgrade now to join the Stronger by Design Professional Circle and access every advanced resource, guide, and toolkit in the series.

Read more

I’m writing this from Sorrento, where I have been sitting on a terrace for the last twenty minutes watching the light change on the Bay of Naples and eating lemon cake - that I’m fairly certain is the best thing I have ever put in my mouth. I’ve been in Italy for a week. I have eaten pasta, pizza, lemon cake, cannoli, cheese, and enough pizza to sink a ship. I have had Limoncello pressed into my hand after dinner more times than I can count - because in Sorrento, Limoncello is not a cocktail menu item, it's an obligation, and it arrives in a frosted glass whether you asked for it or not. I've had red wine with lunch, Aperol spritzes at sunset, and I have not skipped a single dessert that has come within arm's reach.

Before you click away convinced this is going to be some breathless story about portion control and saying no to bread: it is not. I ate the bread (all of it). I had pizza for lunch in Sorrento three days running. I ordered the tiramisu (three times). I had lemon cake on a Tuesday afternoon overlooking the Amalfi Coast, and I did not feel one moment of guilt (okay, maybe one).

So what’s happening? Two things, working together. And sitting here with another week still ahead of me, I find myself thinking about them constantly - because once you understand them, you can’t unsee them. Italy, as it turns out, has known this for centuries.

Part One: The Food Is Different. Genuinely Different.

The first thing I noticed in Italy wasn’t the taste - though yes, a tomato in Sorrento in April tastes like a completely different species from what passes for a tomato in an American supermarket in January. The first thing I noticed was how I felt after eating. Not sluggish. Not bloated. Not that particular brand of American food fatigue where you finish a meal and immediately need to lie down.

I felt satisfied and then, a few hours later, simply hungry again. The way eating is supposed to work.

It took me a few days to understand why. And the answer is not the Mediterranean diet as a concept - it’s what’s actually in the food, and more importantly, what isn’t.

Italian food

• Short ingredient lists

• Seasonal, local produce

• Minimal processing

• No high-fructose corn syrup

• No artificial preservatives

• Real olive oil, always

• Fermented dairy (aged cheeses)

• Slow-risen bread, simple flour

American equivalent

• Ingredient lists that need a chemistry degree

• Shelf-stable, year-round

• Heavily processed

• HFCS in bread, sauces, dressings

• Sodium benzoate, BHA, BHT

• Seed oils, often rancid

• Pasteurized to sterility

• Enriched flour, dough conditioners

American food is engineered to be hyperpalatable - to override your satiety signals and keep you eating past the point of fullness. The combination of industrial seed oils, added sugars, and artificial flavor enhancers is specifically designed to make your brain want more, even when your body has had enough. This is not an accident. It is a business model.

Italian food - real Italian food, eaten in Italy - operates on an entirely different premise. A bowl of pasta in Rome is flour, water, egg, and a sauce made from tomatoes, olive oil, and whatever the cook had fresh that morning. Your body knows what to do with those ingredients. It digests them, absorbs what it needs, and sends you the signal that you’re done. The system works the way it was designed to work.

I have to talk about the bread, because what’s happened this past week has genuinely stopped me in my tracks. At home, gluten, dairy, and sugar are my body’s enemies. Not in a vague, feel-a-bit-heavy way - I mean joint pain so significant I can barely use my hands. Stiffness that lingers for days. I know my triggers, and I respect them, which is why arriving in Italy and throwing caution to the wind felt like either an act of faith or a very delicious mistake.

It was neither. It was a revelation.

I have eaten bread every single day. Pasta. Cheese. Pastry. Lemon cake. Cannoli. I have had all of it, repeatedly, without restraint - and I have had zero pain. No stiffness. No swollen joints the next morning. No price to pay. After a week of eating everything I carefully avoid at home, my body has simply... responded normally.

The difference is almost certainly not the ingredients themselves - it’s what’s been done to them, or more accurately, what hasn’t. Traditional Italian bread is slow-fermented, which breaks down the compounds that cause inflammatory responses in so many people. American mass-produced bread is packed with dough conditioners, emulsifiers, and rapid-rise yeast that skip the fermentation entirely. The dairy here is minimally processed, the sugar in the desserts is just sugar - not high-fructose corn syrup engineered to spike your insulin and keep you reaching for more. The same foods that inflame my body at home are, here, just food.

Part Two: Movement Is Everywhere - and I’m Adding More

Here is the other half of the equation, and it cannot be separated from the first. Italy is a country that was built before cars, designed for walking, and utterly indifferent to your desire for a flat surface. The food is clean. The movement is constant. These two things together create a baseline that most Americans never experience in their daily lives.

I crossed 20,000+ steps every single day without once thinking of it as exercise. That’s simply what Italy requires of you. You walk to the Forum. You climb the steps in Positano and Capri. You wander through the cities that have been frozen in time. By the time I fell into bed each night, my legs were genuinely tired in the most satisfying way possible.

But I’m also moving intentionally, layered on top of all that incidental activity. Because that’s what I do - I’ve spent my career thinking about how the body responds to exercise, and I wasn’t about to stop just because I’m on vacation. Early mornings before the heat and the tourists arrive, I find the spots. Push-ups on flat stones near the Roman Forum. Tricep dips on a bench in Villa Borghese with a view of the pines. Walking lunges on the trail to Monte Solaro in Capri, because that particular stretch of path - with the sea spreading out below in about fourteen shades of blue - is too good not to earn properly. And yes, I have gone to the gym several times to get some weight training in.

How movement has stacked through the trip:

Rome - 20,000+ daily steps pounding ancient cobblestones, push-ups and dips on stone benches older than any gym I’ve ever set foot in

Positano - hundreds of stairs climbed, because in Positano there is no other way to get around

Amalfi & Ravello - clifftop hiking, switchback trails, and the kind of vertical terrain that makes your legs tremble on the way back down

Sorrento - cliff descents to the marina and back up again, because the view at the bottom is worth every step of the return climb

Capri - walked every metre to Monte Solaro rather than taking the chairlift, walking lunges on the trail, push-ups on clifftop boulders with a view to die for

Herculaneum & Pompeii - hours of walking through ancient streets on uneven volcanic stone, more steps than I counted, history beneath my feet at every turn

Here in Sorrento I've fallen completely in love with the evening passeggiata - the Italian tradition of the slow after-dinner stroll. Every night, without fail, we walked. Thirty minutes, sometimes an hour, never rushed, never tracked. Just movement for the pure sake of it, in the warm evening air, with full bellies and nowhere to be. It settled the digestion, cleared the head, and sent us to bed ready for the kind of deep, uninterrupted sleep that I'd honestly forgotten was possible. The Italians have been doing this for centuries. The research on post-meal walking for digestion and blood sugar management caught up with them eventually - but they never needed the research. They just knew.

Part Three: The Way Italians Eat Is as Important as What They Eat

Here’s something I didn’t expect to notice, and it took me almost a full week to see it clearly: Italians don’t just eat differently. They eat differently. The meal itself — the act of sitting down, ordering, talking, waiting, eating slowly, lingering — is treated as an event worth showing up for. Not a pitstop between other things. Not something to multitask through. An actual, deliberate pause in the day.

Lunch in Italy is not a sandwich eaten over a keyboard. It is a table, a cloth, a proper plate, and at least an hour - often more. Dinner starts late and ends later. Nobody is glancing at their phone waiting for the check. The check, in fact, does not arrive until you ask for it, because the assumption is that you are still there because you want to be, and that is entirely correct. You order another glass. You finish the conversation. You let the meal be what a meal is supposed to be.

I think this matters more than we realize. Eating slowly, without stress, in good company, gives your body the time and the conditions it needs to actually register fullness, process what it’s receiving, and feel satisfied rather than simply stuffed. The pace of the Italian meal is not a cultural quirk. It is, I’m now convinced, a significant piece of why you can eat so much here and feel so well.

“Nobody is glancing at their phone waiting for the check. The check doesn’t arrive until you ask for it. The assumption is that you are still there because you want to be. And that is entirely correct.”

What I’m Taking Home With Me

I still have a week left, and I intend to use every day of it - more steps, more stairs, more plates of pasta eaten slowly at a table outside with a glass of something cold. But I’m already thinking about what I carry back with me, because the contrast between how I’m eating here and how I eat at home is becoming impossible to ignore.

I’m not naive enough to think I can perfectly replicate the Italian food environment in an American kitchen. The supply chains are different, the agricultural systems are different, the entire food culture is different. But I’m leaving with a much clearer understanding of what I’m working against - and what I’m working toward. The preservatives, the additives, the engineered hyperpalatability - these things are not neutral. They work against your body’s natural signals. They make it harder to feel satisfied, harder to stop eating, harder to feel well.

The answer isn’t deprivation. It isn’t saying no to pasta or bread or cheese or joy. It’s getting closer to the source. Reading labels and choosing shorter ones. Cooking more. Finding the farmers market. And moving - intentionally and incidentally - every single day. Not to punish yourself for eating. But because your body was built to move, and when you feed it well and move it consistently, it responds in ways that no supplement on any shelf can replicate.

I’ll report back when I’m home. Right now, there is more bread and olive oil, and the light on the bay has gone completely golden, and I have absolutely nowhere else to be.

Subscriber Bonus - How to Make Your One Limoncello

Because one frosted glass in Sorrento is never enough - and the good news is, you can bring the whole ritual home with you. It takes patience. It is completely worth it.

The Limoncello they place in your hand after dinner in Sorrento is not the bright yellow syrup you find on the bottom shelf of an American liquor store. It is made from the zest of Sorrento lemons - thick-skinned, fragrant, almost obscenely aromatic - steeped in pure alcohol until the oils surrender completely, then cut with a simple syrup and chilled until it is almost viscous. It is cold, intensely lemony, and it lands at the end of a meal like a full stop on a very good sentence.

You cannot get Sorrento lemons at home. But you can get the best unwaxed organic lemons you can find, and the result will be far better than anything bottled. Here’s how:

Before you start: Use only unwaxed, organic lemons. The zest is everything here - any pesticides or wax coating will end up in your Limoncello and you will taste them. This recipe makes about 1.5 litres and keeps in the freezer indefinitely. Which is exactly where it should live.

INGREDIENTS

10 large unwaxed organic lemons 750ml grain alcohol or high-proof vodka (100 proof or higher) 4 cups water 3 cups white sugar

THE TIMELINE

Day 1 - Zest and steep Days 7 to 21 - Wait. This is the hard part. Day 21 and beyond - Bottle, freeze, and pour generously.

METHOD

Step 1. Wash your lemons thoroughly. Zest them using a microplane or fine grater, taking only the bright yellow outer layer - stop before you hit the white pith, which is bitter and will ruin the whole batch. This step takes time and it is worth every minute. Your kitchen will smell extraordinary.

Step 2. Place the zest in a large glass jar with a tight-fitting lid. Pour the alcohol over the top. Seal it, give it a gentle shake, and put it somewhere dark and cool. Now wait. Minimum one week, ideally three. The longer it steeps, the deeper and more complex the flavour. Shake the jar gently every few days when you remember.

Step 3. When the alcohol has turned a deep, gorgeous yellow and the zest looks pale and spent, make your simple syrup. Combine the water and sugar in a saucepan over medium heat, stirring until the sugar dissolves completely. Do not boil. Remove from heat and let it cool completely to room temperature - adding hot syrup to your infusion will dull the flavour.

Step 4. Strain the alcohol through a fine mesh sieve or cheesecloth into a large bowl or pitcher, pressing gently on the zest to extract every last drop. Discard the spent zest. Add the cooled simple syrup and stir to combine.

Step 5. Pour into clean glass bottles - swing-top bottles work beautifully and look the part. Seal and place in the freezer. Leave it for at least four hours before serving, ideally overnight. Limoncello lives in the freezer permanently. It does not freeze solid due to the alcohol content - it becomes cold, slightly syrupy, and absolutely perfect.

HOW TO SERVE IT

The way they do it in Sorrento: small frosted glasses, straight from the freezer, poured generously, after dinner, with no apology. You are not measuring. You are not garnishing. You are sitting down, slowing the evening, and letting the meal end the way a meal should end - slowly, in good company, with something cold and lemony in your hand.

Round two is done. This was the second of three consecutive monthly cycles, and I noticed real differences this time. The transition into ketosis came faster. My mind was clearer by day three. And this time, I wasn’t just enduring five days of discomfort (which honestly was not that bad) - I was doing something with a purpose I could actually feel. Knowing that my cells were being cleaned up and recycled, that I was actively reducing my risk of diabetes, heart disease, and cancer, made every hangry moment worth it.

That’s not just a mindset shift. That’s biology, and the research is catching up to what many FMD veterans have observed: the benefits compound with each cycle. One month in, I was learning the protocol. Two months in, my body already knows the way.

When I first wrote about starting the ProLon 5-Day Fasting Mimicking Protocol alongside my husband, I touched on the metabolic mechanics - how insulin drops, glycogen depletes, and the body shifts toward fat-burning and ketone production. But I kept the science deliberately light, because we were just beginning. Now that I’ve completed two rounds, it’s time to go deeper. Here’s what’s actually happening inside my body - and why round two matters more than I realized.

The Autophagy Piece: Now Proven in Humans

For years, autophagy - the body’s built-in cellular “clean-up” process - was discussed almost entirely in the context of animal models. We knew it happened in mice and yeast. We assumed it happened in humans. But rigorous human data was scarce.

That changed in late 2025, when researchers from Cedars-Sinai Medical Center and UT Health San Antonio published the first randomized controlled trial to directly measure autophagic flux in humans during a dietary intervention. The results were striking.

BREAKTHROUGH RESEARCH • GeroScience, 2025

Participants in the ProLon arm demonstrated a measurable increase in autophagy flux - an enhanced rate and efficiency of cellular clean-up activity. Crucially, this elevated autophagic turnover remained detectable even two days after the fast ended, suggesting that a short dietary intervention may recalibrate cellular maintenance pathways well beyond the five days themselves.

My cells have now been through this process twice. The machinery that breaks down damaged proteins, clears out dysfunctional organelles, and recycles cellular debris has been activated and accelerated - not once, but twice.

The study also clarified something important: autophagy engagement was formulation-dependent. Only the standard ProLon diet - not a calorie-matched alternative - produced the measurable increase. This suggests that macronutrient composition, not just calorie restriction, is what triggers meaningful cellular recycling. The specific ratio of low protein, low carbohydrate, and higher plant-based fat appears to be the actual signal the body responds to.

What Three Cycles Does to Biological Age

Here’s where the cumulative story gets genuinely exciting. Researchers at the USC Longevity Institute, led by Dr. Valter Longo - the scientist who developed the FMD protocol - analyzed participants who completed three consecutive monthly cycles of the fasting-mimicking diet.

The findings went well beyond metabolic markers. Participants showed a reduction in biological age of approximately 2.5 years, independent of weight loss. This was measured using validated clinical tools that assess morbidity and mortality risk - not just how you feel, but how your biology is performing relative to your chronological age.

The specific improvements across three cycles included:

• Reduced subcutaneous, visceral, and liver fat - with 5 out of 15 participants experiencing a 50% reduction in liver fat

• A 20% decrease in HOMA-IR scores, indicating meaningfully improved insulin sensitivity

• Lower blood pressure, reduced IGF-1, lower fasting blood glucose, and reduced C-reactive protein (a key inflammatory marker)

• Improved lymphoid-to-myeloid ratio, a measure of immune system health and resilience

USC LONGEVITY INSTITUTE • Dr. Valter Longo’s Research

Three cycles of the fasting-mimicking diet were associated with a decrease in biological age, independent of weight loss - linked to reductions in insulin resistance, hepatic fat, and improvements in immune system composition.

I am already two-thirds of the way to that three-cycle threshold. My thought is that if my body can biologically be 69 when I am 80, it is worth the temporary and occasional sacrifice.

The IGF-1 and mTOR Connection: Why Protein Matters

One of the most important - and least discussed - mechanisms behind the FMD is its effect on IGF-1, a growth hormone linked to accelerated aging and increased cancer risk when chronically elevated.

Research published in 2025 in Clinical Nutrition found that both low-protein and higher-protein versions of the FMD reduced IGF-1 levels by approximately 35% compared to a control group. Fasting plasma glucose dropped roughly 10% in both groups as well. The total calorie restriction, it turns out, is the primary driver of these hormonal shifts - not macronutrient ratios alone.

Why does this matter? IGF-1 signals through a pathway called mTOR, which tells cells to grow and divide. When mTOR is chronically activated - as it tends to be in modern, always-fed lifestyles - cellular repair takes a back seat to cellular growth. The FMD essentially flips that switch. By dropping IGF-1 and downregulating mTOR, the body shifts its priorities from building to repairing.

This is the molecular basis of the “cellular housekeeping” I mentioned in my first post. And it’s not just a metaphor - it’s a measurable, reproducible physiological shift that I have now triggered twice.

The Gut Microbiome Surprise

One finding that doesn’t always make the FMD headlines: improved gut microbiome diversity. The University of Nottingham study published in 2025 found that a higher-protein version of the FMD significantly improved microbiome diversity - and also improved heart rate variability and circulating lipid profiles in ways the low-protein version did not.

This is a reminder that the FMD isn’t a monolithic intervention. The specific formulation matters, and so does what I do in the 25 days between cycles. My gut microbiome is a living ecosystem that responds to the full arc of how I eat, sleep, and move - not just to the five days of fasting itself.

If I’ve been curious about adding more fermented foods, diverse plant fibers, or cutting ultra-processed foods in the weeks between rounds - this is the science that supports exactly that instinct.

The Psychological Compound Interest

Beyond the biomarkers, there’s something the studies don’t fully capture: the second round is different in your head - and I felt it.

The first time, I was white-knuckling day two. Negotiating with myself at 3 pm. Checking the clock between allowed snacks. The second time, there was a quiet confidence - a cellular memory, almost - that said: I’ve been here before. I know this passes. I know what’s on the other side. Not to say that by day five, I wasn’t ready to go to bed at 7pm so I could wake up and eat!

That psychological shift is itself a form of progress. The FMD doesn’t just reset my metabolism. Done repeatedly, it resets my relationship with food - revealing the habitual eating patterns I didn’t know were habitual, and proving to myself that I can exist, think clearly, and even thrive on far less than I thought I needed.

I love food. I enjoy everything I eat throughout the day. I plan my meals, and if I’m being honest, I daydream about dinner. So five days of structured restriction is not nothing for me. But what I didn’t expect was what it would do for my head. There is a mental toughness that gets built here - a quiet proof that I am not controlled by food, that I can choose discomfort deliberately and come out the other side stronger for it. That shift in mindset is something I carry well beyond the five days.

I say “mental toughness” knowing exactly what it is not. In my twenties, I put my body through things I am not proud of - bingeing and purging, drug use, years of injecting myself with HCG, every diet that promised a shortcut, and a body dysmorphia that meant I never once saw myself clearly in the mirror. I came out of that decade worse off than when I entered it, physically and mentally. So when I say this feels different, I mean it in the most literal sense. This is not restriction for restriction’s sake. This is not punishment. This is not another desperate attempt to shrink myself. This is five intentional days, once a month, backed by decades of peer-reviewed science, that asks my body to heal itself on a cellular level. For someone who spent years destroying her body in the name of looking a certain way, there is something profound about finally doing something that is genuinely, measurably good for it.

People who complete multiple FMD cycles consistently report that emotional eating patterns become more visible and more manageable. The discipline required during the five days seems to echo forward into how they relate to food the rest of the month.

What I’m Watching for After Round Two

As I move through my refeeding days and back into normal eating, here are a few things I’m paying attention to:

• Energy and mental clarity: I’ve noticed a cognitive lift that persists for days after the fast ends - likely a combination of ketone residue, reduced inflammation, and heightened insulin sensitivity. I’m tracking how long it lasts this time.

• Sleep quality: Improved metabolic health often shows up first in sleep. I’m looking for changes in deep sleep and resting heart rate in the week following the fast.

• Hunger signals: Hunger hormones - particularly ghrelin - recalibrate during and after an FMD. I’ve noticed my appetite feels more accurate and less reactive for weeks afterward. I’m treating this as a window to use intentionally.

• Refeeding pace: I learned this the hard way - when they say SLOW, they mean SLOW. The gut flora that was quietly reorganizing during the fast is still in a sensitive state. I ease back in with broths, soft vegetables, and light proteins before returning to normal volume.

A Word on Frequency: What the Research Supports

The protocol Dr. Longo’s team used in their trials - and what ProLon recommends as a general wellness protocol for healthy adults - is one five-day cycle per month for three consecutive months, followed by maintenance cycles every two to four months thereafter.

For people with metabolic concerns such as elevated blood glucose, high blood pressure, or excess visceral fat, more frequent cycling appears to produce the most robust improvements. For healthy individuals focused on longevity and cellular maintenance, quarterly cycles appear to be sufficient to sustain the benefits. I fall into the latter category, so after round three I plan to move to a maintenance schedule.

As always, I would encourage anyone doing this to involve their physician - especially if managing any chronic conditions or taking medications. The FMD is powerful precisely because it produces real physiological change, and that warrants real medical context.

What the Broader Research Says About Disease Risk

One of the questions I kept asking myself going into this was: beyond the biomarkers, what does this actually do to my long-term risk of the diseases I’m most afraid of? I went looking outside the ProLon-specific studies, into the broader fasting and caloric restriction literature. Here’s what I found - with the caveats included, because I think honesty matters more than a clean headline.

On diabetes: a Nature Communications analysis using data from two independent clinical trials modeled the long-term effect of periodic FMD cycles starting at age 50. The simulation estimated a reduction in 20-year all-cause mortality risk from 81.1% to 57.5% - nearly 24 percentage points. That’s not a diabetes-specific number, but it reflects the compounding effect of improved insulin sensitivity, reduced liver fat, and lower HbA1c that FMD cycles consistently produce. The clinical trials themselves showed long-term reductions in insulin resistance markers that persisted months after the intervention ended.

On cancer: a large 20-year Swedish follow-up study - one of the longest of its kind - found that sustained caloric restriction was associated with a 29% reduction in cancer incidence and a 20% reduction in cancer death. This was in the context of bariatric surgery rather than FMD specifically, but the underlying mechanism is the same one the FMD targets: sustained lowering of IGF-1, insulin, and systemic inflammation. A PLOS ONE meta-analysis of animal studies found that approximately 91% of relevant caloric restriction studies showed an anti-cancer effect. Human clinical data is still catching up, but the direction of the evidence is consistent.

On heart disease: what the FMD reliably improves are the risk factors - blood pressure, LDL cholesterol, C-reactive protein, and triglycerides. A 2025 network meta-analysis of 56 intermittent fasting studies found that periodic fasting outperformed a usual diet in lowering LDL cholesterol. And, research has shown, that even modest reductions of 2 to 5 mmHg in systolic blood pressure at a population level correspond to meaningful declines in stroke and coronary heart disease rates. The FMD consistently moves those numbers in the right direction. Whether that translates to a specific percentage reduction in heart disease over decades is still being studied - and I’d rather cite what’s proven than inflate what isn’t.

NATURE COMMUNICATIONS • Brandhorst, Levine et al., 2024

A Nature Communications simulation estimated that FMD cycles starting at age 50 could extend median life expectancy at age 70 from 83.2 years to 88.3 years - a difference of about 5 years. Even under conservative assumptions, the model suggests that prolonged practice of FMD may slow the rate of biological aging and extend disease-free life expectancy.

None of these numbers are. guarantees. Science rarely delivers those. But the direction of the evidence, across multiple independent research groups and multiple disease pathways, points the same way. And for me, that’s enough to keep showing up for round three.

The Bigger Picture

Fasting mimicking isn’t a diet in the traditional sense. It’s not about restriction as an ongoing state. It’s about creating a periodic metabolic shift - a brief window in which the body can do the repair work it rarely gets the chance to do when we’re always eating, always fueling, always signaling growth.

Science is now confirming what the body seemed to already know: that periods of intentional, structured low intake aren’t deprivation. They’re maintenance. The kind of deep maintenance that keeps the system running well, not just for next month, but for decades. My thought is that if my body can biologically be 69 when I am 80, it is worth the temporary and occasional sacrifice.

The research says the third cycle is where biological age begins to shift in measurable ways. I’ve done two rounds. The cellular work is accumulating. And my body is quietly better for it.

—

As always, this is shared from lived experience and backed by published research - not as medical advice. Consult your physician before beginning or continuing any fasting protocol, particularly if you have a health history that warrants additional consideration.

REFERENCES

Espinoza SE, Park S, Connolly G, Qi W, Zhang N, Semwal M, Li Y, Lauzon M, Salmon AB, Hsu W, Wei M, Musi N. Effect of fasting-mimicking diet on markers of autophagy and metabolic health in human subjects. Geroscience. 2025 Dec 11. doi: 10.1007/s11357-025-02035-4. Epub ahead of print. PMID: 41372565.

Burns L, Cooper S, Sarmad S, Funke G, Di Mauro A, Gaitanos GC, Tsintzas K. Effects of fasting-mimicking diets with low and high protein content on cardiometabolic health and autophagy: A randomized, parallel group study. Clin Nutr. 2025 Sep;52:299-312. doi: 10.1016/j.clnu.2025.08.004. Epub 2025 Aug 6. PMID: 40816210.

USC Longevity Institute (2025). 3 Cycles of Fasting-Mimicking Diet Indicate a 2.5 Years Reduction in Biological Age. gero.usc.edu

Popa AD, Gherasim A, Mihalache L, Arhire LI, Graur M, Niță O. Fasting Mimicking Diet for Metabolic Syndrome: A Narrative Review of Human Studies. Metabolites. 2025 Feb 23;15(3):150. doi: 10.3390/metabo15030150. PMID: 40137116; PMCID: PMC11943686.

Brandhorst, S., Levine, M.E., Wei, M. et al. Fasting-mimicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk. Nat Commun 15, 1309 (2024). https://doi.org/10.1038/s41467-024-45260-9

Carlsson LM, Peltonen M, Ahlin S, Anveden Å, Bouchard C, Carlsson B, Jacobson P, Lönroth H, Maglio C, Näslund I, Pirazzi C, Romeo S, Sjöholm K, Sjöström E, Wedel H, Svensson PA, Sjöström L. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012 Aug 23;367(8):695-704. doi: 10.1056/NEJMoa1112082. PMID: 22913680.

Lv M, Zhu X, Wang H, Wang F, Guan W. Roles of caloric restriction, ketogenic diet and intermittent fasting during initiation, progression and metastasis of cancer in animal models: a systematic review and meta-analysis. PLoS One. 2014 Dec 11;9(12):e115147. doi: 10.1371/journal.pone.0115147. PMID: 25502434; PMCID: PMC4263749.

Read more

Your Gut Is a War Zone - And You’re Losing

Trillions of microbes live in your digestive tract right now. Some of them are protecting you. Others - and this is where it gets uncomfortable - may be quietly contributing to cancer.

The gut microbiome has emerged as one of the most consequential frontiers in cancer research. What was once considered background biology is now understood to play a direct role in cancer initiation, progression, immune response, and even how well chemotherapy works.

This isn’t fringe science. A January 2026 review in npj Biofilms and Microbiomes laid out precisely how gut microbial communities reprogram immune, metabolic, and inflammatory networks within the tumor microenvironment. The picture is both alarming and, crucially, actionable.

The Bacteria That Promote Cancer

Two bacterial species keep appearing in colorectal cancer research as major villains.

The Two Key Offenders

Fusobacterium nucleatum

Originally a mouth bacterium, F. nucleatum has been found enriched in colorectal tumor tissue. It promotes cancer through direct DNA damage, suppresses anti-tumor immune cells, and creates a pro-inflammatory environment that helps tumors grow. Higher levels are associated with worse outcomes and resistance to chemotherapy.

pks+ Escherichia coli

Certain E. coli strains carry a gene cluster called pks that produces colibactin - a genotoxin that directly damages DNA and leaves a distinctive mutational signature found in human colorectal cancer genomes. Research in 2025 confirmed this as one of the most consequential microbial drivers of cancer.

Enterotoxigenic Bacteroides fragilis rounds out the trio - producing a toxin that disrupts the gut epithelial barrier, triggers chronic inflammation, and promotes tumor formation. What all three share: they thrive when microbial diversity is low, and they are suppressed when beneficial bacteria are abundant.

The Bacteria That Fight Back

The microbiome isn’t just a source of risk - it’s one of the body’s most powerful cancer defense systems. Short-chain fatty acid (SCFA) producers are the heroes of this story.

Bacteria like Faecalibacterium prausnitzii, Roseburia intestinalis, and Akkermansia muciniphila ferment dietary fibre to produce butyrate, propionate, and acetate - SCFAs that have been shown to suppress colorectal tumor growth, reinforce the gut lining, and regulate immune cell behavior. Butyrate in particular has demonstrated direct anti-tumor activity in colon cells.

Butyrate: The Anti-Cancer Metabolite

When gut bacteria ferment dietary fibre, they produce butyrate - a short-chain fatty acid that colon cells use as their primary fuel. Butyrate has multiple anti-tumor mechanisms: it inhibits histone deacetylases (enzymes that regulate gene expression in cancer cells), promotes programmed cell death (apoptosis) in abnormal cells, and reduces inflammatory signalling. Population studies consistently show that higher dietary fibre intake - and the butyrate it produces - correlates with significantly lower colorectal cancer risk.

Why Your Gut Microbiome Determines Whether Immunotherapy Works

One of the most striking recent discoveries is that the composition of your gut microbiome may predict - and directly influence - how well you respond to cancer immunotherapy.

Immune checkpoint inhibitors like PD-1/PD-L1 blockers have transformed cancer treatment, but only about 20% of patients respond. Traditional biomarkers like PD-L1 expression fail to explain the variability. Increasingly, researchers are pointing to the gut microbiome as a key missing variable.

A 2026 review in Cancer Biology & Medicine identified the gut microbiota as a systemic regulator of immune responsiveness - essentially a master switch that determines whether the immune system can be unlocked to attack tumors. Patients with more diverse microbiomes, enriched with specific beneficial species, show dramatically better response rates.

Perhaps the most dramatic evidence came from a University of Florida study published in December 2025: researchers identified a single metabolite produced by gut bacteria - called Bac429 - that doubled the response rate to lung cancer immunotherapy in mice. When injected directly into tumors, it reduced tumor growth by 50%. A drug derivative is now being developed for human trials.

Fermented Foods: The Live-Culture Intervention

If dietary fibre feeds your good bacteria, fermented foods directly deliver them. Fermentation - the ancient preservation technique used to make yogurt, kefir, kimchi, sauerkraut, miso, tempeh, and sourdough - produces foods teeming with live bacterial cultures that can survive the journey to your colon and take up residence.

The science on fermented foods and the microbiome has moved quickly. A landmark 2021 Stanford study published in Cell found that a high-fermented-food diet for 10 weeks significantly increased microbiome diversity - the gold-standard marker of gut health - and reduced 19 inflammatory proteins. A high-fibre diet, by contrast, increased SCFA production but did not increase diversity as reliably.

The Key Fermented Foods and What They Do

Kefir

A fermented milk drink containing up to 61 strains of bacteria and yeast. Multiple studies link regular kefir consumption to reduced colorectal cancer risk, reduced inflammatory markers, and improved immune response. Contains Lactobacillus kefiri, which has shown direct anti-tumor activity in cell studies.

Kimchi

Fermented Korean cabbage rich in Lactobacillus plantarum and L. brevis. Korean population studies associate frequent kimchi consumption with lower gastric cancer rates. Its fermentation byproducts include sulforaphane precursors - compounds with well-established anti-cancer properties.

Miso

Fermented soybean paste. Japanese epidemiological studies consistently show that miso soup consumption is associated with reduced stomach and breast cancer risk. Contains L. acidophilus and delivers isoflavones (plant estrogens with anti-proliferative effects on cancer cells).

Sauerkraut

Fermented cabbage containing L. plantarum and glucosinolates - compounds converted by gut bacteria into cancer-fighting isothiocyanates. Must be raw/unpasteurised (from the refrigerated section) to retain live cultures; shelf-stable versions are pasteurised.

Tempeh

Fermented whole soybeans - a complete protein with active Rhizopus mould cultures. Fermentation increases bioavailability of isoflavones and produces unique bioactive peptides with demonstrated anti-proliferative activity in colon cancer cell lines.

Live Yogurt

The most accessible source of live cultures. Strains including L. acidophilus and Bifidobacterium bifidum have been shown to bind to carcinogens in the colon, reduce their absorption, and stimulate immune surveillance. Must show ‘live and active cultures’ on the label.

The Golden Rule: Never Heat Your Fermented Foods

Live bacterial cultures are destroyed at temperatures above 115°F (46°C). This is the most common mistake people make with fermented foods - cooking them kills the very benefit you’re eating them for. Always add kimchi, sauerkraut, miso, and yogurt after cooking, as a cold topping or dressing. The one exception is sourdough bread, where the structural and prebiotic benefits survive baking even though the live cultures do not.

How to Add a Fermented Food to Every Meal

• Breakfast: swap regular milk for kefir in smoothies, or drizzle live yogurt over oatmeal

• Lunch: add a tablespoon of sauerkraut or kimchi as a side to salads or grain bowls

• Dinner: stir miso paste into dressings or sauces at the end of cooking (off the heat), or serve tempeh as your protein

• Snack: plain live yogurt with berries is the easiest live-culture hit of the day

It’s Not Just Colorectal Cancer

Early research focused on colorectal cancer - the most obvious connection, given the gut’s proximity. But the microbiome’s influence on cancer now extends well beyond the gut wall.

The gut-lung axis is perhaps the most surprising frontier. Gut bacteria regulate systemic immune tone, and this affects immune surveillance in the lungs. The UF Health Bac429 discovery involved lung cancer. Studies in breast cancer have found that the gut microbiome influences estrogen metabolism - with implications for hormone receptor-positive tumors.

A March 2026 systematic review in Bulletin du Cancer found that bacteria living inside tumors themselves - not just in the gut - may influence immune cell infiltration and response to immunotherapy. The microbiome isn’t just a gut phenomenon; it may be a systemic one.

The Obesity-Gut-Cancer Triangle

Over 40% of US adults are obese, and colorectal cancer is the second leading cause of cancer death in the US. These two facts are not unrelated - and the gut microbiome is the mechanism connecting them.

A November 2025 review in Oncoscience mapped the chain precisely: Western diets high in ultra-processed food and low in fibre reduce microbial diversity, promote the growth of pro-inflammatory bacteria, and create insulin resistance and systemic inflammation - all of which create conditions favorable to tumor development.

The authors described the gut microbiome as both a biomarker and a therapeutic target. The implication: improving diet composition doesn’t just affect weight. It reshapes the internal microbial ecosystem in ways that may directly reduce cancer risk.

What the Science Says You Should Eat

Translating microbiome research into practical dietary advice is still an evolving science, but several principles are well-supported:

Evidence-Based Gut-Protective Diet Principles

• Aim for 30+ different plant foods per week - diversity of plants drives diversity of microbes

• Prioritise prebiotic-rich foods: garlic, leeks, onions, oats, barley, asparagus, green bananas

• Eat fermented foods daily: kefir, live yogurt, kimchi, sauerkraut, miso, tempeh

• Load up on polyphenol-rich foods: berries, red wine (moderate), dark chocolate, walnuts, green tea

• Consume oily fish 2-3x per week for omega-3 fatty acids that reduce gut inflammation

• Minimise ultra-processed food, excess red meat, and refined sugar - all associated with dysbiosis

• Consider resistant starch: cooled cooked rice, green bananas, cooked-and-cooled potatoes

Where the Science Is Heading

The frontier of microbiome-cancer research points toward genuinely transformative clinical applications. Microbiome profiling before cancer treatment could predict who will respond to immunotherapy. Personalized microbial interventions - targeted probiotics, fecal microbiota transplantation, engineered bacteria with immune-stimulating payloads - are all under active investigation.

Synthetic biology approaches are particularly striking: researchers are designing bacteria with built-in safety kill-switches that can be programmed to deliver immune-modulating signals directly within tumors. What begins as dietary science may end as precision oncology.

For now, the most powerful lever remains the simplest: what you eat, every day, shapes the microbial community that either protects you from cancer or quietly promotes it.

FREE BONUS for all Subscribers:

Download - One-Day Gut Reset Meal Plan

Upgrade to Paid and Gain Instant Access:

The science told you what to eat. The program shows you exactly how.

You’ve read the research. Paid members get everything translated into a week-by-week eating plan - complete recipes, shopping lists, and a new drop every month as the science moves forward.

What you unlock:

• 7-Day Gut Fix - 21 full recipes, 3 meals/day, step-by-step cooking instructions

• Weekly shopping lists, organised by category

• Fermented foods deep dive - 12 recipes covering kimchi, kefir, miso, tempeh & more

• Downloadable PDF versions - yours to keep even if you cancel

• Monthly research + recipe drops as the science moves forward

  ---

  Stronger by Design is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

* This article is for educational purposes. It is not a substitute for medical advice. Consult your healthcare provider before making significant dietary changes, particularly if you have an existing health condition or are undergoing cancer treatment.

Read more

Doctors are brilliant. Doctors are trained. Doctors save lives every single day.

They are also human. And humans make mistakes.

I have spent years in this work - sitting with clients, watching, over and over again, what happens when the medical system moves too slowly, asks too few questions, or simply tells someone to watch and wait.

They watch. They wait. And by the time someone finally orders the right test, they are looking at a Stage 3 or Stage 4 diagnosis - a cancer that, caught a year or two earlier, would have meant a completely different treatment, a completely different prognosis, and in some cases, a completely different outcome.

This is not a rare tragedy. This is a pattern. And I have stayed quiet about it for too long.

My Mother

My mother survived breast cancer - twice. She did everything right - she got treated, she got through it, and she moved forward with her life. For twenty-three years, she was a survivor.

Then the cancer came back. Stage 4.

When we dug into the details, something stopped me cold. Her cancer was ER/PR positive - meaning it was driven by estrogen and progesterone. This is not obscure information. Testing for hormone receptor status is a standard part of breast cancer pathology. And yet across her original diagnosis, her treatment, and more than two decades of follow-up care, no one had ever tested her for it.

Had they known, she almost certainly would have been placed on hormonal ablation therapy - a treatment designed to suppress the very hormones feeding her cancer. She might never have had a recurrence. She might never have reached Stage 4.

She was not failed by a negligent doctor. She was not failed by a bad hospital. She was failed by a system that didn’t ask the right questions - and by a lifetime of being told that doctors know best, that you don’t push back, that you trust the process.

The Woman Who Waited

My mother’s story is about a test that was never ordered. But some stories are about barriers that cut even deeper.

I think often about a client - 43 years old, full of life - who found a lump in her breast. She knew something was wrong. She felt it. But she didn’t have the money for a mammogram, so she waited. Weeks passed. Then months. Then one day her breast started bleeding.

A friend stepped in and paid for the mammogram.

Stage 3 breast cancer.

Her doctors recommended a mastectomy. She refused. She was single, and she carried a belief that no man would ever love her if she lost her breast. She chose that fear over her own survival.

She passed away from breast cancer.

I do not share this story to judge her. Not for a single second. The fear she carried was real, and it was shaped by a world that had taught her that her value lived in her body. I share it because it shows us something we don’t talk about enough: the barriers to early detection are not always about access or information. Sometimes they are about what we believe we deserve.

Had she been able to afford that mammogram when she first felt the lump, her story might have been different. Had someone - a doctor, a friend, anyone - looked her in the eyes and told her that she was worth fighting for regardless of what surgery required of her body, her choice might have been different too.

This is why advocacy means more than demanding tests. It means demanding that every person understands they are worth saving.

And Then There Was Me

I am not just writing this from professional experience. I am writing it from personal experience too.

I had rectal bleeding for several days. I called my doctor. His response: “It probably isn’t cancer. You had a colonoscopy two years ago.”

No test. No follow-up appointment. Just a probability and a dismissal.

I waited a few weeks - bleeding continuing - and called again. This time I didn’t ask. I pushed. I told him I was still bleeding and that I wanted to be seen. I made it clear I was not going away.

They found three polyps. Benign, thankfully. But here is what I could not stop thinking about afterward: what if I had accepted his first answer? What if I had trusted the “probably” and waited the standard three years for my next colonoscopy?

Polyps do not announce themselves. They grow quietly. And the difference between a benign polyp today and Stage 4 colon cancer in three years is not as wide as most people think - it is just a matter of time and the absence of intervention.

My doctor is not a bad person. He was working from statistics and making a reasonable assumption. But reasonable assumptions are not the same as answers. And I was not willing to let a probability be the last word on my own body.

Neither should you be.

The System Working Against You

Before we talk about what you can do, it is worth understanding one more layer of why this happens - because it is not always about a doctor’s oversight. Sometimes it is about the system those doctors are operating inside.

Insurance companies routinely use a practice called prior authorization - a process that requires doctors to get approval before ordering certain tests, scans, or procedures. On paper, it exists to prevent unnecessary care. In practice, it creates friction that delays or discourages testing, even when a physician believes it is warranted.

Doctors know this. Many of them spend hours every week fighting with insurance companies on behalf of their patients - hours they are not reimbursed for, on top of already overloaded schedules. Some give up. Some learn over time which tests will be approved without a fight and which ones will trigger a lengthy appeals process. That knowledge, however unconsciously, can shape what they order.

The result is a quiet rationing of care that most patients never see. You sit in the exam room believing the decision about your testing is purely medical. Often, it is also financial.

This is not an accusation against every insurer or every doctor. It is simply the reality of a healthcare system in which coverage decisions are made by people who have never examined you, based on criteria designed to manage cost.

What this means for you practically: if your doctor says a test is not covered or not necessary, those are two very different statements - and it is worth asking which one they mean. If it is a coverage issue, ask about appealing the decision, about cash-pay options, or about whether a different diagnostic pathway might be covered. If you are told a test is medically unnecessary, ask why, and ask what would need to change for that assessment to be different.

You are entitled to those answers. The system may not make it easy to get them - but you are entitled to them.

Doctors Are Not Gods

Let me be direct: this is not an attack on physicians. Many of the doctors I have encountered over the years are extraordinary - compassionate, brilliant, genuinely dedicated people working inside a system that is overloaded, underfunded, and structurally designed to rush them through appointments in seven minutes or less.

But “doing their best” is not the same as “always getting it right.”

Diagnostic errors affect an estimated 12 million Americans every year. That number comes from research out of Johns Hopkins - one of the most respected medical institutions in the world. Twelve million. That is a public health crisis that most of us have never been told about.

Doctors miss things for reasons that have nothing to do with incompetence:

• They have minutes with you, not hours

• Your symptoms don’t match the textbook presentation

• You are a woman, and women are statistically more likely to be dismissed, undertested, and told their symptoms are stress or anxiety

• You are younger than the “typical” patient for a given condition

• They are making decisions based on assumptions rather than data

• They simply don’t order the test because you didn’t ask

That last reason is the one that keeps me up at night. Because that is the one you can do something about.

The Tests You May Have to Ask For

You are allowed to ask. You are allowed to push. You are allowed to say I want to rule this out and not apologize for it.

Here are screenings worth knowing - and worth requesting proactively:

Breast Cancer: Mammograms are recommended annually starting at 40, but if you have dense breast tissue or a family history, that conversation should start earlier (I was 28 when I had my first mammogram). The American College of Radiology recommends that all women, but especially Black women and women of Ashkenazi Jewish descent, be evaluated by a doctor to find out if they’re at higher-than-average risk for breast cancer no later than age 25. Dense tissue can hide tumors on a standard mammogram - ask specifically about ultrasound or MRI as supplemental screening. And if you have had breast cancer before, ask your doctor about hormone receptor testing. Ask what your results mean. Ask what they should mean for your ongoing care.

Colon Cancer: Colonoscopies are recommended starting at 45 for average-risk adults - but earlier if you have family history, and sooner if something feels off. Do not let a doctor tell you that you are too young to be concerned. Stage 4 colon cancer does not care how old you are. James Van DerBeek passed recently from colon cancer and shares his story here.

Cervical and Ovarian Cancer: Know when your last Pap smear and HPV co-test were, and know when you are due again. Ovarian cancer is particularly insidious because there is no reliable standard screening for it - which means that if you have symptoms (bloating, pelvic pain, changes in your cycle), you need to be vocal and persistent until someone takes you seriously.

Skin Cancer: An annual full-body skin check with a dermatologist takes fifteen minutes and costs very little. I found a brown mole with an unusual shape and texture and called my dermatologist on Friday. Yesterday I had it evaluated and frozen off. Thank God it was nothing! Melanoma caught early is highly treatable. Melanoma caught late is not. Ask your primary care doctor for a referral if you have never had one.

Lung Cancer: If you are a current or former smoker, ask specifically about low-dose CT lung cancer screening. Most people do not know it exists. It does, and it saves lives. The early symptoms of lung cancer can vary widely, but common signs that need attention include a persistent cough that doesn't go away or worsens over time, shortness of breath during everyday activities that previously felt manageable, and chest pain that persists or worsens with deep breathing, coughing, or laughing - which may also radiate to the shoulders or back. Additional warning signs include coughing up blood or rust-colored sputum, a hoarse or raspy voice that lasts more than two weeks without explanation, and unexplained weight loss with no change to diet or exercise. In most people, lung cancer doesn't cause symptoms until it spreads to other parts of the body - which makes it much harder to treat. This is exactly why waiting for symptoms before asking for a scan is the wrong strategy.

Heart Disease Cardiovascular disease kills more women than all cancers combined - and women’s symptoms are routinely dismissed or misread as anxiety. Don’t wait for something to go wrong. Ask about cholesterol panels, blood pressure patterns, and whether a coronary calcium scan is appropriate for your age and risk profile. Last October, a routine pre-surgery workup that included an EKG delivered news I never saw coming. The results showed that I had suffered a previous myocardial infarction - a heart attack - at some point in the past, completely without my knowledge. What followed was a cascade of appointments with two cardiologists, multiple EKGs, echocardiograms, and a CT scan with contrast, all working to piece together what had happened to my heart and when.

What to Say When You Walk Into That Room

You are not being difficult. You are not being dramatic. You are not a hypochondriac.

You are a person with one body and every right in the world to participate in your own care.

Try these:

“I’d like to talk about whether there are any screenings I might be overdue for.”

“Given my family history, I want to be proactive. What early testing options do we have?”

“I’ve had this symptom for [X weeks]. I’d feel more comfortable ruling something out. What can we order?”

“I’d like a second opinion before we decide on a plan.”

"I'm not comfortable leaving today without a plan to investigate this further. What are my options?"

And if your doctor dismisses you, minimizes you, or tells you that you are worrying over nothing - ask again. Ask differently. See someone else. Find a physician who treats your concern as information, not inconvenience.

Your persistence is not a burden on the healthcare system. It is how the healthcare system is supposed to work.

If You Have Ever Been Told “You’re Fine”

Trust your body.

You live in it every day. You know when something is different. A doctor sees you for minutes, once a year if you are lucky, and makes decisions based on whatever information is in front of them in that moment. They are working with a snapshot. You are living the whole film.

I am not asking you to distrust medicine. I am asking you to partner with it. To show up informed, to ask hard questions, to refuse to leave an appointment with unresolved fear when a test could resolve it.

And I am asking you to do the same for the people you love.

Check in on your friend who keeps saying she’ll schedule that mammogram “soon.” Sit with your father at his colonoscopy prep appointment. Pay for the test when someone you love cannot afford it. Tell the women in your life - loudly, repeatedly, without apology - that they are worth the scan, worth the follow-up, worth the fight.

The Bottom Line

Be the patient who asks questions. Be the caregiver who pushes back. Be the friend who pays for the mammogram. Be the person who refuses to accept “watch and wait” without demanding to know: watch for what, and wait until when?

Be inconvenient if you have to.

Because the cost of staying quiet is one I have watched too many people pay. And it is a cost that, in so many cases, did not have to be theirs to bear.

Have you ever had to fight for a diagnosis - for yourself or someone you love? I’d like to hear your story in the comments. These conversations matter more than you know.

Every year, well-meaning fitness professionals work with cancer patients and survivors using the same tools, the same instincts, and the same programming logic they use with every other client. They have certifications. They have experience. They care deeply about the people they train.

And they cause harm.

Not because they are negligent. Because cancer is not a fitness population - it is a medical population. And the gap between a general fitness certification and the clinical knowledge required to work safely with cancer patients is wider, and more dangerous, than most professionals realize.

These are the five mistakes that define that gap. And for each one, what an OncoVie® Cancer Exercise Specialist does instead.

MISTAKE 1 - Treating Surgical History as Background Information

A client mentions they had surgery - a mastectomy, a colectomy, a lymph node dissection. The trainer receives a general physician clearance and moves forward. The surgical history becomes a checkbox. A note in the file. Background information.

This is where untrained professionals cause the most direct physical harm.

Take the ileostomy as one example. A client with a temporary or permanent ileostomy has an opening in the abdominal wall through which waste exits the body. The Valsalva maneuver - the breath-holding and straining that occurs naturally during heavy resistance exercise, coughing, or even some yoga poses - dramatically increases intra-abdominal pressure. In an ileostomy patient, this pressure can cause stoma prolapse, parastomal hernia, or serious damage to the surgical site.

No breath holding. Ever. Continuous breathing through every repetition of every exercise. This is non-negotiable.

A trainer who doesn’t know what an ileostomy is - let alone how it changes every exercise prescription - cannot safely work with this client. And an AI-generated program will not ask whether the client has a stoma before recommending core work.

Lymphedema is another critical example. Breast cancer-related lymphedema affects anywhere from 20% to 40% of survivors following axillary lymph node dissection, with rates varying based on the extent of surgery, radiation, and individual risk factors.¹˒² Repetitive, high-intensity upper body exercise in a survivor with undiagnosed or unmanaged lymphedema can trigger or worsen a condition that significantly impacts quality of life - and once established, lymphedema is chronic, progressive, and incurable.

Stronger by Design is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

What most trainers miss entirely is the relationship between breast cancer surgery, radiation, and range of motion. Radiation dramatically increases the risk of lymphedema - and it also causes soft tissue fibrosis, scarring, and progressive loss of shoulder and chest mobility (add this to any scar tissue or adhesions from mastectomy and/or breast reconstruction). Range of motion restoration is the top clinical priority following breast cancer surgery and radiation. Strength training in planes of motion where ROM is limited should not begin until the client has achieved 90% or better of the normative range. Starting strength work too early, in restricted ranges, loads compromised tissue, can worsen scar tissue contracture, and create long-term dysfunction that is entirely preventable.

What an OncoVie® Cancer Exercise Specialist Does Instead:

An OncoVie® specialist conducts a thorough surgical history intake that goes far beyond a general physician clearance. They are trained in the specific contraindications for 26 cancer types and their associated surgeries. They know which movements are contraindicated, which require modification, and which can be progressed carefully over time.

The ileostomy client gets a complete breathing protocol built into every exercise. The mastectomy client gets lymphedema screening, ROM assessment, and upper extremity programming that respects the lymphatic system and the healing tissue as well as correction of muscle imbalances that can lead to compensation, joint degeneration, and pain. The colectomy client gets core work that rebuilds intra-abdominal stability without ever compromising the surgical repair.

MISTAKE 2 - Ignoring Treatment Cycle Timing

A client is receiving chemotherapy. They feel reasonably well and come in for their session. The trainer programs a moderate workout and the client finishes it feeling depleted in a way that lingers for days.

What the trainer didn’t know: their client’s blood counts were too low to exercise at such an intensity.

Typically, days 7 to 14 following a chemotherapy infusion, are when blood counts reach their lowest point. White blood cell counts drop, leaving the immune system severely compromised. Platelet counts fall, increasing bleeding and bruising risk. Red blood cell counts decline, worsening fatigue and reducing oxygen-carrying capacity.

Exercise is not simply less effective, depending on the client’s counts, it can be actively dangerous. A client with a platelet count below 50,000/µL requires extremely conservative exercise modifications. Below 20,000/µL, resistance training should not occur at all.⁹ Clients who are immunocompromised should consider an outdoor workout or ZOOM session rather than going to a crowded gym.

A general fitness professional has no framework for this. They see a client who showed up. They train them.

What an OncoVie® Cancer Exercise Specialist Does Instead:

An OncoVie® specialist builds the treatment cycle into the exercise programming from day one. Sessions are scheduled around the clients’ treatment schedule whenever possible - typically in the window before the next infusion when counts have had time to recover (once treatment is well-established, the client usually has a pretty good sense of how many days following treatment they will need to be out of commission). They know the specific timing for the chemotherapy agents their client is receiving. They educate their clients on symptom monitoring and establish clear stop criteria. And when counts are low, they adjust intensity, duration, and exercise selection accordingly - not based on how the client feels, but based on where they are in their treatment cycle.

MISTAKE 3 - Missing Cardiovascular Red Flags

A client is on chemotherapy and mentions heart palpitations during their last workout. The trainer notes it, assumes it’s deconditioning or anxiety, and continues the session.

This is a potential medical emergency treated as a nuisance.

5-fluorouracil (5-FU) - one of the most commonly used chemotherapy agents in the world, present in FOLFOX, FOLFIRI, and other standard colorectal, gastric, and head and neck cancer regimens - is the second most common chemotherapy agent associated with cardiotoxicity.³ Its cardiac effects include coronary vasospasm, arrhythmia, myocarditis, and in rare cases - sudden cardiac death. Coronary vasospasm - which can present identically to a heart attack - occurs in approximately 1.7% to 2.2% of patients receiving 5-FU-containing regimens.⁴˒⁵ Critically, it occurs without warning and without pre-existing heart disease - younger patients with no cardiovascular risk factors are not protected.⁴

Oxaliplatin, also present in FOLFOX, prolongs the QT interval, creating conditions for dangerous cardiac arrhythmias. Anthracyclines such as doxorubicin cause cumulative cardiotoxicity that can lead to cardiomyopathy.

Palpitations in a client receiving any of these agents is not background noise. It is a stop-everything, refer-immediately situation.

A trainer who is not familiar with the cardiac profiles of common chemotherapy agents cannot recognize this signal. An AI-generated program has no mechanism to ask what chemotherapy the client is receiving, let alone flag the cardiac implications.

What an OncoVie® Cancer Exercise Specialist Does Instead:

An OncoVie® specialist knows the cardiac profiles of the most common chemotherapy regimens. They require cardiovascular screening before working with a client, establish written stop criteria that the client understands, and communicate directly with the oncology team when cardiac symptoms appear. Palpitations, chest pain, unusual shortness of breath, or dizziness during exercise triggers immediate session termination and oncology notification - not reassurance and continuation.

MISTAKE 4 - Pushing Through Cancer-Related Fatigue

A client reports feeling exhausted. The trainer - drawing on years of experience with general populations - encourages them to push through. Movement will help. Getting the heart rate up will boost energy. Rest makes fatigue worse.

In a general population, this logic is often correct.

In a cancer patient or survivor, it can cause serious setbacks.

Cancer-related fatigue (CRF) is the most commonly reported and most debilitating symptom experienced by cancer patients and survivors.⁸ It is physiologically distinct from normal fatigue. It is not resolved by rest. It is not a sign of deconditioning that will improve with harder training. It is driven by inflammation, cytokine dysregulation, anemia, hormonal changes from treatment, disrupted sleep, and the profound systemic effects of cancer and its treatment.

Overexertion in a client experiencing CRF does not build resilience. It triggers post-exertional malaise - a worsening of symptoms that can last days and set the client back significantly in their recovery.

Stronger by Design is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

What an OncoVie® Cancer Exercise Specialist Does Instead:

An OncoVie® specialist assesses fatigue at every session using validated tools and adjusts programming in real time. They understand that the dose-response relationship for exercise in cancer patients is fundamentally different from healthy populations.⁹ They know that low-to-moderate intensity exercise - not high intensity - is what the evidence supports for CRF management. They monitor RPE carefully, keep sessions shorter than conventional wisdom would suggest, and build rest into the programming rather than treating it as failure.

MISTAKE 5 - No Screening for Bone Fragility and Metastatic Disease

A client is a cancer survivor who wants to get strong again. The trainer programs squats, deadlifts, and loaded carries. The client has been cleared by their physician for exercise. Everything looks appropriate.

What the trainer doesn’t know: the client has bone metastases. Or their long-term hormone therapy has caused significant bone density loss. Or their steroid use during treatment has compromised skeletal integrity in ways that don’t show up on a general physical.

In a client with undetected bone metastases or severe osteoporosis, a heavy squat is not a strength exercise. It is a fracture risk.

The numbers make this a non-negotiable screening priority. Five-year bone metastasis incidence rates reach 41% for breast cancer, 52% for prostate cancer, and 33% for lung cancer.⁶ These are not rare cases - they are the clients fitness professionals encounter every day. Additionally, aromatase inhibitors and other hormone therapies used long-term in breast and prostate cancer treatment cause accelerated and clinically significant bone density loss,⁷ and long-term corticosteroid use - common in many cancer treatment protocols - compounds this risk further.

What an OncoVie® Cancer Exercise Specialist Does Instead:

An OncoVie® specialist screens for bone health risk at intake - asking specifically about hormone therapy type and duration, corticosteroid use, and metastatic disease status. They know which cancer types have the highest rates of bone metastasis. They understand the difference between exercise that builds bone density and exercise that puts fragile bone at risk. And when bone health status is unknown or concerning, they communicate with the oncology team before loading the skeleton.

BONUS for Paid Subscribers: The Scenarios Most Likely to End in the Emergency Room - And How They Are Prevented

These are not hypothetical. They are the direct consequences of the mistakes above, playing out in real clinical settings. Each one is preventable. Each one requires knowledge that a general fitness certification does not provide.

Stronger by Design is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

BONUS for PAID subscribers: The Scenarios Most Likely to End in the Emergency Room - And How They Are Prevented

These are not hypothetical. They are the direct consequences of the mistakes above, playing out in real clinical settings. Each one is preventable. Each one requires knowledge that a general fitness certification does not provide.

Emergency Scenario 1 - Stoma Prolapse or Parastomal Hernia

A client with a temporary ileostomy following colorectal cancer surgery is working with a trainer who has received general physician clearance. The trainer programs a core circuit - planks, dead bugs, cable rotations. The client strains during a set. Days later they report pain, visible bulging around the stoma site, and difficulty managing their ostomy appliance.

Read more

In a previous issue, we explored the science behind melittin - the primary active compound in honeybee venom - and why researchers are so excited about its potential to fight cancer. We covered the basics: how it disrupts cancer cell membranes, triggers programmed cell death, and why the toxicity problem has kept it out of clinical use.

A lot has happened since.

The pace of melittin research has accelerated significantly in 2024 and 2025, with scientists tackling the toxicity barrier in genuinely novel ways. Here's what's new - and what it means.

The Delivery Problem Is Being Solved

The core challenge with melittin has always been the same: it works brilliantly in the lab but destroys healthy tissue when administered systemically. Free melittin doesn't know the difference between a cancer cell and a red blood cell.

Nanoparticle-based delivery systems have emerged as the most promising strategy for overcoming these barriers, offering improved tumor targeting, reduced off-target effects, and enhanced stability.¹ What's changed in the last year is the sophistication of those systems.

Researchers at the University of Western Australia have engineered a targeted form of melittin that can be injected directly into the bloodstream in preclinical studies. With just one injection, cancer cell death was observed within six hours, with the therapeutic effect lasting up to a week, while having minimal effect on normal cells.² Early findings involving ovarian cancer showed a sixfold improvement in effectiveness compared to melittin alone.²

That sixfold figure is significant. It suggests that precision delivery doesn't just reduce harm - it actually makes melittin more effective.

A New Mechanism: The Immune System Angle

Your previous article covered how melittin kills cancer cells directly. What's newer in the literature is growing evidence that melittin may also activate the immune system against tumors - a mechanism researchers call immunogenic cell death (ICD).

Melittin not only exhibits a potent direct tumor cell-killing effect but also possesses immunomodulatory functions, showing minimal chances for developing resistance - a property that has led researchers to recognize it as a promising broad-spectrum antitumor drug.³

This dual mechanism matters. Most cancer therapies work through one pathway. The possibility that melittin works through two - direct cell killing and immune activation - is part of why resistance appears unlikely, unlike many conventional chemotherapy agents.

New Cancer Types in the Research Pipeline

Your original article focused heavily on breast cancer, colorectal cancer, and lung cancer models. The 2025 literature has expanded significantly into two new areas worth watching.

The first is glioblastoma - the most aggressive form of brain cancer, with a median survival of around 18 months and a five-year survival rate below 5%. The blood-brain barrier has historically made drug delivery to brain tumors extraordinarily difficult. Targeted lipodisk delivery systems functionalized with specific peptides have been employed to target glioma cells, demonstrating superior cytotoxicity compared to free melittin, and co-delivery of melittin with paclitaxel produced synergistic cytotoxic effects and reduced tumor burden in intracranial mouse models.¹ This is still animal-model research - but the blood-brain barrier problem, long considered nearly insurmountable, is showing real cracks.

The second emerging area is ovarian cancer, which shares with glioblastoma a notorious resistance to conventional treatment. Early preclinical data on targeted melittin delivery to ovarian cancer cells is described as promising, with clinical trials in preparation.²

Triple-Negative Breast Cancer: A Specific Update

For breast cancer specifically, the most clinically significant research continues to focus on triple-negative breast cancer (TNBC) - the subtype that lacks estrogen, progesterone, and HER2 receptors and therefore doesn't respond to the most common targeted therapies.

Research published in npj Precision Oncology demonstrated that honeybee venom and melittin potently suppress the activation of EGFR and HER2 receptors by interfering with phosphorylation in the plasma membrane of breast carcinoma cells, with engineering of an RGD motif further enhancing targeting of melittin to malignant cells with minimal toxicity to normal cells.⁴

For survivors and patients following TNBC treatment, this is an area worth watching - not because it's available, but because it's targeting the exact biological mechanisms that make TNBC so difficult to treat.

Where Things Actually Stand

It would be easy to read all of this and conclude that melittin-based cancer therapy is imminent. It isn't - and being honest about that matters.

Several challenges still need to be addressed: bioavailability and systemic toxicity, significant individual variation due to genetic background, immune status, and tumor microenvironment, and the need for more human data before safety and efficacy can be verified.⁵

No completed human clinical trials exist. No FDA approvals. No standard dosing. The oncology community is unified on this point: melittin remains a preclinical research compound, not a treatment.

What has changed is the trajectory. In 2023 the question was whether melittin could ever be delivered safely. In 2025 the question has shifted to how best to optimize delivery systems already showing promise in animal models. That's a meaningful scientific shift even if it doesn't yet translate to the clinic.

What This Means for Cancer Survivors and the Professionals Who Support Them

The practical guidance from the previous article hasn't changed: do not attempt DIY bee sting therapy, do not seek out venom injections outside of a clinical trial, and do not substitute emerging research for evidence-based treatment.

What has changed is the quality of the science. Melittin research is no longer fringe - it's appearing in Nature journals, being funded by major research institutions, and attracting serious oncology researchers. The gap between laboratory promise and clinical reality remains wide, but the bridge is being built with more sophisticated tools than ever before.

For cancer survivors, the most empowering path remains the same: structured exercise, anti-inflammatory nutrition, adequate sleep, and close collaboration with your oncology team. For the professionals supporting them, staying current on emerging science - even when it isn't yet actionable - is part of what separates a knowledgeable specialist from the rest.

Nature keeps surprising us. The science of the sting is far from finished.

Stronger by Design is a reader-supported publication. If this kind of evidence-based oncology content is valuable to you, consider becoming a paid subscriber. Paid members receive full clinical case applications, treatment-specific programming breakdowns, and access to the CETI specialist community.

References

¹ Wang X, Zhang H, Cui Z, et al. Melittin-based nanoparticles for cancer therapy: mechanisms, applications, and future perspectives. Pharmaceutics.2025;17(8):1019. doi:10.3390/pharmaceutics17081019

² Wang E, Bhatt D, Domaschenz R, et al. Engineered targeted melittin demonstrates enhanced anticancer activity with reduced toxicity in preclinical models. University of Western Australia. Reported in: Newsweek.August 5, 2025. https://www.newsweek.com/bee-venom-could-help-cure-type-cancer-2108354

³ Wu J, Zhang T, Chen Q, et al. Recent advances in melittin-based nanoparticles for antitumor treatment: from mechanisms to targeted delivery strategies. J Nanobiotechnology.2023;21(1):449. doi:10.1186/s12951-023-02223-4

⁴ Duffy C, Sorolla A, Wang E, et al. Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer. npj Precis Oncol.2020;4:49. doi:10.1038/s41698-020-00129-0

⁵ Cui Z, Zhou Z, Sun Z, et al. Melittin and phospholipase A2: promising anti-cancer candidates from bee venom. Biomed Pharmacother.2024;179:117385. doi:10.1016/j.biopha.2024.117385

⁶ Daniluk K, Strzelecka P, Chmielewska-Krzesinska M, et al. Anticancer activity of melittin-containing bee venom fraction against glioblastoma cells in vitro. Int J Mol Sci. 2025;26(6):2376. doi:10.3390/ijms26062376

⁷ Fornari Laurindo L, Pereira de Lima E, Fornari Laurindo L, et al. The therapeutic potential of bee venom-derived apamin and melittin conjugates in cancer treatment: a systematic review. Pharmacol Res. 2024;209:107430. doi:10.1016/j.phrs.2024.107430

The rapid emergence of artificial intelligence (AI) tools has transformed many industries, including health, fitness, and wellness. Within seconds, AI systems can generate exercise programs, training templates, and periodized workout plans based on simple user prompts. While these tools may provide general fitness ideas, their increasing use in clinical and medically complex populations raises serious professional, ethical, and legal concerns.

One population for which exercise programming requires exceptional clinical awareness is individuals undergoing or recovering from cancer treatment. Cancer patients frequently experience profound physiological, neurological, and musculoskeletal changes related to surgery, chemotherapy, radiation therapy, immunotherapy, and hormone treatments. These changes require careful screening, specialized programming strategies, and continuous monitoring.

Artificial intelligence systems, regardless of their sophistication, are not capable of independently assessing patient-specific medical risk, treatment toxicity, or surgical complications. As a result, reliance on AI-generated exercise prescriptions without appropriate professional education may expose both the patient and the fitness professional to unnecessary risk.

Cancer Exercise Programming Is Fundamentally Different From General Fitness

Cancer exercise programming differs substantially from traditional fitness programming because cancer treatments can significantly alter physiology and physical capacity. Medical treatments used to treat cancer may impact cardiovascular function, immune status, bone density, neurological function, and tissue integrity.

Chemotherapy can result in cardiotoxicity, peripheral neuropathy, and profound fatigue. Radiation therapy can lead to fibrosis, reduced tissue elasticity, and long-term vascular changes. Surgical procedures frequently alter lymphatic drainage pathways, increase the risk of lymphedema, and permanently change biomechanical function.

Because of these treatment-related changes, exercise professionals must understand when exercise is appropriate, when it must be modified, and when it should be temporarily avoided. Improper programming may contribute to complications such as lymphedema exacerbation, fractures in individuals with compromised bone density, wound complications following surgery, severe fatigue episodes, or cardiovascular stress beyond safe limits.

For these reasons, oncology exercise is recognized as a specialized clinical discipline that requires targeted education and training.

Limitations of Artificial Intelligence in Oncology Exercise Programming

Artificial intelligence tools are typically trained on large generalized datasets rather than medically curated oncology-specific clinical information. As a result, AI systems cannot evaluate many of the critical factors that determine whether exercise programming is safe for a cancer patient.

These factors may include the presence of bone metastases, tumor location, recent surgical procedures, chemotherapy-related cardiotoxicity, immunosuppression, radiation-related tissue damage, and neurological complications. While AI-generated exercise routines may appear reasonable in a general fitness context, they cannot replace the professional judgment required to safely work with medically complex individuals.

Equally important, artificial intelligence systems do not assume responsibility for the outcomes associated with their recommendations. Responsibility ultimately rests with the professional implementing the program.

Share Stronger by Design

Legal and Professional Liability Considerations

From a legal standpoint, reliance on AI-generated exercise programs does not replace the requirement that professionals meet the accepted standard of care for the population they serve.

In the event that a cancer patient experiences injury or adverse outcomes during an exercise program, courts typically evaluate whether the professional possessed appropriate education, credentials, and competency related to the medical population they were serving.

Courts generally examine whether the professional demonstrated reasonable clinical judgment and whether they had received appropriate training related to the condition of the client. Stating that an exercise program was generated using artificial intelligence is unlikely to provide legal protection or reduce liability. The responsibility for program design and implementation remains with the professional.

The Role of Specialized Oncology Exercise Education

The Cancer Exercise Training Institute (CETI) developed the OncoVie® Cancer Exercise Specialist Program to address the critical gap between medical cancer treatment and safe physical recovery.

Since its introduction in 2004, the program has educated health and fitness professionals worldwide on evidence-based methods for safely and effectively working with individuals during and after cancer treatment.

The curriculum provides comprehensive instruction on cancer biology, treatment side effects, exercise contraindications, screening procedures, and condition-specific programming modifications. Professionals are also trained to recognize clinical warning signs, collaborate appropriately with healthcare providers, and implement exercise interventions that prioritize patient safety while supporting recovery, functional capacity, and quality of life.

Release of the 15th Edition of the OncoVie® Cancer Exercise Specialist Handbook

As cancer treatment continues to evolve, oncology exercise education must remain aligned with the most current scientific and clinical evidence.

In response to rapidly advancing medical treatments and survivorship research, CETI is releasing the 15th Edition of the OncoVie® Cancer Exercise Specialist Handbook, which incorporates extensive updates reflecting developments in 2025 and 2026 across multiple areas of cancer care.

This updated edition includes expanded coverage of current research in exercise oncology, modern surgical procedures and post-operative considerations, advances in chemotherapy, immunotherapy, and targeted therapies, and the long-term physiological implications of these treatments.

In addition, the handbook includes updated information on nutritional strategies that support recovery and inflammation management, emerging integrative and complementary medical approaches used in oncology care, and updated screening and risk-management protocols for fitness professionals working with cancer populations.

These updates ensure that professionals completing the program are equipped with the most current scientific, medical, and practical knowledge available for safely guiding cancer patients through exercise participation.

Artificial Intelligence as a Supplementary Tool

Artificial intelligence technologies may serve as useful supplementary tools for brainstorming exercise programming ideas or organizing training concepts. However, these tools should not replace professional education, clinical awareness, or responsible decision-making when working with medically vulnerable populations.

In oncology exercise, the expertise of the trained professional remains the primary safeguard for patient safety. Technology may assist the professional, but it cannot substitute for the specialized education required to interpret complex medical conditions and treatment histories.

The Growing Need for Oncology Exercise Professionals

The global population of cancer survivors continues to grow as medical treatments improve and survival rates increase. Exercise is now widely recognized as a critical component of supportive cancer care, contributing to improvements in functional capacity, fatigue management, treatment tolerance, and quality of life.

Hospitals, rehabilitation centers, and fitness facilities increasingly require professionals who possess appropriate education in oncology exercise programming. Professionals who pursue specialized training not only enhance patient safety but also position themselves as leaders in an expanding area of healthcare-integrated fitness services.

Professional Responsibility and the Future of Oncology Exercise

Health and fitness professionals who wish to work responsibly with individuals affected by cancer are strongly encouraged to pursue formal oncology exercise education.

The CETI OncoVie® Cancer Exercise Specialist Program provides the clinical framework, evidence-based methodology, and practical tools required to safely support patients during and after cancer treatment.

With the release of the 15th Edition of the OncoVie® Cancer Exercise Specialist Handbook, professionals now have access to the most current research, clinical insights, and applied exercise strategies available in the field of oncology exercise.

Through appropriate education, careful clinical judgment, and adherence to evidence-based practice, fitness professionals can play an important role in improving recovery, functional capacity, and quality of life for individuals living with and beyond cancer.

Premium Subscriber Bonus

AI vs Clinical Judgment in Oncology Exercise

Detailed Case Application Template: Colon Cancer, Standard Treatment, Ileostomy, and Exercise Decision-Making

This premium resource is designed to show, in practical terms, where artificial intelligence may be useful as a secondary support tool and where it is clearly inadequate without formal oncology exercise education. Cancer exercise prescription requires interpretation of diagnosis, surgery, treatment toxicities, functional limitations, nutrition-related complications, and symptom variability. Current guidance supports exercise during and after cancer treatment, but it also emphasizes individualized clinical judgment, screening, and modification rather than generic programming.

In colorectal cancer, that need for judgment becomes even more important when the client has undergone bowel surgery, is receiving oxaliplatin-based chemotherapy, and is living with an ileostomy. Ileostomy formation is associated with dehydration and electrolyte disturbance risk, and chemotherapy-induced peripheral neuropathy can affect gait, balance, and exercise safety. Exercise is beneficial, but the professional must determine not only what the client can do, but what they should avoid, what needs modification, and what requires medical follow-up.

Read more

For many breast cancer survivors, finishing chemotherapy or radiation feels like crossing the finish line. Yet for those with hormone-receptor–positive disease, the journey often continues for years through endocrine therapy - and one of the biggest questions becomes:

Do I stop at five years… or continue treatment longer?

This is where the Breast Cancer Index (BCI) has become one of the most important tools in modern survivorship care. It offers something patients and professionals have wanted for decades - personalized insight into late recurrence risk and whether extended endocrine therapy may actually help.

What Is the Breast Cancer Index?

The Breast Cancer Index is a genomic test performed on preserved tumor tissue from individuals with early-stage, hormone receptor–positive breast cancer. Unlike tests that guide chemotherapy decisions immediately after diagnosis, BCI focuses on a different window:

Risk that occurs years later - specifically years 5–10 after diagnosis.

The test analyzes gene expression patterns, combining:

• HOXB13/IL17BR ratio (H/I) – associated with endocrine therapy responsiveness

• Molecular Grade Index (MGI) – linked to tumor biology and proliferation

Together, these components generate two key insights:

1. Risk of late distant recurrence

2. Likelihood of benefit from extended endocrine therapy beyond five years

This distinction is critical - because not every survivor benefits equally from prolonged medication.

Why Late Recurrence Matters More Than Many People Realize

Hormone receptor–positive breast cancers behave differently from other subtypes.

While some cancers recur early, HR+ disease carries a persistent risk that can extend 10–20 years after initial treatment. That reality creates a difficult balance:

• Continuing endocrine therapy may reduce recurrence risk.

• But extended therapy can bring side effects such as joint pain, fatigue, bone loss, cognitive changes, or metabolic shifts.

Historically, clinicians had to make extended-therapy decisions based largely on tumor size, lymph node involvement, and general risk factors. Those variables are helpful - but they don’t fully capture tumor biology.

Who Is the Breast Cancer Index Typically Used For?

BCI is most often considered in individuals who are:

• Estrogen receptor-positive (ER+)

• Early stage

• Node-negative or limited node-positive

• Approaching the five-year mark of endocrine therapy

It is not designed for triple-negative or HER2-driven treatment decisions, and it is not a screening tool.

Instead, think of it as a strategic checkpoint - a way to reassess long-term risk at a moment when many survivors are deciding whether to continue medication or transition into a different phase of survivorship.

What Makes BCI Different From Other Genomic Tests?

Many professionals are familiar with assays used at diagnosis, such as tests that help determine chemotherapy benefit. Those tests answer early-stage questions:

• Is chemotherapy needed?

• How aggressive is this tumor right now?

BCI asks a different question entirely:

“What happens after year five?”

That makes it uniquely positioned for long-term survivorship planning - a phase where many patients feel less monitored but still carry meaningful risk.

Personalization Over One-Size-Fits-All

Extended endocrine therapy has historically been recommended broadly for higher-risk individuals. But more therapy isn’t always better.

Some patients gain significant benefit from continuing treatment.
Others experience side effects without measurable advantage.

BCI helps clinicians and patients weigh:

• The biological likelihood of late recurrence

• The potential benefit of continuing medication

This shift toward precision medicine is especially powerful for survivors who are exhausted by treatment fatigue and trying to reclaim quality of life.

Why This Matters for Exercise and Recovery Professionals

For oncology exercise specialists, rehabilitation professionals, and health coaches, understanding tools like BCI helps contextualize a survivor’s trajectory.

A person continuing endocrine therapy for another five years may experience:

• Bone density changes

• Musculoskeletal discomfort

• Fatigue fluctuations

• Altered metabolic response to training

Knowing that extended therapy decisions are being guided by genomic risk - not just blanket protocols - allows movement professionals to tailor programming more intelligently.

Exercise strategies may emphasize:

• Progressive resistance training to support bone health

• Recovery-based periodization

• Monitoring perceived exertion during hormonal fluctuations

• Long-term adherence over aggressive short-term loading

In other words, BCI doesn’t just influence medication decisions - it shapes how survivorship care evolves across disciplines.

Limitations and Misconceptions

As valuable as BCI is, it’s not a crystal ball.

It does not:

• Guarantee recurrence or prevention

• Replace imaging or clinical follow-up

• Override physician expertise

It provides probabilistic insight, not certainty.

Additionally, insurance coverage, accessibility, and eligibility criteria may vary, which means conversations around testing should always happen within the oncology care team.

How to Request the Breast Cancer Index (BCI)

The Breast Cancer Index is not a direct-to-consumer test — it must be ordered by a qualified medical provider. Most commonly, this includes:

• Medical oncologists

• Breast surgical oncologists

• Oncology nurse practitioners or physician assistants

Because BCI analyzes preserved tumor tissue from the original surgery or biopsy, no new procedure is usually required. The pathology lab retrieves the stored sample once the test is ordered.

Step-by-Step Process

1. Start the conversation early
The ideal timing is when someone approaches year 4-5 of endocrine therapy. Patients can ask:

“Would genomic testing like the Breast Cancer Index help guide whether I should continue hormone therapy beyond five years?”

2. Provider determines eligibility
Typical candidates include:

• ER-positive, early-stage breast cancer

• Node-negative or limited node-positive disease

• Completed or nearing 5 years of endocrine therapy

3. Order and pathology coordination
The ordering physician submits the request, and the testing company coordinates retrieval of tumor tissue.

4. Results discussion
Results are returned to the oncology provider - not directly to the patient - and interpreted within the broader clinical picture.

Will Insurance Cover the Breast Cancer Index?

Coverage has improved significantly in recent years, but it is not universal, and policies vary by insurer and clinical scenario.

Medicare

Medicare in the United States typically covers BCI when criteria are met, particularly for postmenopausal individuals with hormone receptor–positive early-stage disease being evaluated for extended endocrine therapy decisions.

Private Insurance

Many commercial insurers provide coverage, but approval often depends on:

• Clinical indication (late recurrence risk assessment)

• Stage and receptor status

• Documentation that results will influence treatment decisions

Preauthorization may be required.

Out-of-Pocket Considerations

If coverage is denied:

• Financial assistance programs may be available through the testing company.

• Patients should always request a benefits investigation before proceeding.

Encourage readers to speak with both their oncology office and insurance provider - most clinics have staff who handle genomic test authorizations routinely.

Why Insurance Decisions Can Vary

Insurers evaluate genomic tests based on clinical utility - meaning whether the test meaningfully changes medical management.

The Breast Cancer Index stands out because studies show it can help determine:

• Who benefits from extended endocrine therapy

• Who may safely avoid additional years of medication

That potential to reduce unnecessary treatment - and associated costs - is a major reason coverage has expanded.

Practical Questions Patients Can Ask Their Oncologist

• “Am I a candidate for the Breast Cancer Index?”

• “Would the results change whether I continue hormone therapy?”

• “Does my insurance typically cover this test?”

• “Can your office check coverage before ordering?”

These questions shift the conversation from curiosity to actionable planning.

The Emotional Side of Genomic Testing

One aspect that often gets overlooked is the psychological impact.

For some survivors, genomic clarity reduces anxiety by offering a clearer path forward. For others, seeing quantified risk can feel overwhelming.

The most effective use of BCI happens when results are integrated into a supportive, multidisciplinary discussion - where patients understand not just their risk, but their options.

A Shift Toward Long-Term Survivorship

The Breast Cancer Index represents something larger than a single test.

It reflects a shift in oncology from:

“Did we treat the cancer?” to “How do we support this person safely for decades?”

As survivorship expands, tools that refine long-term risk allow clinicians to move away from blanket protocols and toward truly individualized care plans.

And for many survivors, that means fewer unknowns - and more confidence in the next phase of life after cancer.

If you or someone you support is approaching the five-year milestone of hormone therapy, conversations about long-term risk are not just medical - they’re deeply personal.

The Breast Cancer Index doesn’t make the decision for you, but it can help ensure that the decision is grounded in biology, not guesswork.

REFERENCES:

1. Sanft TB, Wong J, O'Neal B, Siuliukina N, Jankowitz RC, Pegram MD, Fox JR, Zhang Y, Treuner K, O'Shaughnessy JA. Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study. J Natl Compr Canc Netw. 2024 Mar 4;22(2):99-107. doi: 10.6004/jnccn.2023.7087. PMID: 38437792.

2. Foldi J, Tsagianni A, Salganik M, Schnabel CA, Brufsky A, van Londen GJ, Pusztai L, Sanft T. Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer. BMC Cancer. 2023 Jun 30;23(1):606. doi: 10.1186/s12885-023-11104-w. PMID: 37391697; PMCID: PMC10314405.

3. O'Regan RM, Ren Y, Zhang Y, Siuliukina N, Schnabel CA, Kammler R, Viale G, Dell'Orto P, Munzone E, Láng I, Tondini C, Gomez HL, Chini C, Nicoletti SVL, Puglisi F, Zaman K, Goetz MP, Stearns V, Martino S, Salim M, Loibl S, Geyer CE, Bonnefoi HR, Ciruelos EM, Loi S, Colleoni M, Fleming GF, Francis PA, Walley BA, Pagani O, Treuner K, Regan MM. Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index. JAMA Netw Open. 2025 Nov 3;8(11):e2540931. doi: 10.1001/jamanetworkopen.2025.40931. PMID: 41182766; PMCID: PMC12584034.

4. Noordhoek I, Treuner K, Putter H, Zhang Y, Wong J, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, van de Velde CJH, Schnabel CA, Liefers GJ. Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR⁺ Early-stage Breast Cancer for 10 Years of Endocrine Therapy. Clin Cancer Res. 2021 Jan 1;27(1):311-319. doi: 10.1158/1078-0432.CCR-20-2737. Epub 2020 Oct 27. PMID: 33109739.

Yesterday, my husband and I began a fast together.

Not as punishment. Not as a trend. Not because we’re chasing another quick-fix after a weekend of gluttony.

My son told me about a brand that he was doing some work for - ProLon - and I decided to look into it out of curiosity. Mind you, when I hear the term “fast,” I want to run! I dread one day of fasting every few years for a colonoscopy, let alone 5 days of fasting. Unlike water fasting, where caloric intake drops to zero, ProLon is designed to simulate the metabolic effects of fasting while still providing small, structured amounts of food. The plan uses carefully portioned, plant-based soups, nut bars, teas, olives, and micronutrient support to keep calories low - typically ranging from about 700-1,100 calories per day - while shifting the body toward a fasting-like physiological state. I discussed the possibility of doing this with my husband, not for weight loss, but for the following health benefits:

• Activation of cellular cleanup processes like autophagy
• Improved insulin sensitivity and glucose regulation
• Reduced inflammatory signaling
• Enhanced metabolic flexibility
• Potential support for stem cell regeneration pathways during refeeding phases

I realized how much food “rules” my life. Whether it is calorie-counting and watching every morsel that I put in my mouth, or a weekend binge of pizza and Margaritas, it’s always in the forefront of my mind. I have been hooked on energy drinks for decades and my husband easily drinks a pot of coffee per day! Although it took a little bit of coaxing on both of our parts, we agreed to take on the physical and mental challenge of this 5-day fast.

Fasting Is Not Starvation - It’s Metabolic Flexibility

When done strategically, fasting is not about deprivation. It’s about giving the body space to shift gears.

Most people live in a constant fed state, relying heavily on glucose for energy. During a fasting window, insulin levels drop, stored glycogen begins to deplete, and the body gradually transitions toward fat metabolism and ketone production. It’s less about weight loss and more about metabolic housekeeping - the kind we rarely allow to happen because the kitchen never closes in our house.

Autophagy: The Body’s Internal Cleanup Crew

One of the most fascinating biological processes associated with fasting is autophagy - a term that literally means “self-eating,” though it sounds far more dramatic than it is.

Autophagy is a regulated cellular recycling process where damaged proteins, dysfunctional mitochondria, and cellular debris are broken down and repurposed. Think of it as a deep spring cleaning at the microscopic level. My high family risk for cancer was a big motivator for me here!

As nutrient intake decreases and cellular stress signals shift, pathways like AMPK activate while mTOR signaling quiets down. This environment encourages cells to repair rather than simply grow.

Why does this matter?

Because aging, chronic disease, and metabolic dysfunction are often tied to accumulated cellular damage. Autophagy doesn’t make us immortal, but it may help the body function more efficiently by clearing what no longer serves us. Having celebrated my 60th birthday just three weeks ago, the desire to support my body from the inside out - to invest in vitality, resilience, and true quality of life as I step into this next chapter - became a powerful motivator for me.

The Fasting-Mimicking Approach: Structured, Supported, Strategic

While traditional fasting can feel intimidating or unrealistic for many people, structured protocols like the 5-day fasting-mimicking approach offer a different path.

The concept is simple: instead of complete food restriction, carefully designed low-calorie, plant-based nutrition creates a physiological environment that mimics fasting while still providing essential nutrients.

Programs like the ProLon 5-Day Fasting Mimicking Protocol are designed to:

• Reduce caloric intake while maintaining micronutrient support
• Promote mild ketosis without full starvation stress
• Support metabolic reset cycles
• Encourage adherence for people who would struggle with water fasting

What I appreciate most is that it introduces intentionality and self-discipline. It turns fasting into a structured practice rather than an all-or-nothing torturous experiment fueled by willpower alone. Those who know me will probably attest to the fact that I am very disciplined, and that I have a great deal of willpower. However, anything related to food deprivation presses a button for me. After decades of body dysmorphia and every diet you can imagine, I have a difficult time with food deprivation or restraint at this time in my life.

Starting it together with my husband has added a layer of accountability. There’s something grounding about sharing the experience, even though we are both lethargic and craving something more than soup and tea. It is definitely challenging - I have thought about throwing in the towel on day two, but we are keeping each other moving forward!

A Very Important Reality Check: Fasting Is Not for Everyone

As excited as I am to explore the benefits, I want to be crystal clear about something deeply personal.

My son cannot do this with us - because he lives with type 1 diabetes.

For individuals who rely on insulin, fasting protocols can carry significant medical risk, including dangerous blood sugar fluctuations and potential metabolic complications. What may be therapeutic for one person can be unsafe for another.

And that’s the truth we don’t talk about enough in the wellness space.

Fasting - especially prolonged fasting or fasting-mimicking protocols - may be contraindicated for:

• Type 1 diabetes
• Insulin-dependent diabetes or unstable blood sugar regulation
• Pregnancy or breastfeeding
• Active eating disorders or history of disordered eating
• Underweight individuals
• Certain medications requiring food intake
• Some medical conditions or active treatment phases without physician oversight

Health is not one-size-fits-all, and responsible wellness means knowing when something is powerful… and when it’s simply not appropriate.

The Emotional Side of Fasting No One Talks About

Fasting isn’t just physiological. It’s psychological.

I have noticed habits I didn’t realize I had (at least not on a daily basis)- reaching for food during stress, boredom, sad times, or celebration. I now realize how often eating fills space rather than actual hunger. I have not been feeling my best of late and attributed it to gluten and dairy; especially the brain fog. While there is certainly a connection, I am hoping for more.

Clarity.

I would like to be steadier and quieter in my mind and not always need the artificial buzz of caffeine.

There’s also humility in the process. Some moments feel empowering. Others feel uncomfortable. Both are part of the experience.

Movement During a Fast: Less Heroics, More Listening

As someone who thrives on hard workouts and the rush of pushing limits, fasting challenges me to shift gears - to ease off the gas, respect recovery, and let restraint become part of the training instead of intensity. I have been waiting for snow ALL winter, and today we are finally getting a storm. To my complete surprise, I am allowing myself to stay home and stay quiet.

Gentle movement often feels best while on a pasting protocol:

• Walking
• Mobility work
• Light resistance training
• Breathing and recovery practices

High-intensity training can be appropriate for some experienced individuals, but the goal during a fasting cycle is adaptation - not proving toughness (this is a challenge for me). The body is already working hard internally.

Sometimes the strongest choice is simply slowing down; something that I have never been good at!

What I’m Noticing So Far

It’s early in our experience, but even within the first day, there’s a noticeable shift in awareness.

Meals feel intentional. Hunger feels more honest. Energy feels less tied to external stimulation.

And perhaps most importantly, it feels like a reset - not just physically, but mentally.

We often talk about health as something we build through action. Fasting is teaching me that health also grows through restraint.

The Bigger Picture

Fasting will never replace consistent nutrition, movement, sleep, and emotional well-being. It’s not a miracle intervention.

But when used thoughtfully - and safely - it can be a powerful reminder that the body has innate intelligence. Sometimes it needs support. Other times it needs space.

Right now, we’re simply giving it both.

And I’m curious to see what unfolds over the next few days. I’ll keep you posted!

Exclusive Bonuses for Paid Subscribers

Movement During a Fast - Precision-Dosed Training Guide
Train intelligently while fasting with structured intensity zones, recovery markers, and nervous system-focused programming.

Longevity Habits Beyond Fasting
A comprehensive 50+ longevity playbook covering strength, circadian rhythm, metabolic stability, and recovery strategies that extend far beyond nutrition alone.

Advanced Refeed Strategy Guide
A clinically informed roadmap for safely transitioning out of a fast, including protein timing, electrolyte balance, digestive support, and how to avoid the binge-restrict cycle.

Read more

The loss of James Van Der Beek at just 48 years old isn’t simply another celebrity headline, it represents a shift that oncology professionals have been watching for years - colon cancer is no longer just a disease of aging.

Today, colorectal cancer is becoming one of the leading causes of cancer death in adults under 50, with mortality in younger populations continuing to rise despite overall declines in older age groups.

Many younger adults diagnosed today are active, health-conscious, and without obvious risk factors.

That forces us to ask a bigger question:

If genetics and age are no longer enough to explain risk, what role do lifestyle, movement, and metabolic health play - not only in prevention, but in recurrence?

Why Early-Onset Colon Cancer Is Increasing

Researchers don’t yet have a single explanation, but several trends are emerging:

• Increased sedentary behavior and metabolic dysfunction

• Diet patterns high in processed foods and red meat

• Microbiome changes and chronic inflammation

• Obesity and insulin resistance

• Environmental exposures

Even so, many younger patients don’t fit traditional risk profiles - which is why symptoms are often dismissed and diagnoses delayed.

The rise in early-onset disease means prevention strategies can no longer start at midlife.

They must start earlier - and they must include movement and nutrition.

Physical activity is one of the strongest modifiable lifestyle factors linked to reduced colon cancer risk.

Higher activity levels are associated with a 30–50% reduction in colon cancer incidence, particularly for colon (not rectal) tumors.

Even modest changes matter:

• Walking briskly for 30 minutes daily has measurable protective effects.

• Greater daily movement - not just intense workouts - is linked to significantly lower cancer risk overall.

Why does movement matter so much?

Because exercise influences multiple biological pathways tied to cancer risk:

• Insulin sensitivity

• Inflammation regulation

• Immune surveillance

• Gut motility and microbiome diversity

• Body composition and visceral fat

In short, exercise changes the internal environment in ways that make tumor development less favorable.

Exercise After Diagnosis - and Why It Matters for Recurrence

One of the biggest paradigm shifts in oncology over the past decade is the recognition that exercise is not just supportive care - it’s a survival intervention.

Recent research shows:

• Structured exercise programs reduce recurrence rates and improve long-term survival in colon cancer survivors.

• Higher physical activity levels can narrow or even eliminate survival gaps between cancer survivors and the general population.

• Exercise interventions have demonstrated fewer recurrences and fewer deaths compared to standard education alone.

This is critical because most colon cancer recurrences occur within the first 2–3 years after treatment - a window where lifestyle may influence long-term outcomes.

From an oncology exercise perspective, the message is clear:

Movement is not optional in survivorship, it is part of risk management.

Diet and Metabolic Health: Prevention Starts on the Plate

Diet patterns influence inflammation, insulin signaling, and gut microbiome composition - all factors tied to colorectal cancer risk.

Research consistently shows:

• Diets high in fruits, vegetables, and whole grains are associated with improved outcomes and lower risk.

• High intake of red or processed meats, alcohol, and ultra-processed foods increases risk.

Plant-forward dietary patterns help regulate:

• Oxidative stress

• Chronic inflammation

• Gut microbial balance

These factors play a role in whether precancerous polyps progress or remain dormant.

Diet After Diagnosis - Reducing Recurrence Risk

Survivorship nutrition is not just about weight management - it may influence recurrence biology.

Studies have shown:

• Survivors adhering closely to cancer prevention nutrition guidelines had a 42% lower risk of death and significantly lower recurrence rates.

• Western dietary patterns and sugar-sweetened beverages after diagnosis may increase recurrence and mortality risk.

What does that mean practically?

Nutrition becomes part of long-term disease control - not just recovery.

The Combined Effect: Lifestyle Is Stronger Than One Habit Alone

Perhaps the most powerful finding across studies is that exercise and diet work synergistically.

Patients who aligned their lifestyle with cancer prevention guidelines - including physical activity, healthy body weight, and nutrient-dense eating - experienced dramatically better survival outcomes compared with those who did not.

This reinforces a critical truth:

There is no single “superfood” or “perfect workout.”

Risk reduction comes from consistent patterns over time.

What Prevention Actually Looks Like in Real Life

Current prevention guidelines from the American Cancer Society emphasize a multidimensional lifestyle framework rather than a single intervention. Evidence supports accumulating 150-300 minutes of moderate-intensity aerobic activity per week, minimizing prolonged sedentary time, and maintaining healthy body composition through consistent nutritional and movement strategies.

These recommendations are not arbitrary targets. Regular physical activity influences insulin signaling, systemic inflammation, immune surveillance, gut motility, and metabolic flexibility - all biological pathways implicated in colorectal carcinogenesis.

Importantly, prevention does not require perfection or elite-level training. Emerging research demonstrates that even short bouts of higher-intensity movement - sometimes only a few minutes distributed throughout the day - are associated with meaningful reductions in cancer risk markers. The cumulative effect of repeated physiological stimulation appears to be more relevant than isolated peak intensity.

From a behavioral standpoint, adherence and sustainability consistently outperform extremes. Long-term consistency, rather than sporadic intensity, is the variable most strongly associated with reduced disease risk.

The Hard Truth Behind James Van Der Beek’s Story

High-profile cases remind us that lifestyle modification reduces risk - it does not eliminate it.

Cancer development is multifactorial, influenced by genetics, environment, microbiome dynamics, and stochastic cellular events. Individuals may engage in regular exercise, maintain healthy nutrition, and still receive a diagnosis.

However, lifestyle behaviors significantly influence several modifiable outcomes:

• Baseline metabolic and inflammatory risk profiles
• Tolerance to surgery, chemotherapy, or radiation
• Functional recovery trajectories
• Long-term survivorship and recurrence risk

These factors do not guarantee prevention, but they can alter the biological terrain in which cancer develops and progresses. Perhaps most importantly, they remain within an individual’s sphere of influence - even after diagnosis.

The Message for Younger Adults and Survivors

Colorectal cancer is increasingly diagnosed in individuals who would historically be considered low risk by age alone. As incidence patterns shift, prevention conversations must expand beyond traditional clinical settings and into fitness environments, coaching relationships, and everyday lifestyle decision-making.

Movement should not be framed solely as a tool for appearance or performance. Nutrition should not be reduced to calorie balance alone. Together, they form a foundation of physiological resilience - supporting immune function, metabolic stability, and systemic recovery capacity.

The rising incidence of early-onset colorectal cancer reinforces a critical paradigm shift:

Prevention is not a passive state defined by absence of disease.
It is an ongoing, adaptive process shaped by daily behaviors and long-term patterns.

Paid Subscriber Bonus:

Anti-Inflammatory Nutrition Framework
Fiber-forward, microbiome-supportive meal strategies drawn from the Wellness Reboot series - adapted for gut health and long-term risk reduction.

Precision-Dosed Movement Blueprint
Evidence-aligned weekly training structure using RPE and recovery-aware programming to support metabolic stability and sustainable activity.

Circadian Rhythm Reset Guide
Simple daily anchors that improve recovery, reduce inflammatory load, and support consistent energy regulation.

Foundational Movement Reset
Low-barrier mobility strategies to reduce sedentary stress and build a sustainable movement base.

Read more

I still vividly remember my first health club job in 1984 at Holiday Spa Club in Rockville, Maryland. I showed up in a metallic blue leotard and tights, white leg warmers, a white headband, and K-Swiss sneakers. Duran Duran blasted through the speakers while chrome accents and pink neon lights bounced off the mirrors. It was loud, electric, and unapologetically 80s - and it felt like the very center of the fitness universe. In the 1990s, I learned from the icons - watching Kathy Smith, Jane Fonda, Billy Blanks, and other fitness legends on a 200 lb. 36-inch TV that felt cutting-edge at the time. In the 2000s, I taught kickboxing, drilling the same patterns again and again until my joints paid the price.

Then came the last decade, when fitness culture doubled down on the belief that effectiveness had to look extreme. High-intensity interval training became the default prescription - stacked circuits, minimal rest, repeated metabolic stress - regardless of age, recovery capacity, or training history. CrossFit culture amplified this further, normalizing high-skill, high-impact work performed with speed. I found myself trying to “keep up” with 20-year-olds - pushing through double unders, repeating high-rep Olympic lifts, chasing intensity instead of adaptation - until there were days I could barely walk. Success was measured by how depleted someone looked at the end of a session. Volume and intensity were layered simultaneously, often with little attention to tissue tolerance, movement variability, or cumulative joint load.

In 2026, that model is being systematically dismantled.

The dominant fitness trend is not a new modality, box gym, device, or coaching platform. It is a dose-response recalibration of exercise itself that is grounded in physiology, recovery science, and healthspan research.

Exercise is now prescribed for adaptation efficiency, not maximal workload tolerance.

The Scientific Drivers Behind the Shift

1. The Dose-Response Curve Has Been Ignored for Too Long

Exercise follows the same biological principle as pharmacology:
more is not always better.

• Too little stimulus = no adaptation

• Optimal stimulus = positive adaptation

• Excessive stimulus = maladaptation, injury, or regression (this has always been my M.O.)

For years, mainstream programming favored higher volumes and intensities, often overlooking the reality that recovery capacity is finite, variable, and highly sensitive to age, stress, and prior physiological load.

In reality:

• Adaptive capacity declines with age - Adaptive capacity is the body’s ability to respond to stress (like exercise), recover from it, and improve function. As we age, this capacity gradually decreases due to changes in muscle protein synthesis, connective tissue elasticity, neural drive, and hormonal support.

• Treatment history alters tissue tolerance - Treatment history refers to past medical interventions such as surgery, cancer treatment, medications, or prolonged immobilization, that permanently or semi-permanently change how tissues respond to mechanical and metabolic stress.

• Chronic psychosocial stress reduces recovery bandwidth - Chronic psychosocial stress includes prolonged mental, emotional, and environmental stressors (work demands, caregiving, financial pressure, trauma, poor sleep). These stressors activate the same physiological stress systems as exercise.

• Hormonal transitions - Hormones regulate how tissues respond to exercise stress. Transitions such as menopause, androgen deprivation therapy, or thyroid dysfunction alter this regulation, changing how sensitive the body is to training stimuli.

Each of these factors reduces the margin for error in exercise programming. When they overlap (as they often do) traditional high-volume, high-intensity training models become increasingly mismatched to the body’s actual capacity.

This is why modern fitness must shift from asking:
“How much can this person do?” to “What is the most effective dose this body can recover from and adapt to?”

2. Recovery Capacity Is Now the Limiting Variable

In healthy, young populations, training load often determines progress.

The primary limiting factor for modern adult performance is the inability to recover efficiently.

Key factors constraining recovery in today’s population:

• Sleep fragmentation

• Inflammatory load

• Metabolic dysregulation

• Prior injury or surgery

• Cancer treatments and long-term toxicities

• Cognitive and emotional stress

Training without adequate recovery produces chronic inflammation and suppressed performance as well as:

• Plateaued strength

• Increased pain

• Reduced adherence

• Fear of movement

The 2026 model designs training within recovery constraints, not in opposition to them.

3. Functional Outcomes Have Replaced Aesthetic Goals

Emerging consensus across exercise oncology, active agers, and preventive medicine, shows that function predicts outcomes better than appearance.

These outcomes are now prioritized:

• Strength preservation

• Rate of force development (explosive, high velocity performance)

• Balance and fall resistance

• Gait efficiency

• Joint integrity

• Energy availability

This shift has moved exercise programming away from:

High-volume hypertrophy models
Programs built around excessive weekly sets, frequent training to failure, and redundant movement patterns - often exceeding the amount of volume required to stimulate strength or muscle retention, particularly in non-athletic or aging populations.

Repeated metabolic conditioning circuits
Workouts designed to maximize cardiovascular strain and fatigue through continuous, low-rest circuits, where metabolic stress becomes the primary goal rather than a byproduct of purposeful loading.

Undirected intensity and novelty-driven sessions
Frequent variation in exercises, tempos, and formats introduced for engagement rather than progression, making it difficult to assess adaptation, manage cumulative load, or establish meaningful performance benchmarks.

And toward:

Targeted mechanical loading
The intentional application of load to specific tissues and movement patterns to support strength, bone density, and neuromuscular efficiency, with progression based on tissue tolerance rather than maximal effort.

Deliberate incorporation of rest and recovery
Planned rest intervals within sessions and between training days, recognizing that adaptation occurs during recovery and that fatigue management is central to long-term progress.

Measurable functional outcomes
Programming that prioritizes observable improvements in strength, balance, mobility, gait, or task performance - outcomes that translate directly to daily function rather than relying solely on subjective markers like soreness or exhaustion.

What Precision-Dosed Training Looks Like in Practice

Precision-dosed training is not “easy” training.
It is strategic stress exposure that is designed to stimulate adaptation while staying within the body’s ability to recover.

Rather than asking how much work can be tolerated, this approach asks:
What is the smallest amount of stress that produces a meaningful improvement?

Key Characteristics

1. Minimal Effective Volume

The body adapts to exercise when a stimulus crosses a threshold, not when it is repeated excessively. Once that threshold is reached, additional volume often adds fatigue without additional benefit.

What this looks like:

• Fewer working sets performed with high focus and good technique

• Training sessions that feel purposeful rather than exhaustive

• Longer periods between increases in load or difficulty to allow tissues to adapt

Why is this important:
Reducing unnecessary volume lowers joint stress, limits inflammation, and preserves recovery capacity - especially important as people age or manage health conditions.

2. High-Value Movement Selection

Exercises are chosen based on how well they translate to real-world strength, balance, and mobility, not how trendy or entertaining they are.

Priority is given to movements that:

• Involve multiple joints working together (compound movements)

• Apply meaningful load to bones and muscles

• Challenge balance and coordination

• Support daily activities (ADL’s) like lifting, walking, reaching, and rising from the floor

Why is this important:
These movements deliver a stronger adaptation signal per repetition, making training more efficient and more relevant to everyday life.

3. Built-In Autoregulation (Without Technology Dependence)

Training decisions are adjusted based on how the body is responding, not based on a preset plan that ignores real-time feedback.

Progression is guided by:

• Movement quality and control (how well the movement is performed, not just completed)

• RPE (how demanding the effort feels on that day, even at familiar loads)

• Symptom response during and after sessions (pain, dizziness, excessive soreness, or unusual fatigue)

• Fatigue that carries into daily life (reduced energy, disrupted sleep, or delayed recovery)

• Observable recovery patterns across days and weeks

Why is this important:
A load that registers as a moderate effort (for example, a Rate of Perceived Exertion [RPE] of 6–7) one week may feel disproportionately difficult the next due to stress, poor sleep, illness, or hormonal shifts. When RPE rises without an increase in load, it signals reduced recovery capacity.

Perceived exertion is simply a way to describe how hard an activity feels to you while you’re doing it. Instead of relying on numbers like heart rate, speed, or weight, it asks you to tune into your breathing, muscle fatigue, and overall effort and rate that experience on a simple scale - usually from 1 (very easy) to 10 (maximal effort). Because your capacity changes from day to day based on sleep, stress, health, and recovery, perceived exertion helps adjust exercise intensity in real time, ensuring the workload matches what your body can handle in that moment rather than what a preset plan assumes.

Interpreting these changes requires human judgment - the ability to adjust volume, intensity, or rest without abandoning the training stimulus altogether, and without technology. This is not automated decision-making; it is skilled coaching, using subjective effort and objective observation to keep training effective rather than excessive.

Why This Approach Elevates Skilled Professionals

Precision-dosed training depends on interpretation, not automation.

It requires the ability to:

• Identify early signs that the body is not adapting well

• Distinguish normal muscle soreness from overload or injury risk

• Adjust training stress without causing strength loss

• Maintain progress while respecting vulnerability

This is especially important for people navigating:

• Cancer recovery

• Post-surgical rehabilitation

• Menopause or testosterone suppression

• Bone density loss

• Neuropathy or balance impairment

In 2026, the industry is shifting from flashy, unsustainable trends to evidence-based, results-driven programming.

Common Misinterpretations - Explained

“Lower training volume produces inferior results.”
This assumes adaptation is proportional to total work performed. In reality, adaptation is driven by whether a sufficient stimulus threshold is reached and supported by adequate recovery. Once that threshold is met, additional volume often increases fatigue without improving outcomes.

“This approach only applies to older or medically complex populations.”
Precision dosing is frequently used in athletic settings to manage training load, reduce injury risk, and sustain performance over longer careers. The principles are not population-specific; they reflect universal constraints of human physiology. The same philosophy can be applied to NFL players, Olympic gymnists, cancer patients, and the aging population.

“Training won’t feel demanding enough to be effective.”
When recovery is respected, individuals often experience training as more productive rather than less challenging. Effort is concentrated where it matters, resulting in improved energy availability, fewer setbacks, and greater consistency over time.

Research and clinical practice consistently show:

• Better strength maintenance with less joint irritation

• Higher long-term adherence

• Fewer recurring injuries

• Improved balance and coordination

• Greater tolerance during medical or hormonal transitions

Precision-dosed training is likely to endure because it is rooted in human physiology rather than novelty. As populations age and chronic conditions become more common, the limiting factor in exercise is no longer access to variety, but the ability to dose stress appropriately within recovery constraints. This shift reframes fitness away from maximal effort and visible exhaustion toward intentional loading, sufficient recovery, and measurable adaptation. In this model, success is defined not by how depleted someone feels after a session, but by how well their body responds over time, placing the greatest value on professionals who understand stress, recovery, and individual variability.

For Paid Subscribers

If you want to move beyond theory and understand how to apply precision-dosed training in real bodies and real lives, this is where to go deeper. Paid subscribers gain access to a practical, evidence-informed toolkit designed to support sound decision-making, including a Precision-Dosed Training Playbook (for professionals and the general population) and case-based programming examples that show how and why training is adjusted over time. You’ll also have direct Q&A access to submit real scenarios for professional interpretation and guidance. Upgrade to explore how smarter exercise dosing translates into safer, more effective, and more sustainable outcomes.

Read more